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General introduction
10
GenerAl IntroDuctIon
Inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic debilitating disease, with inflammation 
of the gastrointestinal tract as main characteristic. IBD has two main types; Crohn’s 
disease (CD) and ulcerative colitis (UC). In patients who have IBD colitis that cannot 
(yet) be classified into CD or UC, the term IBD-unclassified (IBD-U) is used. IBD is 
characterized by periods of active disease (relapses, with increased symptoms) and 
periods of clinical remission (no symptoms present). Both CD and UC share common 
symptoms such as abdominal pain, bloody diarrhea, anemia, and systemic symptoms 
such as fatigue, lack of appetite and weight loss [1, 2]. CD usually has an insidious 
onset and can affect any part of the gastrointestinal tract from mouth to anus. In 
CD, inflammation presents itself often in ‘skip lesions’, in which some parts of the 
intestines are affected whereas other parts may be not. CD can be complicated by 
strictures and/or fistulas between parts of the intestinal tract or from intestine to the 
(perianal) skin. UC often has a more explicit onset, with frequent bloody diarrhea ac-
companied by abdominal cramping [3, 4]. Suspicion of IBD is present in case of typical 
symptoms and laboratory abnormalities in blood and stool. A confirmed diagnosis of 
IBD can only be made after extensive endoscopy of both upper and lower part of the 
intestinal tract with multiple mucosal biopsies. With respect to the complex etiology, 
several factors have been implicated. It has been shown that a genetic susceptibil-
ity in combination with a dysregulated immunological response to the bacterial gut 
flora is present. Environmental factors such as infection, certain foods, smoking and 
psychological stress can further trigger this dysregulation [1, 3].
IBD in children and adolescents
Approximately 10-25% of all patients receives the diagnosis of IBD before they are 18 
years of age, and for patients up to 25 years of age this is approximately 35% [2, 5, 
6]. Children and adolescents (hereafter referred to as youth) with IBD often present 
with malnutrition, growth failure, or delayed puberty [4]. In Europe, the incidence 
rate for pediatric IBD ranges from 3.11 – 12.00 per 100.000 persons, with somewhat 
higher incidence rates for CD (2.71 – 13.90 per 100.000 cases) than for UC (1.61 – 5.70 
per 100.000 persons). These incidence rates are rising, which can be attributed to the 
rising incidence rates of CD [5]. In the Netherlands over 80.000 patients suffer from 
IBD, of whom 2500 to 3000 are younger than 18 years.
medical treatment
Since IBD cannot be cured, its medical treatment is focused on the suppression of 
the inflammation, aimed at the induction and maintenance of clinical remission 
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and preferably also healing of the inflamed mucosa [7]. For children with active 
CD, the first-line treatment is exclusive enteral nutrition. This is less invasive than 
pharmacological therapy but requires adherence to a liquid formula diet for 8 weeks. 
Corticosteroids are often used for induction of remission in moderate to severe UC 
and CD (if enteral nutrition fails). After remission is induced, immunomodulators are 
used to maintain remission [8, 9]. In case of refractory disease, biologicals such as 
infliximab or adalimumab (anti-TNF treatments) of vedolizumab (anti-integrin) can be 
used. Surgery is indicated when non-inflammatory strictures are present in CD, or in 
UC when all treatments fail.
Psychological aspects of IBD
Psychological problems
The biopsychosocial model implies that psychological and social factors are likely to 
influence disease symptoms and functional outcomes, in addition to disease mecha-
nisms such as inflammation in IBD [10]. Due to the unpredictable course of the disease 
and the chronic nature of IBD adolescents frequently experience psychological and 
social problems [11]. Several studies have shown that youth with IBD have a lower 
health-related quality of life (HRQOL) compared to healthy youth [12]. Youth with IBD 
also can experience problems with their self-esteem or social functioning [13, 14].
The psychological problems most studied in IBD patients are anxiety and depres-
sion. In adults, a meta-analysis of Neuendorf et al. [15] showed that patients with IBD 
have a high risk for having anxiety and/or depression, consisting of either subclinical 
anxiety/depression or clinical anxiety or depressive disorders. In youth, no meta-
analysis is performed yet. However, original and review studies showed that youth 
with IBD also have a high risk for anxiety and/or depression [11, 16-18].
Bidirectional relationship inflammation and anxiety/depression in IBD
In IBD, the relationship between inflammation and anxiety/depression seems bidirec-
tional. Evidence for this bidirectionality mainly comes from studies in adults. On one 
hand, anxiety and depression are associated with clinical relapse during follow-up [19-
21]. More specifically, depression has a negative impact on the disease course [22] and 
is related to a shorter time to relapse when compared to anxiety [23]. In youth with 
IBD, Van Tilburg et al. [24] showed that psychological factors (anxiety, depression, cop-
ing and pain beliefs) impacted self-reported somatic symptoms and disability. On the 
other hand, evidence was found for the impact of clinical disease activity on anxiety 
and depression [25, 26]. In youth, clinical disease activity was associated with more 
symptoms of anxiety [27] and depression [28], and was a risk factor for having anxiety 
and depressive disorders [29]. Recently, two studies in adults with IBD provided even 
more evidence for the bidirectionality of the relationship between inflammation and 
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anxiety/depression. Sexton et al. [30] reported that clinical disease activity predicted 
change in perceived stress, where perceived stress predicted change in clinical disease 
activity. Furthermore, Gracie et al. [31] reported that clinical disease activity gave a 
6-fold risk on anxiety 2 years later, and that baseline anxiety and depression were 
associated with several indicators of increased clinical disease activity.
Brain-gut axis
The brain-gut axis provides an hypothesized explanation for the common combina-
tion of IBD inflammation and psychological problems, such as anxiety, depression 
and stress. This axis involves interactions between the autonomic nervous system, 
the central nervous system, the stress system (hypothalamic-pituitary-adrenal [HPA] 
axis), the corticotropin-releasing factor system, and the intestinal response, that make 
the brain and the gut communicate. This communication seems bidirectional [32]. 
Increased production of pro-inflammatory cytokines (e.g. tumor necrosis factor α; 
TNF-α) is known to directly and indirectly affect the brain, with increased symptoms 
of anxiety and depression as result [33, 34]. On the other hand increased anxiety 
and/or depression can increase inflammation. In this way a vicious circle arises in 
which inflammation and anxiety/depression negatively influence each other, to an 
increasing extent. More inflammation can lead to more anxiety/depression, and vice 
versa more anxiety/depression can lead to more inflammation [32]. Evidence for the 
brain-gut hypothesis comes from animal studies showing that stress induces reactive 
inflammation in colitis models [35]. In addition, studies in humans showed elevated 
levels of inflammatory markers in otherwise healthy patients with depression [36-39] 
and anxiety [40-42]. The last decades more evidence has become available for this 
psychoneuroimmunological approach to mental health problems, such as anxiety 
and depression [43, 44].
other psychological factors
Apart from the above described psychological problems, other psychological aspects 
of IBD also need to be considered. Earlier studies have shown that several psychologi-
cal factors – often tested separately – were related to negative outcomes in IBD, e.g. 
functional disability or anxiety and depression. Coping and illness perceptions are 
two factors that are important in youth with IBD.
Coping. Coping refers to the cognitive and behavioral strategies one uses to deal with 
negative experiences, such as having a chronic illness [45]. Often a distinction is made 
between coping styles that are associated with favorable psychological outcomes 
(adaptive coping), or those associated with unfavorable psychological outcomes (mal-
adaptive coping). Although it is still unclear whether youth with IBD cope differently 
than healthy controls, it appears that coping impacts psychological outcomes in these 
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patients [46, 47]. For example, maladaptive or passive coping was associated with 
more anxiety and depression [48], and adaptive coping (i.e. positive strategies) was 
associated with better HRQOL [49].
Illness perceptions. Illness perceptions are representations someone has about the ill-
ness, its treatment, and consequences of the illness [50]. There are several dimensions 
of representations: identity (the label that the persons uses to describe the illness), 
consequences (expected effects of the illness), cause (personal ideas about the cause 
of the illness), timeline (how long the patient believes the illness will last), and cure 
(the extent to which the patient believes treatment cures or controls the illness). In 
patients with IBD, illness perceptions have been shown to affect outcomes and adjust-
ment [47, 51-53], with unfavorable perceptions being related to unfavorable adjust-
ment. Illness perceptions have been less studied in children and adolescents than in 
adults. However, the few studies conducted suggest that also in youth with IBD, illness 
perceptions are associated with psychological problems [29].
To describe the potential relationships between illness, illness perceptions, coping, 
and illness outcomes, Diefenbach & Leventhal developed the Common Sense Model 
(CSM) [54]. In this model, illness characteristics (such as clinical disease activity) lead 
to certain thoughts about the illness, the so-called illness perceptions of a patient. 
These illness perceptions influence the type of coping the patient uses to deal with 
his/her symptoms. These factors lead to positive or negative illness outcomes, for 
example anxiety, depression, HRQOL, or adjustment. In turn, via a feedback loop ill-
ness outcomes can influence disease factors, coping, and illness perceptions [54, 55]. 
In adults with IBD, evidence was found for the CSM. That is, illness perceptions and 
coping were important mediators between clinical disease activity and anxiety and 
depression [56]. In youth with IBD these interrelationships have not been tested di-
rectly. Some evidence exists for separate pathways for different factors. For example, 
independent from the impact of disease factors on HRQOL, anxiety and depression 
(separately tested) have a negative impact on HRQOL as well [57-59]. However, the 
precise pathways between the factors included in the CSM are still unknown.
cognitive behavioral therapy for youth with IBD
Considering the possible negative impact of anxiety and depression on the mental 
and somatic health status of children and adolescents with IBD, from a health care 
perspective it is important to treat not only the somatic symptoms, but also the psy-
chological problems. The bidirectionality of the relationship between inflammation, 
and anxiety/depression implies that treating the psychological problems may also 
improve disease course. The most evidence based psychological treatment for anxiety 
and depression in children and adolescents is cognitive behavioral therapy (CBT) [60, 
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61]. In children with other chronic illnesses, such as diabetes and asthma, CBT has 
been shown effective in improving psychological problems [62, 63].
Only a few, and mostly small, studies have been conducted in youth with IBD. In 
2007, Szigethy et al. performed a randomized controlled trial (RCT; n=41) and pub-
lished preliminary, but promising results of cognitive behavioral therapy (CBT) in IBD 
patients aged 11-17 years with subclinical depression [64]. The CBT protocol used was the 
Primary and Secondary Control Enhancement Training – Physical Illness (PASCET-PI), 
a disease-specific CBT protocol. The authors found that 3 months of CBT was more ef-
fective in improving subclinical depressive symptoms than care-as-usual (CAU), which 
consisted of standard medical care plus a written information sheet about depression. 
In a later and larger RCT (n= 217), Szigethy et al. [65] confirmed the effectiveness of the 
PASCET-PI in improving clinical depressive symptoms in IBD youth aged 9-17 years, 
although a control group receiving supportive non-directive therapy showed similar 
results.
Very few studies focused on treating anxiety in youth with IBD. Reigada et al. [66] 
conducted a pilot non-randomized trial (n=22) using CBT in youth (mean age 13.2 
years) with IBD, and found promising results in reducing clinical anxiety. More re-
cently, a large RCT (n=185, aged 8-17 years) was conducted in pediatric IBD patients 
to test the effectiveness of a 3-session social learning CBT (SLCBT) versus educational 
support, although not focusing specifically on anxiety and/or depression. SLCBT led to 
a significant better improvement in IBD-related QOL and school attendance than edu-
cational support, but no differences were observed in improving subclinical anxiety 
and depression symptoms [67].
HAPPY-IBD: a study into anxiety and depression in youth with IBD
Until now, studies in youth with IBD mostly focused on either anxiety or depression. 
Hence, they did not take into account that anxiety and depression are highly comorbid, 
and that anxiety can precede depression [68, 69]. In addition, some studies included 
all youth with IBD, i.e. did not select youth on the presence of any psychological 
problems, such as anxiety and/or depression [67].
Therefore, the current study (HAPPY-IBD) was designed to 1) investigate both anxi-
ety and depression in youth with IBD and 2) test both the short-and long-term effects 
of a disease-specific CBT protocol on both anxiety and depressive symptoms. HAPPY-
IBD included a multi-center RCT, comparing the effects of the CBT protocol to CAU, 
consisting of standard medical care. The CBT protocol used was the disease-specific 
PASCET-PI, which also was used in previous studies.
Until now, no disease-specific CBT protocol was available for youth with IBD and 
their families in the Netherlands. It is innovative that we studied the effects of the 
PASCET-PI on both anxiety and depression, as well as on other psychological and medi-
15
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cal outcomes, both at short-term (3 months, directly after the CBT) and longer-term 
(after 6 and 12 months of follow-up), using internationally validated questionnaires 
and a psychiatric interview.
We included patients with both subclinical anxiety and/or depression, since we were 
interested in the possible effect of a disease-specific CBT a) to prevent that subclinical 
anxiety/depression would develop into clinical psychiatric disorders, and b) to have a 
positive effect on the disease course (e.g. to prevent clinical relapse or worsening of 
disease severity). Furthermore, we wanted our study to resemble daily clinical practice 
as much as possible. Therefore, we chose to use a care-as-usual group. Children with 
clinical anxiety or depressive disorders were excluded from the RCT, since it would 
be unethical to randomize children with a clinical psychiatric disorder to a control 
group.
In this PhD thesis, we aim to answer the following research questions:
1. What is the prevalence of anxiety and depressive symptoms and disorders in 
children and adolescents with IBD (aged 6-18 years)?
2. Which medical variables are associated with the presence of elevated anxiety and/
or depression in youth with IBD (aged 10-25 years)?
3. Which psychological variables are associated with HRQOL in youth with IBD (aged 
10-20 years)?
4. What is the short-term and long-term effectiveness of a disease-specific CBT in 
improving symptoms of anxiety and depression (primary outcomes), HRQOL, nega-
tive illness perceptions, coping, social functioning, and sleep problems (secondary 
outcomes)?
Firstly, we hypothesized that anxiety and depressive symptoms are highly prevalent 
in youth with IBD. Secondly, clinical disease activity and disease duration were 
hypothesized to be medical factors associated with the presence of anxiety and/or 
depression. Thirdly, we expected that illness perceptions, coping, anxiety, and depres-
sion were psychological factors that are associated with HRQOL. Fourthly and lastly, 
we hypothesized that patients in the disease-specific CBT group would improve more 
compared to the CAU group on their symptoms of anxiety and depression, as well as 
on their HRQOL, negative illness perceptions, coping, social functioning, and sleep 
problems. The results of the disease-specific CBT on the medical outcomes will be 
described in a separate PhD thesis, by Gertrude van den Brink, MD.
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Full details of the study design, inclusion, exclusion criteria, the procedure, the inter-
vention, and the used instruments, are described in Chapter 3 (the description of the 
study protocol) and can be found in the Methods section of Chapter 5, 6, and 7 as well. 
In short, the study is a RCT with a baseline screening and three follow-up assessments; 
at 3 months after the baseline screening (i.e. after the disease-specific CBT for those 
in the CBT group), at 6 months, and at 12 months after the baseline screening, see 
Figure 1. The follow-up assessments consisted of the same instruments as the baseline 
screening. The timing and method was similar for both groups.
Inclusion: adolescents and young adults (10-25 years) with a confirmed diagnosis 
of IBD (CD, UC, or IBD-U) were eligible. They were recruited between October 2014 
and October 2016 from the pediatric or (pediatric) gastroenterology departments of 
two academic and four community hospitals. The study consisted of two parts: 1) a 
baseline screening on symptoms of anxiety and depression and 2) for patients with 
subclinical anxiety and/or depressive symptoms, a RCT with two conditions (CAU + 
CBT versus CAU only).
Part 1, baseline screening: after providing informed consent, patients, and if applicable 
parents, filled out online questionnaires for the baseline screening (see below for the 
included variables). Using age-appropriate questionnaires, patients were screened 
for anxiety and depression. Patients had elevated symptoms if they scored equal to 
or higher than the validated cutoffs for elevated anxiety or depression. Those who 
showed elevated symptoms were invited for a psychiatric interview to determine 
whether they had clinical anxiety and/or depression. For this study, patients were 
considered to have clinical anxiety or depression if they met DSM-5 criteria for an 
anxiety or depressive disorder on the psychiatric interview, and scored equal or above 
the clinical cutoff on an age-appropriate severity rating scale for anxiety or depres-
sion. Scores on these instruments were rated by two independent raters.
Part 2, RCT: patients that showed subclinical anxiety and/or depression (i.e. who had 
elevated scores on the questionnaires, but did not show clinical anxiety or depres-
sion according to the psychiatric interview and rating scales) were included in the 
RCT. This was a multi-center, parallel group RCT, designed according to the guideline 
for trials in non-pharmacologic treatments [70]. Patients were randomized at a ratio 
1:1 to receive either CAU + CBT versus CAU only. Patients in the control group (CAU 
only) received standard medical care, since this resembles the current care for these 
patients best. Patients in the CBT group (CAU + CBT) received a disease-specific CBT 
protocol (Primary and Secondary Control Enhancement Training for Physical Illness; 
PASCET-PI) [64] added to standard medical care. See Chapter 3, 5 and 6 for more details 
of the PASCET-PI.
17
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Psychological and medical variables
In this thesis, the focus will be on the psychological aspects of IBD in youth. The 
following psychological variables were included in the online questionnaires:
•	 Primary psychological outcomes: anxiety symptoms, depressive symptoms
•	 Secondary psychological outcomes: HRQOL, social functioning
•	 Other psychological variables: illness perceptions, coping styles, quality of sleep, 
parental anxiety and depression, life events, and family functioning
Simultaneously, information on the following medical variables were collected:
•	 Primary medical outcome: clinical relapse/remission
•	 Secondary medical outcomes: clinical disease activity, inflammatory markers (C-reac-
tive Protein [CRP], Erythrocyte Sedimentation Rate [ESR], and fecal calprotectin), 
use of IBD medications, necessity of surgical intervention
•	 Other medical variables: disease phenotypes, treatment strategy, Irritable Bowel 
Syndrome (IBD)-like symptoms, RNA expression profiles and cytokine levels in the 
plasma and peripheral blood mononuclear cells (PMBC’s).
For an extensive description of the assessments instruments, see the Methods sections 
of Chapter 3-7.
Aims and outline of this thesis
The focus of the present PhD thesis is twofold: 1) investigating anxiety and depres-
sion in youth with IBD and 2) evaluating the effectiveness of a disease-specific CBT 
Baseline	screening
Baseline	screening
Subclinical
anxiety	/	depression
Subclinical
anxiety	/	depression
Random
ization
T0 Clinical	
anxiety	/	
depression
Clinical	
anxiety	/	
depression
N
o
anxiety	/	
depression
N
o
anxiety	/	
depression
CAU	+	CBT
CAU
Referral	to	
mental	health	
care
End	of	study
T1
3	months 3	months 6 months
T2 T3
figure 1 | Study design of HAPPY-IBD
Abbreviations: CAU= care-as-usual; CBT= cognitive behavioral therapy
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compared to care-as-usual in improving anxiety and/or depressive symptoms, HRQOL 
and other psychological outcomes in these patients. This study is the first RCT study-
ing the effectiveness of a disease-specific CBT protocol (PASCET-PI) on both anxiety 
and depression. Moreover, we will also examine other psychological and medical 
outcomes, using internationally validated questionnaires and a psychiatric interview.
Chapter 2 contains a systematic review and meta-analysis on the prevalence of 
anxiety and depression in children and adolescents with IBD. Multiple studies have 
examined psychological problems in pediatric IBD. However, it is still not clear to 
what extent children and adolescents with IBD experience subclinical anxiety and/
or depressive symptoms and clinical anxiety and/or depressive disorders. We summa-
rized all available data to provide insight into prevalence rates of anxiety and depres-
sive symptoms and disorders in children and adolescents with IBD. Mikocka-Walus et 
al. [71] wrote an editorial to this chapter. The editorial and our response [72] can be 
found in Appendix A.
Chapter 3 is the description of the study protocol of the RCT, testing the effec-
tiveness of the disease-specific CBT, including information on this intervention, the 
control condition, the assessment instruments and timing.
Chapter 4 and 5 describe the baseline data of our RCT, derived from the screen-
ing phase of the study (part 1). The total group of patients consisted of all patients 
included in the baseline screening preceding the RCT: 1) those without any anxiety 
and/or depression, 2) those with subclinical anxiety and/or depression, and 3) those 
with clinical anxiety and/or depression.
In Chapter 4, we examined which medical variables were associated with the pres-
ence of anxiety and/or depressive symptoms, and whether these associations were 
different for different levels of anxiety/depression (none, subclinical, clinical) or were 
different for patients aged 10-17 years versus patients aged 18-25 years.
In Chapter 5, the results are presented of a study that investigated whether several 
psychological variables (illness perceptions, coping, anxiety, and depression) were 
associated to HRQOL after controlling for several demographic and medical variables.
Chapter 6 presents the short-term results of the RCT, the pre-post treatment ef-
fects of the disease-specific CBT (i.e. directly after the treatment or 3 months after 
the baseline screening) on anxiety and depressive symptoms, as well as on HRQOL, 
compared to CAU.
In Chapter 7 we describe the longer-term effects of the disease-specific CBT on 
several psychological outcomes at the long-term follow-up, at 6 and 12 months after 
then baseline screening.
Finally, Chapter 8 provides an overview of all the previous chapters, an overall 
discussion of the findings, as well as directions for future research and clinical impli-
cations.
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SummArY
Background The co-existence of psychological problems and paediatric inflamma-
tory bowel disease (IBD) is receiving increasing attention in literature. Most studies 
investigated anxiety and depression, with prevalence rates varying greatly from 0% 
to 50%. A systematic review is necessary to provide clear insight in the prevalence of 
anxiety and depression in paediatric IBD.
Aim To systematically evaluate available data on the prevalence of anxiety and de-
pressive symptoms and disorders in paediatric IBD (aged 6-18 year).
methods Comprehensive searches were performed in Embase, Medline Ovid, Web 
of Science, Cochrane, PubMed, PsychInfo Ovid, Google scholar for studies published 
from 1994 to 2017. Pooled prevalence rates were calculated using inverse variance 
heterogeneity models. Meta-regression was used to study if disease type, disease activ-
ity and gender influence prevalence.
results 28 studies (N= 8107, mean age: 14.3) were identified. Pooled prevalence esti-
mates were 16.4% (95% Confidence Interval [CI] 6.8-27.3%) for anxiety symptoms and 
4.2% (95%CI 3.6-4.8%) for anxiety disorders. Pooled prevalence estimates were 15.0% 
(95%CI 6.4-24.8%) for depressive symptoms and 3.4% (95%CI 0-9.3%) for depressive 
disorders. Meta-regression showed no influence of disease type and gender on these 
prevalence rates, but studies with a higher percentage of active disease had a higher 
rate of depressive symptoms.
conclusion The described pooled prevalence of anxiety and depressive symptoms is 
lower than in adult IBD. However, due to varying instruments/cutoffs for measuring 
symptoms and few studies investigating disorders, the results should be interpreted 
with caution. Cross-cultural use of the same instruments is needed to gain better 
insight into prevalence rates.
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IntroDuctIon
Inflammatory bowel disease (IBD; Crohn’s disease [CD] and ulcerative colitis [UC]) is a 
chronic relapsing inflammatory disorder of the intestine, with increasing incidence 
and prevalence worldwide [1]. Patients may have abdominal pain, (bloody) diarrhoea, 
often accompanied by systemic symptoms such as lack of appetite, weight loss and 
fatigue. IBD has an unpredictable and fluctuating disease course, with relapses and pe-
riods of clinical remission. In up to 25% percent of patients, IBD manifests during late 
childhood and adolescence [2]. Adolescence is already challenging, due to significant 
psychological, physical and social changes. Having IBD during adolescence can pose 
a real threat to a healthy psychosocial development. Studies indicate that paediatric 
IBD patients are at risk for several psychosocial and psychological problems [3, 4]. 
Most studies focussed on anxiety and/or depressive symptoms, and reported greatly 
varying prevalence rates, from 2-50% [5, 6] for anxiety symptoms and 0-33% [7, 8] 
for depressive symptoms. Only a few studies investigated prevalence of anxiety and 
depressive disorders, which ranged respectively from 3-7% [9, 10] and 1-17% [10, 11] .
In mental health care, a distinction is made between anxiety/depressive symptoms 
and anxiety/depressive disorders for several reasons. First, patients with a clinical 
disorder have severe symptoms that cause significant impairment in their daily life. 
Patients with elevated symptoms (who do not meet all criteria of a clinical disorder) 
do suffer from these milder symptoms, but do not experience such a significant im-
pairment in their daily life. Second, disorders comprise a combination of symptoms, 
and are diagnosed using the criteria of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) in a psychiatric interview. On the other hand, symptoms are often 
measured using a questionnaire.
The bidirectional relationship between IBD and psychological problems has been 
previously described and can be explained in terms of the ‘brain-gut’-axis. This axis 
describes that the presence of intestinal inflammation might negatively influence 
mood and vice versa: anxiety and/or depression may increase intestinal inflammation 
and may trigger a relapse of IBD [12-15]. While many individual studies looked at the 
prevalence of anxiety and/or depressive symptoms and disorders in paediatric IBD 
patients, no comprehensive systematic review or meta-analysis has been conducted.
Unfortunately, the few published reviews on psychological outcomes in paediatric 
IBD either differed in scope (e.g. did not focus specifically on prevalence rates of anxiety 
and/or depression) or had several shortcomings. Some reviews only included older stud-
ies published in the previous decade [4, 16], whereas others only included studies with 
a control group [4] or included a small portion of the available paediatric studies [17]. A 
review by Brooks et al. discussed the impact of psychological morbidity in paediatric IBD 
(including anxiety and depression, but not their prevalence rates) [18]. Greenley et al. [4] 
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studied psychosocial adjustment (including anxiety and depression) of adolescents with 
IBD, but only included studies published before 2007, which used a comparison group or 
normative data (thus excluding cross-sectional or cohort studies without a comparison 
group). The authors reported that adolescents with IBD had higher rates of depressive 
disorders than those with other chronic conditions. However, their prevalence rates of 
anxiety and depressive symptoms, and anxiety disorders were not significantly different 
from healthy adolescents or those with other chronic diseases [4]. A third, nearly a de-
cade old review by Ross et al. [16], included studies till 2009, investigating psychosocial 
functioning and quality of life. They found an increased incidence of anxiety and depres-
sive disorders, varying from 25-73%, in adolescents with IBD [16]. A fourth systematic 
review included studies published between 2005 and 2014, but studied comorbidity of 
anxiety and depression in both paediatric and adult IBD, and included only a limited 
number of the available paediatric studies [17]. Considering the previous reviews, there 
is a clear need to perform a systematic review with meta-analysis to provide prevalence 
rates on anxiety and depression in paediatric IBD, including all available studies.
The current systematic review and meta-analysis aims to systematically assess the 
prevalence rates of anxiety and depressive symptoms and disorders specifically in 
paediatric IBD, using all studies published between 1994 and 2017 (aim 1). In addition, 
we aimed to investigate whether disease type, disease activity, or gender influence 
these prevalence rates (aim 2). It is important to gain more clear insight into the 
overall prevalence and risk factors of anxiety and depression in paediatric IBD, in 
order to increase awareness, facilitate early detection of anxiety and depression, and, 
if necessary, early psychological treatment.
mAterIAlS AnD metHoDS
This systematic review and meta-analysis was performed following the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-guidelines [19].
eligibility criteria
Inclusion criteria were studies concerning a) patients 6-18 years of age (or studies with 
sub analyses on this age group), b) with IBD, diagnosed according to the current inter-
national guidelines, c) examining either anxiety and/or depressive symptoms (using 
validated screening instruments with at least child self-report data) or anxiety and/or 
depressive disorders (using a structured psychiatric interview or ICD codes). We chose 
to include any study design that measured prevalence for anxiety and depression in 
a paediatric IBD cohort. For studies measuring anxiety and/or depression at various 
time points, data of only the first assessment was used.
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Exclusion criteria were studies a) published in non-English languages, b) published 
before 1994 (studies using DSM-IV, introduced in 1994, or higher), c) using instru-
ments with no separate anxiety or depression scale (e.g. the Internalizing scale or 
syndrome scale Anxious/Depressed of the Child Behaviour Checklist), d) with a patient 
cohort already partly described in another included study (no unique cohort), e) that 
described case reports, case series, qualitative studies, dissertations, or review papers 
and conference abstracts without published full article.
Information sources and search
An expert research librarian conducted a comprehensive literature search using 
Pubmed, Embase, MEDLINE Ovid, Web of Science, Cochrane, PsychINFO Ovid and 
Google Scholar in December 2017. For Inflammatory Bowel Disease, search terms 
included Crohn’s Disease and ulcerative colitis. For anxiety and depression, search 
terms included both symptoms and disorders, and fear and panic as well as the most 
common treatments for these problems (cognitive behavioural therapy and antide-
pressants), to find intervention trials for their baseline data. The search strategies 
used for each database are provided in Appendix 1.
Study selection
Studies meeting inclusion criteria were eligible. In step 1, two investigators (LS and 
GB) independently screened titles and abstracts of eligible studies. Any disagreement 
was resolved by consensus or a third reviewer. In step 2 abstracts and if necessary 
full texts of selected articles were checked globally for the in-/exclusion criteria (i.e. 
whether a full text was available, if a valid instrument was used, and if the study 
concerned paediatric patients).
In step 3 full texts of the remaining articles were reviewed thoroughly (by LS/GB). All 
reference lists were inspected for additional studies. Figure 1 displays the reasons for 
excluding articles. Reference management was done using EndNote X7.
Data collection process & Data items
Two independent investigators, using a data extraction from, extracted the following 
data for each included study: year of publication, study design (e.g. control group pres-
ent or absent), patient setting (in- or outpatient), country, number of included patients, 
patient demographics (age, gender), disease characteristics (disease type [CD vs UC], 
disease activity [active or remission]), measurement method of anxiety and/or depres-
sion (questionnaire and/or psychiatric interview) and prevalence rates of anxiety and 
depressive symptoms and disorders. If prevalence rates for symptoms and disorders 
were not reported the manuscript, they were calculated using the cutoff for elevated 
symptoms reported by the authors. Disagreement regarding extracted data was re-
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solved by consensus. Original authors were contacted if the data provided in the paper 
was insufficient to extract a prevalence rate. Authors were also contacted if it was 
suspected that several articles reported about the same or overlapping patient cohorts. 
If that was the case, only the article with the most complete data was included in this 
review. After three attempts to contact authors without success, articles were excluded.
Quality and risk of bias
The quality and risk of bias of the individual studies was assessed, using a checklist de-
veloped by the research team a priori and specifically for this study. The checklist, with 
a maximum score of 27, was based on the recommendations of Sanderson et al. [20], 
the NIH Quality Assessment for Observational Cohort and Cross-sectional studies [21, 
22] and previously published checklists [17, 23]. Included studies were rated on their 
method (definition of aim/primary outcomes), recruitment, sample size, whether or 
not they included a control group, instruments used (psychological and medical), and if 
confounders were taken into account (see Appendix 2 for the complete checklist). The 
checklist was piloted using a subsample of studies with minor adjustments afterwards.
Data synthesis and statistical analyses
Extracted prevalence rates were pooled using inverse variance heterogeneity models 
(including a double arcsine transformation), that handle between study heterogeneity 
better than the widely used random effects model [24]. Heterogeneity was assessed 
using the I2 statistic, with values ≥75% indicating considerable heterogeneity [25]. 
Reporting bias across studies (e.g. publication bias) was examined visually using 
“funnel plots” and the more sensitive “Doi plots” and formally using the Luis Furuya-
Kanamori (LFK) index [26-29], to see if the prevalence rates changed with increasing 
sample size. In the funnel plots and Doi plots a higher prevalence is displayed by 
a higher “Double Arcsin Prevalence”, and a higher standard error indicates a lower 
sample size. To evaluate whether disease type, disease activity or gender influence the 
prevalence of anxiety and/or depressive symptoms or disorders (aim 2), we repeated 
the meta-analyses and included disease type (% CD), disease activity (% active disease) 
or gender (% male) as covariates in three separate weighted meta-regression analyses. 
Only studies that reported on these covariates were include in these meta-regression 
analyses. Sensitivity analyses were performed by excluding studies in the lowest 
tertile of the reported ‘quality/risk of bias score’ (i.e. with a score of 10 or lower) and 
removing the largest study for each separate analysis. Additional sensitivity analyses 
were performed using the random effects model, to provide the opportunity to com-
pare the results with the inverse variance heterogeneity models. All analysis were 
performed using MetaXL version 5.3 [28] and STATA version 15.0 (Stata corp, College 
station, TX).
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reSultS
Study selection
During the database search 2020 records were found, 4 additional studies were 
identified through other sources (i.e. reference lists of included records). 495 out 
of 2024 records were removed as duplicates. Of 1529 records the title and abstract 
was screened, 1344 records did not meet inclusion criteria (step 1). In this first step 
agreement between the investigators was 87.2%. In step 2, 185 articles were glob-
ally screened on the inclusion and exclusion criteria, of which 122 were excluded in 
this step, leaving 63 full-articles to be assessed (step 3). Of these 63 articles, 27 were 
excluded because they reported on a patient cohort that was already included, for 
8 prevalence data were not available after request. The remaining 28 articles were 
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figure 1 | PRISMA flow diagram
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included in the meta-analysis. For 13 of the 28 articles, prevalence rates were provided 
after request form the original authors. See Figure 1.
Study characteristics
A total of 8107 participants were included in the analyses (of which 2 studies provided 
more than half ), 51.3% was male. One study included only female patients [7]. The 
number of participants per study ranged from 21 to 2733, which a median sample 
size of 85. Two studies were relatively large with n = 2144 [9] and n = 2733 [11]. Mean 
age was 14.3 (based on 25 studies that reported a mean age). Three studies included 
only patients with CD [6, 9, 30]. In the remaining studies that reported disease type, 
67.1% had CD. In total, 9 out of 28 studies used a control group. Three studies included 
healthy adolescents, the other 6 included patients with other chronic diseases (e.g. 
Cystic fibrosis, Diabetes, Juvenile Idiopathic Arthritis) [5, 9, 31-37]. With respect to 
geography, 20 studies were from the United States of America, 7 studies were from 
Europa [10, 32, 35, 36, 38-40], and 1 study from Asia [34]. See Table 1 for an overview 
of the study characteristics.
Finally, in 23 out of 28 studies, clinical disease activity was measured for CD, with 
the following indices: Paediatric Crohn’s Disease Activity Index (PCDAI) [5, 10, 31, 35, 
37, 38, 40-44], short-PCDAI [45], abbreviated PCDAI [44, 46], Harvey Bradshaw Index 
[6, 47], Physician Global Assessment (PGA) [32, 37, 44, 48, 49], (part of) Children’s 
Somatisation Inventory [8], IBD-symptom questionnaire [33], and Short-Crohn’s Dis-
ease Activity Index [30, 50]. 25 studies included UC patients and in 21 disease activity 
was measured using the following indices; Paediatric Ulcerative Colitis Activity Index 
(PUCAI) [10, 35-38, 40, 42, 44, 46, 47, 50], Physician Global Assessment (PGA) [31, 32, 
37, 44, 48, 49], (part of) Children’s Somatisation Inventory [8], IBD-symptom question-
naire [33], Clinical score of Kozarek [41, 43], Lichtiger Colitis Activity index [45], and 
PCDAI [5]. Of the 17 studies that reported percentage active disease, 35.9% of patients 
had active disease and 64.1% was in remission.
Study Quality/risk of bias
Mean score on our checklist was 12.64 (reported range 8-17) with a standard deviation 
of 2.34. Especially on the items regarding using a control group, sample size, and 
taking into account confounders, many studies scored 0 or 1 point(s).
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Prevalence of anxiety symptoms
Ten studies [5, 6, 8, 30, 35, 39, 44, 47, 49, 50], including 1155 participants, reported on 
the prevalence of anxiety symptoms, using seven different instruments. The pooled 
estimate of prevalence of anxiety symptoms was 16.4% (95% Confidence Interval [CI] 
6.8-27.3%) with a high level of heterogeneity between estimates (I2 = 92.9%, p < .001). 
See also Figure 2a. Although visual inspection of the funnel plot indicates some asym-
metry (see Appendix 3, few studies present with a lower prevalence and a relatively 
high standard error), the LFK index revealed no significant asymmetry (LFK index: 
0.96). This indicates that heterogeneity in outcomes between studies may not be due 
to publication or reporting bias, but to other factors.
Meta-regression analyses showed that disease type (% CD, ß = .004, p = .699) and 
gender (% male, ß = .027, p = .506) did not explain the heterogeneity in outcomes. The 
meta-regression analysis for disease activity could not be performed due to lack of 
data (only 5 out of 10 studies reported % active disease).
To check whether prevalence rates would change if we removed the 5 studies with a 
score in the lowest tertile of reported quality/risk of bias (15.5% [95%CI 2.6-31.5%], I2 = 
95.6%) or removed the largest study with 280 participants (20.2% [95%CI 9.5-32.3%], I2 = 
91.1%) we reran our analyses. Results did not change significantly, and heterogeneity 
in outcomes was still high. The random effects analysis provided a prevalence rate of 
18.1% (95%CI 10.1-27.8%).
Prevalence of anxiety disorders
Only three studies [9-11] reported on the prevalence of anxiety disorders, with a total 
of 4924 participants (respectively n=2144 [9], n=47 [10], n=2733 [11]). The pooled 
estimate of prevalence of anxiety disorders was 4.2% (95%CI 3.6-4.8%). See also Figure 
2b. The heterogeneity was low and not significant (I2 = 2.1%, p = .346). The number 
of included studies was too low to investigate reporting bias, meta-regression or to 
perform sensitivity analyses. The random effects analysis provided a prevalence rate 
of 4.2% (95%CI 3.6-4.8%).
Prevalence of depressive symptoms
Twenty-two studies [5, 7, 8, 30-38, 40-46, 48-50] reported on depressive symptoms 
(including 2911 participants), using 9 different instruments, including 3 versions of 
the Child Depression Inventory (CDI). The pooled estimate of prevalence of depressive 
symptoms was 15.0% (95%CI 6.4-24.8%), with a high level of heterogeneity (I2 = 95.0%, 
p < .001). See also Figure 2c.
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The funnel plot and Doi plot showed significant asymmetry (LFK index: -2.80) (see 
Appendix 3). Visual inspection of the funnel plot indicates that there is a lack of studies 
with a low prevalence rate with a relatively high standard error. Hence, heterogeneity 
between studies may be due to publication or reporting bias. Meta-regression analyses 
showed that disease type (% CD, ß = -.009, p = .125) and gender (% male, ß = -.003, p = 
.748) did not explain the heterogeneity in prevalence rates of depressive symptoms 
between studies.
Disease activity (% active disease) showed a significant effect on the prevalence 
of depressive symptoms (ß = .021, p < .05), indicating that in studies with a higher 
percentage of active disease the prevalence rate of depressive symptoms was higher. 
Removing the 6 studies with a score in the lowest tertile of reported quality/risk of 
bias (15.5% [95%CI 5.3-27.2%], I2 = 95.6%) or removing the largest study with 765 partici-
pants (10.2% [95%CI 4.9-16.2%], I2 = 91.8%) did not significantly change the prevalence 
rate for depressive symptoms, heterogeneity was still high. In addition, excluding the 
study with only female patients [7] did not change the results. The random effects 
analysis provided a prevalence rate of 12% (95%CI 6.9-18.2%).
Prevalence of depressive disorders
Four studies [9-11, 42] reported on the prevalence of depressive disorders, with a total 
of 5689 participants (respectively, n=2144 [9] , n=47 [10], n=2733 [11], n=765 [42]). The 
pooled estimate of prevalence of depressive disorders was 3.4% (95%CI 0-9.3%), with 
a high level of heterogeneity (I2 = 98.3, p < .001). See also Figure 2d. The number 
of included studies was too low to investigate reporting bias, meta-regression or to 
perform sensitivity analyses. The random effects analysis provided a prevalence rate 
of 6.2% (95%CI 1.6-13.1%).
DIScuSSIon
This first systematic review and meta-analysis examining the prevalence of anxiety 
and depression in paediatric IBD showed that the estimated prevalence rate was 16.4% 
for anxiety symptoms (based on 10 studies), 4.2% for anxiety disorders (based on 3 
studies), 15.0% for depressive symptoms (based on 22 studied) and 3.4% for depressive 
disorders (based on 4 studies). Differences between the prevalence rates calculated 
using the two different methods were small.
Our findings show higher prevalence rates of anxiety and depressive symptoms 
compared to a community sample of Dutch adolescents [51], but a lower prevalence 
of depressive symptoms compared to a community sample in the United States. The 
prevalence rate of anxiety symptoms was comparable [52]. Furthermore, our meta-
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analysis shows that the prevalence of anxiety /depressive symptoms is lower in pae-
diatric IBD, compared to available meta-analyses in other paediatric patient groups, 
such as diabetes and asthma (range 27-33%) [53, 54]. The same trend has been shown 
in adult IBD; a higher prevalence of anxiety/depression, compared to the general 
population/ healthy controls, but a lower prevalence compared to patients with an-
other chronic disease [17]. In addition, prevalence rates are also lower than reported 
in adult IBD. Neuendorf et al. showed a pooled prevalence rate of 35.1% for anxiety 
symptoms (based on 51 studies), 20.7% for anxiety disorders (based on 4 studies), 21.6% 
for depressive symptoms (based on 67 studies), and 15.2% for depressive disorders 
(based on 5 studies) [55]. There are several possible explanations for the differences in 
prevalence rates between children and adults. The prevalence rates of anxiety and de-
pressive symptoms are found to be higher in adults than in children and adolescents 
[56, 57], and for some anxiety disorders and for depressive disorders it has been found 
that their prevalence increases with age [58, 59]. Furthermore, with longer disease 
duration of IBD, disease related complications due to irreversible bowel damage will 
occur, thus increasing the burden of disease. Finally, the increasing responsibilities in 
adulthood, and the detrimental influence of IBD on relationships and work, impact 
daily life even more than in childhood. However, one has to bear in mind that compar-
ing pooled prevalence rates to each other is difficult, considering the great variation 
in the used instruments and cutoffs. A similarity between adult and paediatric studies 
is, that compared to studies investigating anxiety and depressive symptoms, studies 
investigating anxiety/depressive disorders are underrepresented.
In our meta-analysis, we did not find an influence of disease type on prevalence 
rates of anxiety symptoms, anxiety disorders and depressive disorders. In contrast, 
in adult IBD, an influence of disease type was found, with a higher prevalence rate of 
depressive symptoms in CD patients than in UC patients [55]. Methodological differ-
ences might explain these contrasting findings: we could only study disease type as 
a proportion (e.g. % CD of the total sample), whereas Neuendorf et al. could statisti-
cally compare the prevalence in patients with CD versus UC. Unfortunately, it was 
not possible to assess the influence of disease activity on anxiety symptoms, whereas 
this has been shown to significantly influence prevalence in adult IBD [55]. Disease 
activity did significantly influence the prevalence rate of depressive symptoms: a 
higher prevalence was found in studies with more patients with active disease. These 
findings are in accordance with earlier findings in adult IBD [17, 55]. Future studies 
should investigate whether patients with higher disease activity (e.g. moderate or 
severe) also have a higher prevalence of anxiety/depression compared to the patients 
with mild disease activity.
Gender did not affect prevalence rates in our study, results of earlier studies showed 
mixed findings [9, 18]. To what extent factors such as socio-economic status, use of cor-
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ticosteroids, disease duration, age of diagnosis, or presence of perianal disease impact 
the prevalence of anxiety and depression in paediatric IBD, should be investigated in 
future studies [18].
Several methodological differences of the 28 included studies, give rise to heteroge-
neity and make us cautious in drawing firm conclusions. Firstly, although all studies 
used validated instruments to assess anxiety or depressive symptoms, numerous dif-
ferent instruments were used, not all validated in paediatric IBD. Different cutoffs for 
the same instruments were used, and some used raw total scores, while others used 
(varying) T-scores. For example, for the CDI, cutoff scores ranged from 9 [42] to 19 [38] 
or 20 [35] and for the SCARED, cutoff scores ranged from 20 [6, 47] to 25 [8] (see also 
Table 1). For future cross-cultural comparison of studies, we recommend to use the 
same, comparable cutoffs for each instrument. In addition, only 4 studies investigated 
anxiety/depressive disorders [9-11, 42], and used two different methods (DSM based 
psychiatric interview versus ICD codes). These different methods, added to the low 
number of included studies increased heterogeneity and may limit the reliability of 
the results. More studies investigating anxiety and depressive disorders are warranted 
to evaluate if they are prevalent in paediatric IBD.
Secondly, cross-cultural generalisability of the results is limited, considering that 
most studies came from North America (71%), only a few came from Europe (25%), and 
only one came from Asia (4%). Thirdly, 23 studies measured clinical disease activity, 
but for some studies the suitability of the measures of disease activity is debatable. 
Two studies used non- validated indices for paediatric IBD (i.e. the children’s somatisa-
tion index [8] and the “IBD symptom questionnaire” [33]), and others used (“adult”) 
IBD disease activity indexes, also not validated in paediatric IBD [6, 30, 41, 43, 45, 47, 
50]. None of the included studies reported on mucosal disease activity, 5 measured the 
inflammatory marker C-reactive protein (CRP) [32, 38, 42, 44, 46] and 2 measured fae-
cal calprotectin [32, 44], but none related this to the presence of anxiety or depression.
Fourthly, no study presented prevalence rates separately for IBD subtypes, disease 
activity (active vs remission) and gender. Therefore, if available, these characteristics 
could only be incorporated in the meta-regression analysis as covariates (as percent-
ages, e.g. % CD). Presenting data separately for these and other subgroups (e.g. patients 
that had received bowel surgery or perianal disease) would facilitate the use of meta-
analytic approaches in the future and help understand if certain subgroups are more 
at risk for anxiety and/or depression than others.
Finally, 2 studies provided more than half of the included patients, 19/28 (68%) 
studies were small (N<150), only 9 out of 28 (32%) studies had a control group and 
mean study quality was moderate. Larger studies, preferably cohort studies with a 
control group which control for confounders are warranted to increase the quality of 
research.
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The strengths of our study include a systematic search to include all studies examin-
ing the prevalence of anxiety and depression in paediatric IBD. In addition, providing 
separate analysis for anxiety/depressive symptoms versus disorders is important and 
insightful. Furthermore, the meta-regression approach strengthens our analyses. 
Finally, we performed the meta-analyses with both the inverse variance heterogeneity 
and the random effects model.
Inevitably, this work has some limitations. First, inclusion was limited to English 
published papers. Second, conference abstracts without a full published article had 
to be excluded. This may have introduced bias. Third, the heterogeneity between 
the included studies forces us to be careful drawing conclusions. However, we feel 
performing a meta-analysis (instead of only presenting the data as systematic review) 
was useful for several reasons. Firstly, knowing about this high heterogeneity is very 
important. Secondly, we tried to explore with our meta-regression analyses if cer-
tain factors could explain the high heterogeneity and showed that, in patients with 
depressive symptoms, this was partly explained by disease activity. Future studies 
would benefit from a study design which allows for subgroup-analyses to investigate 
heterogeneity.
Recommendations for future studies to limit this heterogeneity and improve qual-
ity of research are extensively described by Mikocka-Walus and colleagues [17] and 
include using the same validated screening measures and clinical diagnostic measures 
(psychiatric interview) with the same comparable cutoffs, including comparison 
groups (healthy and other chronically ill controls), control for confounders (psychi-
atric history), measuring IBD outcomes, present data separately for IBD subtypes and 
for disease activity categories. At last, the results of the analyses concerning reporting 
bias show that publication and reporting bias cannot be ruled out.
In conclusion, this systematic review and meta-analysis indicates that symptoms 
of anxiety and depression are prevalent in paediatric IBD, with comparable pooled 
prevalence rates of anxiety symptoms and depressive symptoms (16.4% and 15.0%). 
Due to high heterogeneity in used instruments and cutoffs, results must be inter-
preted with caution. To gain better insight into the prevalence of anxiety and depres-
sive symptoms it is necessary to systematically screen paediatric IBD patients with 
the same validated instruments, using the same cutoffs. More studies are necessary 
to determine the prevalence of anxiety/depressive disorders using a standardized 
psychiatric interview following DSM criteria. In order to assess whether certain sub-
groups are more at risk than others, it is advised to use the same validated methods of 
assessing clinical disease activity, and to include objective inflammatory parameters 
(such as CRP, faecal calprotectin).
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APPenDIceS
Appendix 1. Search strategies for all databases
embase.com
(‘inflammatory bowel disease’/exp OR ((inflamma* NEAR/3 bowel* NEAR/3 disease*) 
OR ibd OR crohn* OR (ulcer* NEAR/3 (colit* OR colorectit*)) OR Ileocolit* OR (Terminal* 
NEAR/3 Ileitis)):ab,ti) AND (‘anxiety’/de OR ‘anxiety disorder’/exp OR ‘fear’/de OR 
‘depression’/exp OR ‘antidepressant agent’/de OR ‘cognitive therapy’/de OR ‘emotion’/
de OR (anxi* OR fear* OR depressi* OR panic* OR (cogniti* NEAR/3 therap*) OR emo-
tion* OR antidepress*):ab,ti) AND (child/exp OR adolescent/exp OR ‘young adult’/de OR 
adolescence/exp OR ‘child behavior’/de OR ‘child parent relation’/de OR pediatrics/exp 
OR childhood/exp OR ‘child development’/de OR ‘child growth’/de OR ‘child health’/
de OR ‘child health care’/exp OR ‘child care’/exp OR ‘childhood disease’/exp OR ‘child 
psychiatry’/de OR ‘child psychology’/de OR ‘pediatric ward’/de OR ‘pediatric hospital’/
de OR (adolescen* OR infan* OR child* OR kid OR kids OR teen* OR boy* OR girl* OR 
minors OR underag* OR (under NEXT/1 (age* OR aging)) OR juvenil* OR youth* OR 
kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR 
paediatric* OR school* OR preschool* OR highschool* OR ((young OR early*) NEAR/3 
(adult* OR women OR men OR woman OR man))):ab,ti)
medline ovid
(exp “Inflammatory Bowel Diseases”/ OR ((inflamma* ADJ3 bowel* ADJ3 disease*) OR 
ibd OR crohn* OR (ulcer* ADJ3 (colit* OR colorectit*)) OR Ileocolit* OR (Terminal* ADJ3 
Ileitis)).ab,ti.) AND (exp “anxiety”/ OR exp “Anxiety Disorders”/ OR “fear”/ OR “depres-
sion”/ OR “Depressive Disorder”/ OR “Depressive Disorder, Major”/ OR “Antidepressive 
Agents”/ OR “Cognitive Therapy”/ OR “emotions”/ OR (anxi* OR fear* OR depressi* OR 
panic* OR (cogniti* ADJ3 therap*) OR emotion* OR antidepress*).ab,ti.) AND (exp Child/ 
OR exp Infant/ OR exp Adolescent/ OR exp “Child Behavior”/ OR exp “Parent Child 
Relations”/ OR exp “Pediatrics”/ OR exp “Child Welfare”/ OR “Child Development”/ OR 
exp “Child Health Services”/ OR exp “Child Care”/ OR “Child Psychiatry”/ OR “Psychol-
ogy, Child”/ OR “Hospitals, Pediatric”/ OR (adolescen* OR infan* OR child* OR kid OR 
kids OR teen* OR boy* OR girl* OR minors OR underag* OR (under ADJ age*) OR juvenil* 
OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* 
OR pediatric* OR paediatric* OR school* OR preschool* OR highschool* OR ((young OR 
early*) ADJ3 (adult* OR women OR men OR woman OR man))).ab,ti.)
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Psycinfo ovid
(((inflamma* ADJ3 bowel* ADJ3 disease*) OR ibd OR crohn* OR (ulcer* ADJ3 (colit* OR 
colorectit*)) OR Ileocolit* OR (Terminal* ADJ3 Ileitis)).ab,ti.) AND (exp “depression”/ 
OR exp “Anxiety Disorders”/ OR “fear”/ OR “Depression (Emotion)”/ OR “Major De-
pression”/ OR “Antidepressant Drugs”/ OR “Cognitive Therapy”/ OR “emotions”/ OR 
(anxi* OR fear* OR depressi* OR panic* OR (cogniti* ADJ3 therap*) OR emotion* OR 
antidepress*).ab,ti.) AND (100.ag. OR (adolescen* OR infan* OR child* OR kid OR kids 
OR teen* OR boy* OR girl* OR minors OR underag* OR (under ADJ age*) OR juvenil* 
OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* 
OR pediatric* OR paediatric* OR school* OR preschool* OR highschool* OR ((young OR 
early*) ADJ3 (adult* OR women OR men OR woman OR man))).ab,ti.)
cochrane
(((inflamma* NEAR/3 bowel* NEAR/3 disease*) OR ibd OR crohn* OR (ulcer* NEAR/3 
(colit* OR colorectit*)) OR Ileocolit* OR (Terminal* NEAR/3 Ileitis)):ab,ti) AND ((anxi* 
OR fear* OR depressi* OR panic* OR (cogniti* NEAR/3 therap*) OR emotion* OR 
antidepress*):ab,ti) AND ((adolescen* OR infan* OR child* OR kid OR kids OR teen* OR 
boy* OR girl* OR minors OR underag* OR (under NEXT/1 (age* OR aging)) OR juvenil* 
OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* 
OR pediatric* OR paediatric* OR school* OR preschool* OR highschool* OR ((young OR 
early*) NEAR/3 (adult* OR women OR men OR woman OR man))):ab,ti)
Web of science
TS=((((inflamma* NEAR/2 bowel* NEAR/2 disease*) OR ibd OR crohn* OR (ulcer* NEAR/2 
(colit* OR colorectit*)) OR Ileocolit* OR (Terminal* NEAR/2 Ileitis))) AND ((anxi* OR fear* 
OR depressi* OR panic* OR (cogniti* NEAR/2 therap*) OR emotion* OR antidepress*)) 
AND ((adolescen* OR infan* OR child* OR kid OR kids OR teen* OR boy* OR girl* OR 
minors OR underag* OR (under NEAR/1 (age* OR aging)) OR juvenil* OR youth* OR 
kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR 
paediatric* OR school* OR preschool* OR highschool* OR ((young OR early*) NEAR/2 
(adult* OR women OR men OR woman OR man)))) )
Google scholar
“inflammatory bowel disease”|crohn|”ulcerative colitis” anxiety|fear|depression|dep
ressive|emotion|antidepressants adolescents|adolescence|infants|children|”young|ear
ly adulthood|adults|women|men”
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Appendix 2. Quality/risk of bias checklist
Method
(max. 2 points)
Clearly stated aim/research question (yes = 1 point)
Clearly stated outcome(s) (yes = 1 point)
Recruitment
(Max. 9 points)
Clearly defined in- and exclusion criteria (yes = 1 point)
Convenience sample (0 points) vs. systematic sampling (consecutive, random, 
registries: 1 point)
Response rate reported (Not reported = 0, less < 50% = 1 point, 50-75% = 2 points, 
> 75% = 3 points)
Reasons for non-participation described (yes =1 point)
External validity (monocenter = 0 points, multicenter = 1 point, multicenter and 
mixed [tertiary AND community hospitals] = 2 points)
Study population clearly described? (e.g. age, ethnicity, gender) (yes = 1 point)
Control group?
(Max. 3 points)
Normative data (with ref. and correct language/country; 3 points)
Normative data (with ref. but other language/country; 2 point)
Normative data (otherwise; e.g. not specified, no ref, etc.; 1 point)
OR
Both healthy controls and chronically ill controls (3 points)
Healthy controls (2 points)
Other chronically ill controls (1 point)
Sample Size IBD 
patients
(Max. 4 points)
Interpretation (low <150 = 1 points – medium 150-250 = 2 point – high >250 = 3 
points)1
Power calculation or justification of sample size (yes = 1 point)
Measures IBD 
activity (max. 3 
points)
Disease activity index (e.g. PCDAI/PUCAI/PGA) (1 point)
Inflammatory parameters (CRP, ESR, calprotectin) (1 point)
Endoscopy with severity scoring (1 point)
Measures of 
anxiety and 
depression
(Max. 3 points)
Screening performed with validated self-report scales (1 point)
Diagnostic interview / DSM or ICD 10 codes (1 point)
Additional parent- or caregiver-report (1 point)
Confounders
(Max. 3 points)
‘Taken into account with regard to anxiety/depression prevalence’
Disease activity taken into account (1 point)
IBD subtype taken into account (1 point)
Objectified prior psychiatric history taken into account (1 point)
maximum score: 27
1Based on Arya et al. 2012 – Sample Size Estimation in Prevalence Studies
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Appendix 3. funnel and Doi plots for anxiety and depressive symptoms
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ABStrAct
Introduction Adolescents with inflammatory bowel disease (IBD) show a higher 
prevalence of depression and anxiety, compared to youth with other chronic diseases. 
The inflammation-depression hypothesis might explain this association and implies 
that treating depression can decrease intestinal inflammation and improve disease 
course. The present multicenter randomized controlled trial (RCT) aims to test the 
effectiveness of an IBD-specific Cognitive Behavioral Therapy protocol in reducing 
symptoms of subclinical depression ànd anxiety, while improving quality of life (QoL) 
and disease course in adolescents with IBD.
methods and analysis Adolescents with IBD (10-20 years) from seven hospitals under-
go screening (online questionnaires) for symptoms of depression and anxiety. Those 
with elevated scores of depression (CDI ≥13 or BDI-II ≥14) and/or anxiety (SCARED: 
boys ≥26, girls ≥30) receive a psychiatric interview. Patients meeting criteria for 
depressive/anxiety disorders are referred for psychotherapy outside the trial. Patients 
with elevated (subclinical) symptoms are randomly assigned to medical care-as-usual 
(CAU; n=50) or CAU plus IBD-specific CBT (n=50). Main outcomes: 1) reduction in 
depressive and/or anxiety symptoms after three months, 2) sustained remission for 12 
months. Secondary outcomes: QoL, psychosocial functioning, treatment adherence. 
In addition, we will assess inflammatory cytokines in peripheral blood mononuclear 
cells and whole blood RNA expression profiles. For analysis, multilevel linear models 
and Generalized Estimating Equations will be used.
ethics and dissemination The Medical Ethics Committee of the Erasmus MC ap-
proved this study. If we prove that this CBT improves emotional well-being as well as 
disease course implementation is recommended.
trial registration: ClinicalTrials.gov: NCT02265588
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BAckGrounD
Inflammatory bowel disease (IBD; Crohn’s disease [CD] and ulcerative colitis [UC]) is a 
chronic relapsing inflammatory disorder of the intestine, with increasing incidence 
and prevalence worldwide [1]. Patients have abdominal pain, bloody diarrhea, often 
accompanied by systemic symptoms such as lack of appetite, weight loss and fatigue. 
IBD has a fluctuating course, with relapses (increased clinical disease activity) and 
periods of clinical remission. In up to 25% percent of patients, IBD manifests during 
late childhood and adolescence [2-4]. Adolescence is a challenging life phase, with 
significant psychological, physical and social changes. Having IBD during adolescence 
is a threat to healthy psychosocial development, making transition to adulthood more 
difficult.
Adolescent IBD patients frequently experience psychological and social problems 
[5]. They often have low self-esteem and report stress concerning their disease and 
future [6]. In addition, their quality of life is reduced [2, 7, 8], due to the unpredictable 
course of disease, embarrassing symptoms, frequent hospital visits or admissions and 
(side effects of) medical treatment. Furthermore, the possible extra intestinal mani-
festations (EIM) (e.g. Primary sclerosing cholangitis [PSC], arthritis), complications (e.g. 
strictures) and surgical treatments (e.g. resections) reduce quality of life significantly 
[2, 8-12].
Depressive symptoms are common, and occur in 20-40% of adolescents with IBD 
[13-18]. Anxiety, reported in 30-50% of IBD adolescents, is even more common [7, 19]. 
In many young patients, symptoms of both depression and anxiety occur together 
[20, 21]. Not surprisingly, early onset of mental health problems can predict poor 
long-term medical and psychological outcome [22-24].
Taken together, it is clear that psychological problems are often found in young 
IBD patients. The inflammation-depression hypothesis has been proposed to explain 
the association between psychological problems and IBD, and implies that treating 
emotional symptoms can decrease intestinal inflammation and thus improve disease 
course [25]. This hypothesis will be discussed in detail later in this introduction.
factors associated with depression and anxiety in IBD
Medical, psychological and family factors are associated with depression and anxiety 
in IBD and can influence the effectiveness of treatment of emotional problems in 
IBD. Known medical factors are: being recently diagnosed with IBD [26], a diagnosis 
of Crohn’s disease (versus ulcerative colitis) [27], a history of surgery [27, 28], active 
disease [26-32], non-adherence to therapy [31] and IBS (like) symptoms [33]. Psychologi-
cal factors are: high levels of perceived stress [26], negative cognitive coping [15], low 
self-esteem [8, 34], and sleep disturbance [32]. Family factors are: parental stress [35, 
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36], low socio economic status [26, 27, 31], stressful life events [37], and unhealthy 
family functioning [10, 34, 37]. In pediatric patients, active disease [15, 18, 19, 38, 39] 
and low socio-economic status [15] are associated with depression and/or anxiety.
In the opposite direction, emotional problems have also been shown to influence 
disease activity. Psychological stress can trigger a relapse in IBD [30, 40-44] and lead 
to a more difficult-to-treat (refractory) disease [30]. Moreover, emotional problems 
decrease the ability to cope with physical symptoms, increase the sensitivity to ab-
dominal pain [45], increase medical service use and decrease therapy adherence [16, 
19, 29, 46, 47].
Altogether, these findings emphasize the existence of a bidirectional relationship 
between emotional problems and disease activity in patients with IBD. We therefore 
expect that early recognition and treatment of emotional problems is necessary to 
improve both mental health and the clinical course of disease.
Inflammation-depression hypothesis
The ‘inflammation-depression hypothesis’ or ´brain-gut hypothesis’ proposes that 
intestinal inflammation, by means of increased production of pro-inflammatory cy-
tokines (e.g. tumor necrosis factor alpha [TNF-α]), is known to directly and indirectly 
affect the brain and thereby increase symptoms of depression [48]. It is also suggested 
that psychological stress can increase depressive symptoms by increasing inflamma-
tion [25, 48, 49].
Most evidence for this hypothesis comes from animal studies in which experimen-
tal (psychological) stress has shown to induce and reactivate inflammation in colitis 
models [44]. It is suggested that these stress induced alterations in inflammation are 
mediated through changes in Hypothalamic-Pituitary-Adrenal (HPA) axis function and 
alterations in bacterial mucosal interactions [25, 44, 50-52]. Similarly, human studies 
also show the pro-inflammatory effect of experimental [25, 50] and (early) life stress 
[52] and show elevated levels of inflammatory markers in depressed patients [49, 53-
56].
There are few pediatric IBD studies examining the relationship between inflam-
mation and depression [48]. Furthermore, the brain-gut hypothesis mainly focuses 
on depression, the relation between inflammation and anxiety has been studied less 
extensively [57]. Reviews by Hou et al. and Salim et al. show the existing evidence 
in animal models linking inflammation with anxiety [58, 59]. In humans, a chronic 
anxiety state has been shown to negatively affect immune function and several stud-
ies report a positive correlation between anxiety and increased inflammatory markers 
[57-60]. To our knowledge, little is known about the association between anxiety and 
inflammation in IBD. The present study will contribute to more understanding of this 
association [19, 31].
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cBt for adolescent IBD patients
From all different psychotherapies, CBT is the most evidence based psychotherapy to 
reduce symptoms of anxiety and depression [12, 61, 62].
For adolescents with IBD, Szigethy et al. developed a disease-specific CBT program 
called PASCET-PI (Primary and Secondary Control Enhancement Training – Physical 
Illness) (see Intervention) [63]. They performed a RCT in adolescents with IBD and 
subclinical depression (total N=41). A 40% reduction in depressive severity in the 
PASCET-PI group was found compared to the control group, receiving care-as-usual 
[17]. These positive effects maintained 1 year after treatment [23]. However, anxiety 
was not addressed. Only a few pediatric studies have integrated the clinical course 
of disease or disease activity as an outcome parameter. Szigethy et al. compared the 
effect of two different psychotherapies in pediatric IBD patients with (sub)clinical 
depression and found that both therapies had a significant impact in improving 
depression while CBT was associated with a greater reduction in disease activity [64]. 
Reigada et al. showed in a CBT-pilot with 9 (pediatric) patients and only comorbid 
anxiety, that 90% no longer had an anxiety disorder and half of the patients had a 
reduction in IBD severity [65].
Although the aforementioned studies showed promising results, larger scale ran-
domized studies are necessary to evaluate the longitudinal effect of CBT in pediatric 
IBD and to identify potential moderators of CBT success. To the best of our knowledge, 
at present there are no randomized controlled trials assessing simultaneously the ef-
fect of CBT on the two psychological outcomes (symptoms of depression or anxiety) 
and the clinical course of disease in adolescent IBD patients.
Aim and hypothesis
The present study’s aim is to test the effectiveness of the disease specific CBT program 
(PASCET-PI) in reducing symptoms of depression and anxiety in adolescents with 
inflammatory bowel disease in order to improve quality of life and to improve the 
clinical course of disease. We hypothesize that the PASCET-PI will reduce symptoms of 
both depression and anxiety, improve quality of life, reduce intestinal inflammation 
and will promote sustained clinical remission.
metHoDS AnD DeSIGn
Study design
This study is a prospective multicenter randomized controlled trial, with baseline 
screening (T0) and three follow-up assessments (T1 – T3). At baseline, adolescents (age 
10-20 years) with IBD are screened for symptoms of depression and anxiety by means 
60
of an online questionnaire. Patients with elevated (subclinical) symptoms of depres-
sion and/or anxiety, but no clinical disorder, are randomized into two conditions. The 
control condition entails standard medical care-as-usual (CAU); psychological care is 
not standard in the Dutch medical care system. Patients in the experimental condi-
tion receive standard medical care plus the disease-specific CBT (PASCET-PI). Patients 
are recruited from 2 academic hospitals and 5 community hospitals in the South-
West region of the Netherlands1. The design of this study is following the CONSORT 
guidelines for RCT’s.
Inclusion & exclusion criteria
Inclusion criteria are 1) patients between 10-20 years with diagnosed IBD and 2) in-
formed consent provided by patients and (if applicable) parents.
Exclusion criteria are 1) mental retardation (parent report), 2) current psychophar-
macological treatment for depression or anxiety, 3) current psychological treatment, 
4) having received manualized CBT in the past year (at least 8 sessions), 5) insufficient 
mastery of the Dutch language, 6) diagnosed bipolar disorder, schizophrenia/psychotic 
disorder, autism spectrum disorders, obsessive-compulsive disorder, posttraumatic 
or acute stress-disorder or substance use disorder, 7) selective mutism (physician 
reported), and 8) already participating in an intervention study.
recruitment and procedure (see figure 1)
The treating (pediatric) gastroenterologist, nurse practitioner or physician assistant 
informs eligible patients about this study and hands out the written patient informa-
tion. Parents are asked for informed consent if patients are younger than 18 years; 
if patients aged 18 years or older still live in their parents’ house, participation of 
parents is optional. After having given informed consent, patients (and parents) 
receive an e-mail with online questionnaires (see Table 1). If this screening shows 
self-reported subclinical symptoms of depression and/or anxiety, a patient is selected 
for further participation in the study. The Dutch versions of the Child Depression 
Inventory (CDI; ages 10-17) [66], Beck Depression Inventory (BDI-II; ages 18-20) [67] are 
used to assess depressive symptoms, whereas the Screen for Child Anxiety Related 
Disorders (SCARED; ages 10-20) [68] is used to assess anxiety symptoms. Subclinical 
depressive symptoms are defined as a score equal to or above the cutoff on the CDI 
(13) [66] or the BDI-II (14) [67]. Subclinical anxiety symptoms are defined as 1) a score 
equal to or above the cutoff on the total scale of the SCARED (26 for boys, 30 for girls) 
or 2) a score equal to or above the cutoff (8) on one of the subscales [69].
1 Erasmus MC(-Sophia), Leiden University Medical Centre (LUMC), Haga (Juliana Children’s) Hospital, Rei-
nier de Graaf Gasthuis, Maasstad Hospital, Amphia Hospital, and Albert Schweitzer Hospital.
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Next, in patients with these subclinical symptoms, the Anxiety Disorders Interview 
Schedule - Child and Parent Version (ADIS-C/P) [70, 71] is administered by a research 
psychologist by telephone. Thereafter, the severity of depressive and/or anxiety symp-
toms is rated by the research psychologist using the Child Depression Rating Scale 
- Revised (CDRS-R; ages 10-12) [72], the Adolescent Depression Rating Scale (ADRS; ages 
13-20) [73], and the Pediatric Anxiety Rating Scale (PARS; ages 10-20) [74]. Patients are 
excluded for randomization if they meet criteria for a clinical depressive or anxiety 
disorder on the ADIS-C/P and score equal to or above the clinical cutoff on the CDRS 
(20) [75], ADRS (40) [73], or PARS (18) [74]. Instead, these patients are referred for at-
tuned psychological treatment, since it would be unethical to randomize them. For 
patients with subclinical depression and/or anxiety, the medical researcher performs 
the randomization and arranges the medical baseline assessment.
All patients included in our study are well phenotyped with regard to duration and 
severity of disease, age at diagnosis, growth and pubertal development, clinical course 
of disease, number and type of surgical interventions and hospitalizations. The Paris 
classification is collected at diagnosis and from the most recent endoscopy, to see if 
extension of disease has occurred.
Diagnostic assessment ADIS-C/P + CDRS-R / ADRS + PARS 
Baseline screening CDI / BDI-II + SCARED 
IF subclinical symptoms 
CDI ≥ 13 or BDI-II ≥ 14 or SCARED ≥ 26 (♂) / ≥ 30 (♀) 
or SCARED subscale ≥ 8 
Informed consent 
Control group  Intervention group 
IF ADIS-C/P not meeting criteria for clinical diagnosis 
AND/OR CDRS-R < 40 / ADRS < 20 OR PARS < 18 
Randomisation & Medical baseline 
Follow up after 3,6,12 months 
figure 1 | Flow chart study design
Abbreviations: CDI= Child Depression Inventory; BDI-II= Beck Depression Inventory – Second 
Edition; SCARED= Screen for Child Anxiety Related Emotional Disorders; ADIS-C/P= Anxiety Dis-
orders Interview Schedule - Child and Parent Version; CDRS-R= Child Depression Rating Scale 
- Revised; ADRS= Adolescent Depression Rating Scale; PARS= Pediatric Anxiety Rating Scale
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randomization and blinding
Patients are allocated to PASCET-PI or CAU group by means of computer-based, block 
randomization, stratified per center. Sealed envelopes sequentially numbered are pro-
vided by the Department of Biostatistics of the Erasmus Medical Center. Participants 
assigned to the treatment group start treatment within a maximum of 4 weeks.
To prevent bias in the assessment, the research psychologist completing the di-
agnostic interviews at T0 – T3 is blinded for the outcome of randomization. In addi-
tion, physicians assessing the patient’s disease activity are blinded. The patients and 
therapists are asked not to discuss the psychotherapy with the treating physician. 
Unblinding takes place if patients are excluded from the study (either by withdrawal 
or an acute need for care).
table 1 | Outcomes, covariates, instruments and informants at each time point
measurements t0
baseline
t1
3 months
t2
6 months
t3
12 months
main psychological outcomes
Change in 
symptoms of 
depression
CDI (10-17 year) Pt Pt Pt Pt
BDI-II (18-20 year) Pt Pt Pt Pt
ADIS-C/P Pt, Pr Pt, Pr Pt, Pr Pt, Pr
CDRS-R (10-12 year) Ps Ps Ps Ps
ADRS (13-20 year) Ps Ps Ps Ps
Change in 
symptoms of 
anxiety
SCARED Pt Pt Pt Pt
ADIS-C/P Pt, Pr Pt, Pr Pt, Pr Pt, Pr
PARS Ps Ps Ps Ps
main medical outcome
Sustained 
remission
M
Secondary psychological outcomes
(Change in) 
Quality of life
TACQOL (10-15 year) [76] Pt Pt Pt Pt
TAAQOL (16-20 year) [77] Pt Pt Pt Pt
IMPACT-III [78] Pt Pt Pt Pt
(Change in) 
Psychosocial 
functioning
SSRS [79] Pt Pt Pt Pt
YSR (10-17 year) [80] Pt Pt Pt Pt
ASR (18-20 year) [81] Pt Pt Pt Pt
Secondary medical outcomes
(Change 
in) Disease 
activity
PUCAI (Ulcerative colitis) M M M M
PCDAI (Crohn’s disease) M M M M
Physician Global Assessment [46] M M M M
Inflammatory 
markers
CRP Pt Pt Pt Pt
ESR Pt Pt Pt Pt
Fecal calprotectin Pt Pt Pt Pt
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table 1 | Outcomes, covariates, instruments and informants at each time point (continued)
measurements t0
baseline
t1
3 months
t2
6 months
t3
12 months
Use of IBD 
medication
Steroids, anti-TNF blockers, 
immunomodulators
M M M M
Necessity 
of surgical 
intervention
M M M M
Psychological covariates
Demographic 
factors
Rotterdam’s quality of life 
interview [82]
Pr
Illness 
perception
B-IPQ [83] Pt Pt Pt Pt
Cognitive 
Coping Styles
CERQ [84] Pt Pt Pt Pt
Quality of 
sleep
SSR [85] Pt, Pr Pt, Pr Pt, Pr Pt, Pr
Parental 
anxiety and 
depression
DASS-21 [86] Pr
Life events Stress scale thermometer [87] Pt, Pr Pt, Pr Pt, Pr Pt, Pr
Life events questionnaire from 
CERQ
Pt Pt
Family 
functioning
FAD-GF [88] Pr Pr Pr Pr
Medical covariates
Disease 
phenotypes
Medical file analysis using Paris 
Classification
M
Treatment 
strategy
Report of treating physician / 
medical file analysis
M M M M
IBS-like 
symptoms
Questionnaire based on ROME III 
criteria IBS
M M M M
RNA 
expression 
profiles
Blood sample M M
Cytokine 
levels in 
plasma & 
peripheral 
blood 
mononuclear 
cells (PMBCs)
Blood sample M M
Abbreviations: CDI= Child Depression Inventory, BDI-II, Beck Depression Inventory – Second Edi-
tion, ADIS-C/P= Anxiety Disorders Interview Schedule - Child and Parent Version, CDRS-R= Child 
Depression Rating Scale - Revised, ADRS= Adolescent Depression Rating Scale, SCARED= Screen 
for Child Anxiety Related Emotional Disorders, PARS= Pediatric Anxiety Rating Scale, TACQOL= 
TNO-AZL questionnaire for Children’s health-related Quality Of Life, TAAQOL= TNO-AZL ques-
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Intervention
The PASCET-PI focuses on behavioral activation, cognitive restructuring and problem 
solving skills to change maladaptive behaviors, cognitions and coping strategies [61]. 
Although originally designed to treat depression, most of the components of PASCET-
PI are common for all CBT protocols, and have much overlap with components of CBT 
protocols specifically designed for anxiety (except for a fear hierarchy). Therefore, 
PASCET-PI can also be properly used for anxiety is. Disease-specific components, en-
compass the illness narrative (i.e. perceptions and experience of having IBD), therapy 
for pain and immune functioning, disease-specific psycho-education, social skills 
training and emphasis on IBD related cognitions and behaviors. Parents are provided 
with psycho-education about being a CBT-coach helping their child coping with IBD 
[17, 89].
The PASCET-PI consists of ten weekly sessions, delivered in three months (see Table 
2). 6 sessions are face to face (1 hour) and 4 sessions are telephone-sessions (30 min-
utes). Three parental sessions are held at the beginning, middle and end of treatment. 
For adult patients (≥ 18 year) who still live with their parents, this is recommended 
but voluntarily. Adult patients who do not live with their parents, participate without 
their parents. Thereafter, three 30-minute booster sessions (one per month) are pro-
vided by telephone. For the current study the original PASCET-PI was translated into 
the Dutch language. During this study patients will receive medical care according to 
the current guidelines. Psychological interventions, other than the PASCET-PI for the 
intervention group, are not allowed.
tionnaire for Adult health-related Quality Of Life, SSRS= Social Skills Rating System, YSR= Youth 
Self-Report, ASR= Adult Self-Report, PCDAI= Pediatric Crohn’s Disease Activity Index, PUCAI= 
Pediatric Ulcerative Colitis Activity Index ,CRP= C-reactive Protein, ESR= Erythrocyte Sedimenta-
tion Rate, B-IPQ= Brief - Illness Perception Questionnaire, CERQ= Cognitive Emotion Regulation 
Questionnaire, SSR= Sleep Self-Report, DASS-21= Depression, Anxiety and Stress Scale - 21-item 
version, FAD-GF= Family Assessment Device - General Functioning scale, IBS= Irritable Bowel 
Syndrome, PMBC= peripheral blood mononuclear cells.CDI: Child Depression Inventory, BDI-II, 
Beck Depression Inventory – Second Edition, ADIS-C/P: Anxiety Disorders Interview Schedule - 
Child and Parent Version, CDRS-R: Child Depression Rating Scale - Revised, ADRS: Adolescent 
Depression Rating Scale, SCARED: Screen for Child Anxiety Related Emotional Disorders, PARS: 
Pediatric Anxiety Rating Scale, TACQOL: TNO-AZL questionnaire for Children’s health-related 
Quality Of Life, TAAQOL: TNO-AZL questionnaire for Adult health-related Quality Of Life, SSRS: 
Social Skills Rating System, YSR: Youth Self-Report, ASR: Adult Self-Report, PCDAI: Pediatric 
Crohn’s Disease Activity Index, PUCAI: Pediatric Ulcerative Colitis Activity Index ,CRP: C-reactive 
Protein, ESR: Erythrocyte Sedimentation Rate, B-IPQ: Brief - Illness Perception Questionnaire, 
CERQ: Cognitive Emotion Regulation Questionnaire, SSR: Sleep Self-Report, DASS-21: Depres-
sion, Anxiety and Stress Scale - 21-item version, FAD-GF: Family Assessment Device - General 
Functioning scale, IBS: Irritable Bowel Syndrome, PMBC: peripheral blood mononuclear cells.
Note: Pr= parent report, Pt= patient (self-report), M= medical file/(pediatric) gastroenterologist, 
Ps= psychologist
65
3
training and protocol adherence
Before providing the PASCET-PI, all licensed (healthcare) psychologists had followed 
a PASCET-PI training (developed and given by Eva M. Szigethy). To prevent protocol 
drifting they receive monthly PASCET-PI supervision by a senior clinical psychologist. 
All treatment sessions are audiotaped and a random 20% is rated by independent rat-
ers (senior clinical psychologist and master’s students Psychology) using the PASCET-
PI Protocol Adherence Checklist (PPAC) [63].
outcome measures
In Table 1 an overview of all variables and instruments at each time point is provided, 
with informants specified. All the psychological questionnaires used are (inter)nation-
ally validated instruments, for which psychometric properties have been established 
in the Netherlands. Due to lack of space, instruments for the main psychological and 
medical outcomes are described in detail below. Instruments for secondary outcomes 
and covariates are mentioned only. Covariates will be analyzed as either confounder, 
mediator, or moderator.
table 2 | Outline of the PASCET-PI [61]
Session number content of session
Session 1
Live
Introduction of ACT & THINK model and PASCET-PI, build alliance, psycho-
education about IBD and depression or anxiety, illness narrative
Session 2
Live
Mood monitoring, explaining link between feelings, thoughts and behaviors, 
discussing feeling good and feeling bad, problem-solving
Session 3
By telephone
Link between behavior and feelings: Activities to feel better
Session 4
Live
Be calm and Confident: relaxation exercises
Session 5
Live
Be Calm and confident: positive self vs negative self, training social skills
Session 6
By telephone
talents: developing talents and skills makes you feel better
Session 7
Live
Social problem solving, discussing the ACT skills and introduction of the THINK 
skills with discussing negative thoughts (think positive)
Session 8
By telephone
Help from a friend, Identify the ‘Silver Lining’, and no replaying bad thoughts
Session 9
By telephone
keep trying – Don’t give up, making several plans to use the ACT & THINK skills
Session 10
Live
Quiz on ACT & THINK model, discussing use of ACT & THINK skills in the 
future, updating illness narrative
Booster 1
By telephone
Several plans to use the ACT & THINK skills, updating illness narrative, 
personalizing ACT & THINK skills
Booster 2
By telephone
Several plans to use the ACT & THINK skills, updating illness narrative, 
personalizing ACT & THINK skills
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main psychological outcome measures: changes in symptoms of depression and 
anxiety
Changes in symptoms of depression are assessed by the CDI and the BDI-II (to cover 
the complete age range). The CDI (used for ages 10-17) is a 27 item self-report scale 
(response categories 0-2: total score 0-54). It has excellent reliability (Cronbach’s alpha 
>.85) and moderate to good validity [66]. The BDI-II (used for ages 18-20) is a 21 item 
self-report scale (response categories 0-3: total score 0-63). The BDI-II has excellent 
reliability (Cronbach’s alpha >.85) and good to excellent validity [67]. In addition, 
(changes in) the severity of the depressive symptoms will be rated with the CDRS-R or 
the ADRS. The CDRS-R (used for ages 10-12) is one of the most used rating scales for 
depression in children [72]. The ADRS (used for ages 13-20) is developed specifically 
for adolescent depression [73]. Changes in symptoms of depression are analyzed using 
Z-scores of CDI and BDI-II, and CDRS-R and ADRS.
Changes in symptoms of anxiety are assessed by the SCARED (used for ages 10-20), 
a 69-item screening instrument (response categories 0-2: total score 0-138) containing 
five subscales: general anxiety disorder, separation anxiety disorder, specific phobia, 
panic disorder, and social phobia. Cronbach’s alpha in the normative sample is .92 
for the total score and between .66 and .87 for the subscales. Satisfactory concurrent 
validity has been shown [68]. In addition, changes in the severity of anxiety symptoms 
will be rated with the PARS [74], for which a high internal consistency has been re-
ported [75].
For both depression and anxiety, the semi-structured interview ADIS-C/P (child and 
parent version) is administered. This diagnostic interview assesses diagnoses of de-
pressive or anxiety disorders. DSM-IV symptoms are reviewed as either present (‘Yes’) 
or absent (‘No’) [70, 71].
table 2 | Outline of the PASCET-PI [61] (continued)
Session number content of session
Booster 3
By telephone
Several plans to use the ACT & THINK skills, updating illness narrative, 
personalizing ACT & THINK skills
Family 1
Live
Parental view on IBD, family situation, psycho-education about IBD and 
depression or anxiety, introduction of ACT & THINK model and PASCET-PI
Family 2
Live
Parental view on progress, the ACT & THINK skills that are most effective for 
patient, expressing emotions within family, family communication, family 
stress game
Family 3
Live
Parental view on progress, family communication, parental depression or 
anxiety
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main medical outcome measure: sustained remission at 12 months
Sustained remission of IBD (absence of clinical relapse) is continued clinical remis-
sion with no relapses, without the need to escalate treatment, use of new induction 
treatment (except for the first 8 weeks after baseline), hospitalize or perform bowel 
surgery during the first 12 months. In case of active disease at the time of enroll-
ment, sustained remission at 12 months means continued remission after 8 weeks 
of induction treatment starting at baseline. The Pediatric Crohn’s Disease Activity 
Index (PCDAI) and the Pediatric Ulcerative Colitis Activity Index (PUCAI) are used 
to score disease activity, and to score remission or relapse. The PCDAI (for Crohn’s 
Disease) is a validated, multi-item, physician-reported measure that comprises items 
on history (abdominal pain, stools, activity level), physical examination, height and 
weight, as well as laboratory parameters. Scores range from 0-100, with higher scores 
representing more active disease [90, 91]. The PUCAI is a clinical index on disease 
activity for ulcerative colitis, scored by the physician, which has been validated in 
multiple international drug studies and comprises items on abdominal pain, rectal 
bleeding, stool frequency and consistency and activity level. Scores range from 0-85, 
with higher scores representing more active disease [92]. For CD and UC patients, 
remission is defined as PCDAI <10, and PUCAI <10 , respectively. For CD, relapse is 
defined as PCDAI >30 or an increase of >15 points and intensification of medical 
treatment. For UC, relapse is defined as PUCAI >34 or an increase of ≥20 points for UC 
and intensification of medical treatment [90, 92, 93].
Secondary outcomes
Secondary psychological outcomes are IBD-related quality of life and social function-
ing.
Secondary medical outcomes are disease activity, inflammatory markers in blood 
(C-reactive protein) and stool (calprotectin), use of IBD medication, and necessity of 
surgery (see Table 1).
Psychological and medical covariates
Several factors associated with depression and anxiety in IBD (e.g. IBS-like symptoms, 
cognitive coping, parental stress) will be assessed because they can confound, mediate 
or moderate the effect of CBT on medical and psychological outcomes. Psychological 
covariates assessed are: illness perception, cognitive coping, quality of sleep, parental 
anxiety and/or depression, stressful life events, family functioning, and demographic 
factors.
Medical covariates encompass: disease phenotype, treatment strategy, disease ac-
tivity, irritable bowel syndrome – like symptoms. Blood samples for immunological 
analysis will be drawn at baseline and after 3 months. For cytokine analysis, one EDTA 
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tube (10 ml) will be drawn. Peripheral blood mononuclear cells (PBMCs) will be isolated 
and the plasma stored at -80°C. Serum levels of pro-inflammatory cytokines (TNFα, Il-
1, Il-1α, IL6, Il-8) will be assessed in plasma and supernatant of PBMCs in culture using 
respectively Cytokine Bead Analysis (CBA) or ELISA. Furthermore, intracellular flow 
cytometry will be performed on in vitro stimulated PBMCs. For the RNA expression 
analysis, 2,5 ml venous blood will be collected in PAXgene tubes (PreAnalytiX) and 
stored at –20°C until RNA extraction. Total cellular RNA will be extracted using the 
PAXgeneTM blood RNA kit (Qiagen) according to the manufacturer’s protocol. Gene 
expression profiles of pro- and anti-inflammatory genes in peripheral blood leucocytes 
will be assessed by Affymetrix U133 2.0 plus GeneChips.
Data collection: follow up assessments
Follow-up assessments take place at similar moments in the CBT and CAU group: 
three (T1), six (T2) and twelve (T3) months after randomization. Each follow-up as-
sessment consists of a regular medical visit and a psychological assessment (online 
questionnaires and diagnostic psychiatric interview) for the patient and, if applicable, 
parents. Patients with a clinical depressive or anxiety disorder (according to the same 
criteria as at baseline) or with an urgent need of psychological help, are excluded. 
To ensure participation throughout the study, patients receive a small reward after 
completing the last follow-up assessment.
Withdrawal
Patients can withdraw from the study without any consequences at any time for any 
reason. Those who withdraw are asked to complete the follow-up assessments.
Sample size
The target population is a group of approximately 350 IBD patients aged 10-20 years. 
Based on our previous studies concerning psychological problems in physically ill ado-
lescents, the expected response rate will be above 80% [94], which corresponds with 
± 280 patients. Based on literature, around 40% of adolescents with IBD will suffer 
from increased symptoms of depression or anxiety. Of those patients 10% will experi-
ence clinical depression or anxiety. Of the remaining ±100 patients 50 patients will be 
randomized to the treatment condition (CBT and CAU) and 50 to CAU. Sample size is 
based on two-tailed tests with size of α = 0.05 using a repeated measures design with 
estimated correlation between time-points of 0.6. For the effect of CBT on symptoms 
of depression small to medium effect sizes are expected (Cohen’s d > 0.3) [95, 96], for 
the effect on symptoms of anxiety medium to large effect sizes are expected (Cohen’s 
d > 0.6) [97, 98] For the effect of CBT on sustainment of remission (no clinical relapse), 
a medium effect size is expected (ω = 0.3). Based on clinical experience in our hospital, 
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in the CAU group 40% of patients will have sustained remission during 12 months. 
We hypothesize that 70% of patients will have sustained remission in the treatment 
group, reflecting a medium effect size. Using the target population of N = 100 and the 
estimated effects on depression, anxiety and sustainment of remission, we will have 
sufficient power (> 0.85).
Statistical analyses
The main analyses will be conducted using an intention-to-treat approach. Where ap-
propriate, secondary analysis will be conducted using a per protocol basis. To test the 
effectiveness of the PASCET-PI, we will compare the CBT group to the CAU group on 1) 
change in symptoms of depression and anxiety, and 2) sustained remission (absence 
of clinical relapse). For 1) multilevel linear models will be used, for 2) a Generalized 
Estimating Equation approach (GEE) will be used. Covariates (e.g. illness perception, 
cognitive coping, disease phenotypes, medical treatment strategy, inflammatory 
markers) will be included into the multilevel linear models and the GEE to identify 
which factors influence the effectiveness of the disease-specific CBT. Multiple imputa-
tion will be used to deal with missing values.
DIScuSSIon
PASCET-PI has proven to be effective in reducing depression in adolescent IBD pa-
tients. However, the effect on anxiety, quality of life, and disease course has hardly 
been studied systematically. We will perform a prospective randomized controlled 
trial to examine the effectiveness of the PASCET-PI on both symptoms of depression 
and anxiety, on quality of life, and on clinical course of the inflammatory disease.
This study has several strengths. First, as this study examines the effect of disease-
specific CBT on both psychological problems and disease course, it will provide insight 
in the complex interplay between inflammation and depression or anxiety in pediat-
ric patients. We will study possible effects of reduction in depression or anxiety on 
cytokine expression and RNA expression profiles before and after CBT for subclinical 
depression or anxiety. Second, the disease-specific CBT will target both depression 
and anxiety, which is important as these problems have a negative impact on medica-
tion adherence and long-term medical and psychological outcomes [16, 19, 23, 24, 
29, 45-47]. Third, this study will provide important information about the prevalence 
of depression and anxiety among adolescent IBD patients in an European country 
such as the Netherlands, as compared to other studies that were performed mainly in 
the United States. Cultural differences may play a role in coping with disease-related 
anxiety and depression. Fourth, the PASCET-PI encompasses IBD-specific components, 
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which matches patients’ IBD-related concerns and problems very well. If proven effec-
tive, the PASCET-PI can be very helpful for treatment of current and also for preven-
tion of future psychological problems. A fifth strength of the study is the random and 
longitudinal nature of the design. Patients will be randomly assigned to the experi-
mental or control condition. It is known that academic hospitals treat more severe 
IBD cases than community hospitals. Therefore, the randomization will be stratified 
for academic versus community hospitals. Randomized patients will complete several 
follow-up assessments, which allows us to evaluate long-term effects of the PASCET-PI.
In conclusion, there is a compelling need to improve the emotional wellbeing of the 
adolescent IBD patients who suffer from (subclinical) depression or anxiety symptoms. 
If the PASCET-PI proves to be effective, in treating both subclinical depression and 
anxiety, in improving quality of life, and in preventing clinical relapse, screening for 
and treatment of psychological problems in IBD adolescents should be incorporated 
in standard care.
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SummArY
Background Youth with inflammatory bowel disease (IBD) are at risk for developing 
anxiety and depressive symptoms with a reported 20-50% prevalence rate.
Aim This prospective study aims to: 1) describe the prevalence and severity of anxiety 
and depressive symptoms in a large Dutch cohort of young IBD patients, and 2) iden-
tify demographic and clinical risk factors for anxiety and depression.
methods IBD patients (n=374; 10-25 years) were screened for anxiety, depression and 
quality of life using validated age-specific questionnaires. Patients with elevated scores 
for anxiety and/or depressive symptoms received a diagnostic interview assessing 
psychiatric disorders. Demographic and clinical characteristics were retrieved from 
medical charts. Multiple logistic regression analysis was performed to identify risk 
factors for anxiety and/or depression.
results Patients (mean age 18.9 years, 44.1% male, Crohn’s disease 60.4%) had dis-
ease in remission (75.4%), or mild, moderate and severe clinical disease activity in 
respectively 19.8%, 2.7% and 2.1%. Mild anxiety/depressive symptoms were present in 
23.6% and severe symptoms in 12.4% of patients. Elevated symptoms of either anxi-
ety (28.3%), depression (2.9%) or both (15.8%) were found and did not differ between 
adolescents (10-17 years) and young adults (18-25 years). Active disease significantly 
predicted depressive symptoms (Odds Ratio (OR) 4.6 [95% Confidence Interval [CI] 2.4-
8.8], p<0.001). Female gender (OR 1.7 [95%CI 1.1-2.7]), active disease (OR 1.9 [95%CI 1.1-
3.2]) and a shorter disease duration (OR 1.3 [95%CI 0.6-1.0) (all p<0.025) significantly 
predicted anxiety and/or depressive symptoms.
conclusions Considering the high prevalence of anxiety and depressive symptoms, 
psychological screening is recommended in young IBD patients. Screening facilitates 
early recognition and psychological treatment. Female patients and patients with ac-
tive disease are the most vulnerable.
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IntroDuctIon
Inflammatory bowel disease (IBD; Crohn’s disease [CD] and ulcerative colitis [UC]) is 
a chronic relapsing inflammatory disorder of the intestine, with rising incidence, 
in the United States as well as in Europe [1]. In up to 25% of patients IBD develops 
and manifests during childhood or adolescence [2], a phase with significant physical, 
cognitive and psychosocial challenges [3].
A chronic disease, at this age, is a threat to a healthy psychosocial development 
[4]. It has been observed that particularly adolescents with IBD are at risk for psycho-
logical problems such as anxiety and depression, and thereby decreased quality of 
life [5, 6]. The bidirectional relationship between IBD and psychological problems has 
been described before and can be explained in terms of the ‘brain-gut’-axis, meaning 
that the presence of anxiety and/or depression can increase intestinal inflammation 
and may contribute to disease relapse, and vice versa: intestinal inflammation can 
negatively influence mood [7, 8].
Symptoms of anxiety and/or depression are often found in pediatric IBD patients. Re-
ported prevalence rates range from 20-50% for anxiety [9-11] and 25-40% for depression [5, 
10, 12]. Although some studies report lower rates [13], prevalence in pediatric IBD seems 
to be higher compared to other chronic diseases [14, 15]. In adult IBD patients, a recent 
systematic review showed similar prevalence rates [16] suggesting that psychological prob-
lems persist or arise in adulthood [17]. As it is known that anxiety can precede depression, 
and anxiety and depressive symptoms often occur together [18], it is worthwhile to study 
them simultaneously. In addition, combining adolescents and young adult patients in 
research is also important [19], considering they are at a unique stage in their emotional, 
cognitive and social development. The impact of a chronic disease and the accompanied 
challenges in this stage are different from their pediatric or adult counterparts.
Insight in risk factors for anxiety and depression in young IBD patients is necessary to 
help health care professionals identify those at risk. It may assist in selecting patients 
that need psychological screening and/or treatment. In patients with emotional prob-
lems, improving psychological health is expected to lead to a decrease in IBD related 
morbidity [20] reduced health care utilization and improvement of quality of life [21].
Previous studies report a variety of risk factors for anxiety and depression. In adult 
IBD, active disease has been associated with both anxiety and depression [16, 22, 23]. 
Other studies showed that female IBD patients [23] and patients with lower socio 
economic status [24] are at risk for anxiety, and that a younger age at diagnosis is 
associated with depression [25]. In addition, prior surgery and perianal disease are 
correlated with both anxiety and depression [26].
In pediatric IBD, the majority of studies also show active disease to be associated 
with both anxiety and depressive symptoms [5, 11, 21]. Furthermore, female gender 
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[13], older age at diagnosis [5], fatigue [27], abdominal pain [12, 28], low socioeconomic 
status [29] and steroid use [5, 29] were correlated with depression. In addition, female 
gender [13] and abdominal pain [11] have shown a correlation with anxiety. In both 
pediatric and adult patients, disease type [5] and anti-TNF-α use [29] did not seem to be 
a risk factor for anxiety and depression.
The current study investigates the presence of and risk factors for anxiety and depres-
sive symptoms in a unique large European cohort of young IBD patients, consisting of 
adolescents (10-17 years) and young adults (18-25 years) from regional as well as tertiary 
hospitals. In addition, this study provided a unique opportunity to also study the severity 
of anxiety and/or depressive symptoms. This study aims (1) to describe the prevalence 
and severity of anxiety and depressive symptoms; and (2) to identify demographic and 
clinical risk factors for symptoms of anxiety and/or depression. We hypothesize that 
clinical disease activity will be the greatest risk factor. Additionally, we expect female 
sex and steroid use to be associated with anxiety and/or depressive symptoms.
mAterIAlS AnD metHoDS
Design
In the present cross-sectional study a large cohort of adolescents (10-17 years) and 
young adults (18-25 years) with IBD were screened for anxiety and depressive symptoms 
and HRQOL. According to the World Health Organization, adolescence encompasses 
individuals in the age group 10-19. In The Netherlands governmental legislation as 
well as medical practice uses the age of 18 years to define the start of adulthood. At 
18, a patient has finished high school and is also transferred from pediatric to adult 
medical care. Therefore, in this study, the adolescent group consists of 10-17 year old 
patients and the young adult group of 18-25 year old patients. This study preceded 
a randomized controlled trial investigating the effectiveness of cognitive behavioral 
therapy in youth with IBD and subclinical anxiety and/or depression (NCT02265588). 
For the randomized trial, based on previous literature regarding the effectiveness of 
CBT for anxiety and depressive symptoms, medium to large effects for anxiety symp-
toms [30] and medium effects for depressive symptoms [31] were expected. This cor-
responds to j >0.40 for anxiety symptoms, and to j >0.30 for depressive symptoms. 
With 70 patients included in the randomized trial, the study had a power of >85% 
for anxiety symptoms (beta-error 0.14) and medium power for depressive symptoms 
(>60%) (beta-error 0.39) with an alpha-error of 0.05 (2 sided test)
To include 70 patients in the randomized trial, a total of 350 patients needed to be 
screened. This was calculated based on the following: a) 5% of patients will have on 
or more exclusion criteria b) an expected participation rate of 80% (based on previous 
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studies in chronically ill adolescents) [32], c) and expected prevalence rate of anxiety/
depressive symptoms of 35% [5, 9, 11]. Taking into account a 5% drop out rate, we 
aimed to include 375 patients.
The following in- and exclusion criteria were used: 1) age 10 to 25 years and 2) 
diagnosis of IBD, according to the current diagnostic criteria [33-35]. Exclusion crite-
ria were: 1) intellectual disability, 2) current treatment for mental health problems 
(pharmacological and/or psychological), 3) insufficient mastery of the Dutch language, 
4) a diagnosis of selective mutism, bipolar disorder, schizophrenia, autism spectrum 
disorder, obsessive-compulsive disorder, posttraumatic or acute stress-disorder, or 
substance use disorder, 5) cognitive behavioral therapy in the past year (at least 8 
sessions), and 6) participation in another interventional study.
Initially, only patients aged 10-20 years were included. A few months after the start 
of recruitment, patients of 21-25 years were also included, to include the young adult 
group and to be able to include a sufficient number of patients for the randomized 
controlled trial.
In-and exclusion criteria were assessed by the treating physicians. Insight into the 
numbers of patients with exclusion criteria was only provided by the pediatric depart-
ments (so for patients 10-17 years of age). In total 384 of these adolescents with IBD 
were treated in the participating hospitals. Of those, 174 patients gave consent to 
participate. Of the remaining 210 patients, 125 patients had no interest in participat-
ing in the study and 85 patients fulfilled the exclusion criteria (intellectual disability 
n=14, current psychological treatment n=33 (exact diagnosis not provided), autism 
spectrum disorder n=20, posttraumatic stress-disorder n=3, obsessive-compulsive dis-
order n=2, already participating in an intervention study n=9, insufficient mastery of 
the Dutch language n=4). This study conformed to the principles of the Declaration of 
Helsinki and was approved by the Institutional Review Board of the Erasmus Medical 
Center and of each participating center.
Procedure
Consecutive patients were recruited between October 2014 and September 2016 from 
the outpatient clinic in two academic hospitals and four community hospitals in the 
Southwest region of the Netherlands. We aimed to include a diverse cohort, including 
all stages of disease. However, the majority of patients was included at least 3 months 
after diagnosis (nine patients were included within 3 months after diagnosis). After 
written informed consent of patients and, if applicable, their parents or caregivers, an 
e-mail with a link to online questionnaires was sent. It was emphasized that results 
would be most valuable if patients and parents completed the questionnaires without 
help of their parents (and vice versa), and if they would give honest answers. Assis-
tance was offered by the research team by email or telephone if necessary. In addition, 
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it was stressed that irrespective of the outcome of the questionnaires, patients could 
decide whether or not to proceed in the randomized controlled trial. It was explained 
to patients that participation in the screening phase was valuable in itself, because 
it would increase insight in the prevalence of anxiety and depressive symptoms of 
adolescents and young adults with IBD and it would give patients insight in their own 
level of anxiety and depressive symptoms.
measures
Demographic characteristics
Gender and age were retrieved from the medical charts. Socioeconomic status was 
classified using the occupational level from the parents or, if patients lived on their 
own, patients themselves [36].
clinical characteristics
clinical disease activity was assessed by four validated instruments. For CD, the 
short Pediatric Crohn’s Disease Activity Index (10-20 years) [37] and the Crohn’s Dis-
ease Activity Index (21-25 years) [38] was used. For UC, the Pediatric Ulcerative Colitis 
Activity Index (10-20 years) [39] and the partial Mayo score (21-25 years) [40, 41].To 
combine all four measures, the categorical predefined classifications remission, mild, 
moderate, and severe were used.
Disease type, age at diagnosis, disease duration, presence of perianal disease 
at diagnosis, previous bowel surgery, current therapy, steroid dependence past 
three months and number of relapses the preceding year were retrieved from 
the medical charts. relapse was defined as ‘physician reported relapse necessitating 
treatment intensification’. Disease location at diagnosis and extension of disease 
was assessed using the Paris or Montreal classification [42]. We defined limited disease 
as ‘E1’ or ‘E2’ for UC and ‘L1’ for CD. Extensive disease was defined as ‘E3’ or ‘E4’ for 
UC and ‘L2’, ‘L3’ or ‘L4a/b’ for CD. The following inflammatory parameters were col-
lected if available: C-reactive protein, Erythrocyte Sedimentation Rate, hemoglobin, 
hematocrit, leukocyte count, thrombocyte count and fecal calprotectin.
Anxiety and depression
Anxiety was assessed using the 69-item Screen for Child Anxiety Related Disorders 
(SCARED, for ages 10-20) and the anxiety scale of the Hospital Anxiety and Depression 
Scale (HADS-A, for ages 21-25), both self-report instruments. Five SCARED subscales 
were used: general anxiety disorder, separation anxiety disorder, specific phobia, 
panic disorder, and social phobia (response categories 0-2: total score 0-138). Satisfac-
tory reliability and validity have been reported [43]. The cutoffs for elevated symptoms 
of anxiety were total SCARED score ≥26 for boys, ≥ 30for girls, or a SCARED-subscale 
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score ≥ 8 [44]. The HADS anxiety scale consists of 7 items, rated on a 4-point scale (re-
sponse categories 0-3; total score 0-21). Excellent reliability has been found. Patients 
had elevated symptoms of anxiety if they scored 8 or higher [45]. Because initially only 
10-20 year old patients were included, we chose to use the SCARED, which is validated 
up to 19 years of age [46], also for 20 year old patients. Later, when 21-25 year old 
patients were included as well, the HADS-A was added.
Depression was assessed using the Child Depression Inventory (CDI, for ages 10-17) 
and the Beck Depression Inventory, second version (BDI-II, for ages 18-25). The CDI is a 
27-item self-report scale (response categories 0-2, total score 0-54). Good reliability and 
validity of the Dutch version have been established and a CDI score of 13 or higher 
reflected elevated symptoms of depression [47]. The BDI-II is a 21-item self-report 
scale (response categories 0-3, total score 0-63), with a score of 14 or higher indicating 
elevated symptoms of depression. It has excellent reliability and good to excellent 
validity [48].
Severity of anxiety and depression
In patients with elevated anxiety and/or depressive symptoms, severity was assessed 
by a (telephonic) psychiatric diagnostic interview performed by a trained psychologist 
(Anxiety Disorders Interview Schedule - Child and Parent Version (ADIS-C/P) [49, 50]. 
Severity of anxiety was rated using the Pediatric Anxiety Rating Scale (PARS; ages 
10-20) [51] and the Hamilton Anxiety rating scale (HAM-A; ages 21-25) [52]. Depressive 
severity was rated using the Child Depression Rating Scale - Revised (CDRS-R; ages 
10-12) [53], the Adolescent Depression Rating Scale (ADRS; ages 13-20) [54], and the 
Hamilton Depression Rating Scale (HAM-D; ages 21-25) [55]. For this study, we grouped 
the patients with anxiety and/or depressive symptoms, to describe the patients with 
‘a psychological burden’. This group includes patients suffering from either anxiety 
symptoms or depressive symptoms, or both. The term ‘anxiety/depressive symptoms’ 
is used to refer to this patient group. Anxiety/depressive symptoms were classified 
as ‘severe’ if they met the criteria for a clinical depressive or anxiety disorder on the 
ADIS-C/P and a score equal to or above the clinical cutoff on the CDRS (40) [56], ADRS 
(20) [54], or PARS (18) [51]. The remaining group of patients was classified as having 
subclinical or mild anxiety and/or depression. See Figure 1.
Health-related quality of life
Health-related quality of Life (HRQOL) was assessed by the IBD-disease specific self-
report questionnaires IMPACT-III (ages 10-20, because initially only 10-20 year old 
patients were included) and IBDQ (ages 21-25), both having good psychometric proper-
ties [57-60]. The IMPACT-III contains of 35 items (score 1-5; range 35-175) which cover 
six domains: IBD-related symptoms, systemic symptoms, emotional functioning, social 
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functioning, treatment related concerns, and body image. The IBDQ contains 32 items 
(score 1-7; range 32-224) that cover four domains: bowel, systemic, social, and emo-
tional functioning. For both questionnaires, a higher score reflects better quality of life.
Statistical analysis
Frequency analyses were conducted to describe the prevalence of anxiety and depres-
sive symptoms (aim 1). Exploratory tests (one-way ANOVA, Kruskal-Wallis and Chi-
Square test) were conducted to provide insight in differences between patients with 
no, mild and severe anxiety and/or depressive symptoms.
Multiple imputation with chained equations (MICE) with ten imputations (m=10) 
was used to impute the missing values in the variable socio-economic status [61]. 
Missing data on outcome variables were not imputed. Results for complete cases and 
multiple imputation analysis were compared. To compare the variables in the regres-
sion model to each other, the continuous variables were standardized and used in the 
model as z-scores.
Screening ques�onnaires anxiety and depression
Above cut oﬀ 
anxiety and/or depression?
Elevated symptoms anxiety and/or 
depression on ques�onnaires
Anxiety
SCARED (10-20 years)
HADS-A (21-25 years)
Below cut oﬀ 
anxiety ánd depression?
Depression
CDI (10-17 years)
BDI-II (18-25 years)
Psychiatric interview (ADIS-C) (10-25 years)
Clinical
anxiety/depressive
disorder
No clinical
anxiety/depressive
disorder
Subclinical / mild 
symptoms
Clinical / severe 
symptoms*
No 
symptoms
figure 1 | Flowchart screening anxiety/depression
Abbreviations: SCARED= Screen for Child Anxiety Related Emotional Disorders; HADS-A= Hospi-
tal Anxiety and Depression Scale – Anxiety scale; CDI= Child Depression Inventory; BDI-II= Beck 
Depression Inventory-second edition ADIS-C= Anxiety Disorders Interview Schedule for Children
Notes: * indicative of a disorder. Cutoff scores for each questionnaire are specified in the text
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To identify risk factors for symptoms of anxiety and depressive symptoms (aim 2), 
we conducted four regression analyses with the following outcomes. I: absence/pres-
ence of anxiety/depressive symptoms, II: severity of anxiety/depressive symptoms, 
III: absence/presence of anxiety symptoms and IV: absence/presence of depressive 
symptoms. Analysis III and IV were performed to investigate risk factors specific for 
anxiety or depressive symptoms. For analysis I, III and IV a binomial logistic regres-
sion and for analysis II an multinomial logistic regression was conducted. Subgroup 
analysis was performed for patients 10-17 and 18-25 years. In the regression analysis, 
the α-level was adjusted for multiple comparison, considering Bonferroni correction 
is considered conservative [62], it was set at p < 0.025. Adequacy of the models was 
assessed using the appropriate ‘Goodness-of-Fit’ tests.
Data analysis were performed using Statistical Package for the Social Sciences, Ver-
sion 21.0 (IBM SPSS Statistics for Windows, Armonk, NY) and the computing environ-
ment R for multiple imputation (R Development Core Team, 2016. R Foundation for 
Statistical Computing, Vienna, Austria).
reSultS
Patients characteristics
A total of 374 adolescents and young adults (mean age: 18.92 years, SD 4.13) completed 
the assessment. Almost fifty percent of patients were <18 years of age. Most patients 
had CD (60.4%) and the majority had inactive disease (75.4%), but 33.4% had relapsed 
in the year prior to this assessment. More than one third of the patients was receiving 
treatment with a biological (35.8%) and 285 patients (76.2%) had extensive disease. 
16.3% received IBD-related surgery in the past, of which half had a resection of small 
and/or large intestine (7.5%) and half had abscess drainages, fistula surgery or balloon 
dilatations (8.8%). See Table 1.
Prevalence of anxiety and depression
372 patients completed the depression questionnaires (CDI and BDI-II), 373 the 
anxiety questionnaires (SCARED, HADS-A). Of the 371 patients with complete data on 
both anxiety and depression, 176 (47.4%) patients experienced elevated symptoms of 
anxiety and/or depression. Anxiety symptoms were more prevalent than depression: 
elevated symptoms of either anxiety, depression or both were found in respectively 
106 (28.3%), 11 (2.9%) and 59 (15.8%) patients. 195 patients (52.1%) did not show any 
elevated symptoms. Of the 371 patients, 168 patients were included in the two ter-
tiary hospitals, 204 in four community hospitals. Prevalence rates did not significantly 
differ between academic or community hospitals for elevated symptoms of either 
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anxiety (27.5% vs 29.4%), depression (2.4% vs 3.4%) or both (15.0% vs 16.7%) (χ2(3)=.98, 
p=0.808).
table 1 | Patient characteristics (N=374)
mean ± SD or n (%)
Gender, Male 165 (44.1)
Age (years) (% <18 years) 18.92 ± 4.13 (45.5%)
Age at diagnosis (years) (% < 18 years) 15.40 ± 4.33 (71.4%)
Duration of disease (years) (Median;IQR) 2.45 (1.1-5.1)
Socioeconomic status
(N = 346)
Low 61 (17.6)
Middle 144 (41.6)
High 141 (40.8)
Type of disease CD 226 (60.4)
UC 128 (34.2)
IBD-U 20 (5.3)
Paris/Montreal classification at 
diagnosis†:
CD: location‡, (N = 226)
L1 38 (16.8)
L2 38 (16.8)
L3 100 (44.2)
+ L4a/L4b 50 (22.1)
CD: behaviour
nonstricturing. nonpenetrating (B1) 216 (95.6)
stricturing. penetrating or both (B2B3) 10 (4.4)
perianal disease 47 (20.8)
UC: extent (N = 148)§
limited: E1 + E2 51 (34.5)
extensive: E3 + E4 97 (65.5)
UC: severity. ever severe 20 (13.5)
Clinical disease activity Remission 282 (75.4)
Mild 74 (19.8)
Moderate 10 (2.7)
Severe 8 (2.1)
Current medication use Aminosalicylates 116 (31.0)
Immunomodulators 175 (46.8)
Biologicals 134 (35.8)
Corticosteroids¶ 36 (9.6)
Topical treatment¥ 20 (5.3)
No medication 26 (7.0)
Steroid dependence past 3 months 55 (14.7)
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Of the patients <18 years, 34.9% showed elevated anxiety, compared to 23.2% in 
the ≥18 age group. This was not significantly different. For depression and anxiety/
depression combined, differences between the <18 and ≥18 age group were small and 
not significantly different.
Of the 131 patients with elevated anxiety, <21 years of age (and who completed 
the SCARED questionnaire), 122 of 131 patients (93.1%) scored above the established 
cutoff for 1 or more anxiety domains. Specified per domain, generalized anxiety was 
found in 45.8%, separation anxiety in 23.7%, specific phobia (consisting of animal 
phobia, blood phobia and situational phobia) in 55.7%, panic symptoms in 19.8% and 
social phobia in 48.8% of the 131 patients.
Health-related quality of life
Mean IMPACT-III score (patients <21 years, N=256) was 142.7 (±19.3 SD, range: 76-174) 
and mean IBDQ score (patients ≥21 years, N=110) was 178.7 (range: 97-224; data not 
shown).
Prevalence of mild and severe anxiety/depressive symptoms
Of the 177 patients with elevated symptoms of anxiety/depression, 134 patients 
completed a psychiatric interview assessing severity of psychological symptoms. The 
other 43 patients did not consent to the interview, because they only consented to 
the questionnaires and/or were not willing to participate in the larger research proj-
ect, including the randomized controlled trial, for which the psychiatric interview 
was a necessary part. Clinical, severe symptoms were found in 46 (34.3%) and mild 
symptoms in 88 (65.6%) patients. Of the 46 patients with clinical symptoms, 23 (50%) 
fulfilled the criteria for an anxiety disorder, 5 (10.8%) for a depressive disorder, and 
15 (32%) fulfilled the criteria for both anxiety and depressive disorders. The other 
table 1 | Patient characteristics (N=374) (continued)
mean ± SD or n (%)
Relapses preceding year 1 relapse 103 (27.5)
≥2 relapses 22 (5.9)
Bowel resection in history 28 (7.5)
Extra intestinal manifestations II 57 (15.2)
Abbreviations: SD= standard deviation, IQR= interquartile range, CD= Crohn’s Disease, UC: ulcer-
ative colitis, IBD-U: IBD-unclassified.
Notes: †UC includes IBD-U patients ‡L1: ileocecal, L2: colonic, L3: ileocolonic, L4a: upper gastro-
intestinal tract proximal and L4b distal from Treitz ligament §E1: proctitis, E2: left sided colitis 
distal of splenic flexure, E3: extensive colitis distal of hepatic flexure, E4: pancolitis ¶prednisone 
(oral and intravenous) and budesonide (oral) ¥aminosalicylate or corticosteroid enemas ||EIM: in-
volving skin (31.5%), eyes (1.75%), liver and biliary tracts (10.5%), joints (33.3%) and bones (28.1%)
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three patients did not fulfill the criteria for an anxiety or depressive disorder, but 
severity of other psychological problems was clearly reported by parents during the 
psychiatric interview. One patient showed extreme rebellious behavior, the other 
irritability and tantrums. For the last patient, only parents reported depressed mood 
and signs of social and specific anxiety. In all three patients, family functioning was 
severely disturbed and continuing in the randomized controlled trial was not ethical, 
so psychological help was provided directly after screening.
Differences between patients with no mild and severe anxiety/
depressive symptoms
Exploratory analysis showed that clinical disease activity was significantly higher in 
patients with severe anxiety/depressive symptoms, compared to patients with mild (U 
= 1092.5, z = -5.1, p<0.001) and no anxiety/depressive symptoms (U = 2255.0, z = -6.8, 
p<0.001). Fecal calprotectin and Erythrocyte Sedimentation Rate were significantly 
higher in patients with severe anxiety/depressive symptoms compared to patients 
with no anxiety/depressive symptoms. See Tables 2 and 3 and Figure 2.
multiple regression analysis: risk factors for anxiety and depressive 
symptoms
risk factors for anxiety/depressive symptoms
Female patients (Odds Ratio [OR] 1.7 [95%CI 1.1-2.7], p=0.021) and patients with active 
disease (OR 1.9 [1.1-3.2], p=0.023) had higher odds of experiencing anxiety/depressive 
symptoms than male patients or patients in remission (see Table 4). Subgroup analysis 
showed that active disease (OR 3.07 [95%CI 1.3-7.3], p=0.011) and disease duration (OR 
0.66 [95%CI 0.5-0.9], p=0.018) were significantly associated with having anxiety/depres-
sive symptoms in patients ≥18 years (data not shown).
risk factors for mild and severe anxiety/depressive symptoms
Overall multinomial logistic regression analysis showed that gender (χ2(2)=9.2, 
p=0.010) and disease activity (χ2 (2)=26.0, p<0.001) significantly influenced severity of 
anxiety/depressive symptoms. Firstly, when comparing no to mild anxiety/depressive 
symptoms, analysis showed that female gender (OR 2.2 [95%CI 1.2-3.8], p=0.008) was 
associated with mild anxiety/depressive symptoms. Secondly, when comparing mild 
to severe anxiety/depressive symptoms analysis showed that active disease (OR 7.1 
[95%CI 2.8-17.7, p<0.001) was associated with severe anxiety/depressive symptoms.
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table 2 | Differences between patients with no, mild and severe symptoms of anxiety/depression†
no
n = 195
mild
n = 88
Severe
n = 46
p
Gender Female n (%) 97 (49.7) 58 (65.9) 34 (73.9) 0.002
Disease 
duration (years)
Median (IQR) 2.7 (1.3-6.1) 2.0 (1.0-4.8) 1.7 (0.9-3.6) 0.014
Disease activity Remission n (%) 162 (83.1) 67 (76.1) 16 (34.8) <0.001
Mild n (%) 26 (13.3) 21 (23.9) 21(45.7) 
Moderate n (%) 6 (3.1) 0 2 (4.3) 
Severe n (%) 1 (0.5) 0 7 (15.2) 
Steroid use n (%) 13 (6.7) 9 (10.2) 9 (19.6) 0.025
Relapse 
preceding year
No n (%) 137 (70.3) 57 (64.8) 22 (47.8) 0.025
1 n (%) 49 (25.1) 27 (30.7) 17 (36.9) 
>1 n (%) 9 (4.6) 4 (4.5) 7 ( 15.2) 
HRQOL IMPACT-III (N=226) Mean ± SD 152.9 ± 13.9 138.4 ± 14.7 115.0 ± 17.4 <0.001
IBDQ (N=101) Mean ± SD 192.8 ± 16.9 164.5 ± 15.4 138.9 ± 26.6 <0.001
Abbreviations: IQR= interquartile range, SD= standard deviation, HRQOL= Health-related quality 
of life, IBDQ= Inflammatory Bowel Disease Questionnaire.
Note: †Total N=329 (134/177 patients with elevated symptoms received the psychiatric interview, 
resulting in 88 patients with mild and 46 patients with severe anxiety/depressive symptoms).
table 3 | Inflammatory parameters in patients with no, mild and severe anxiety/depressive symptoms
no
n = 195
mild
n = 88
Severe
n = 46
p
C-Reactive 
protein (mg/L)
available samples 154 73 37
median (IQR) 2.0 (1.0-5.0) 2.2 (0.7-6.0) 3.0 (1.0-9.0) 0.087
Hemoglobin 
(mmol/L)
available samples 166 82 41
median (IQR) 8.2 (7.7-9.0) 8.2 (7.7-8.7) 7.9 (7.1-8.3) 0.011
Hemocrit (L/L) available samples 160 79 40
median (IQR) 0.41 (0.38-0.44) 0.40(0.38-0.42) 0.39 (0.36-0.40) 0.024
Leukocytes (109/L) available samples 165 81 41
median (IQR) 6.7 (5.4-8.4) 5.8 (5.5-8.8) 7.2 (6.0-10.2) 0.362
Trombocytes 
(109/L)
available samples 164 82 41
median (IQR) 296 (243.3-357.5) 311.5 (246.8-358.8) 326 (228.5-387.5) 0.671
Erythrocyte 
Sedimentation 
Rate (mm/h)
available samples 89 52 23
median (IQR) 7.0 (3.0-19.0) 6.0 (3.3-19.5) 16.0 (6.0-23.0) 0.047
Faecal 
calprotectin (µg/g)
available samples 67 48 23
median (IQR) 106.0
(34.0 -645.0)
295.1
(30.8-807,8)
602.3
(163.0-1173.0)
0.037
Abbreviations: IQR= interquartile range
92
risk factors for anxiety symptoms
Female patients (OR 1.8 [95%CI 1.1-2.9], p=0.013) and patients with active disease (OR 
1.9 [95%CI 1.1-3.2], p=0.019) had higher odds of experiencing anxiety symptoms than 
male patients and patients in remission. See Table 4. Subgroup analysis showed that 
active disease was significantly associated with anxiety symptoms in patients ≥18 
years (OR 2.6 [95%CI 1.1-6.1], p=0.025) (data not shown).
risk factors for depressive symptoms
Patients with active disease had higher odds of having depressive symptoms, com-
pared to patients in remission (OR 4.6 [95%CI 2.4-8.8], p<0.001) (See Table 4). Subgroup 
analysis showed that active disease was significantly associated with depressive 
symptoms in patients ≥18 years (OR 7.7 [95%CI 2.8-21.2], p<0.001) (data not shown).
table 4 | Factors associated with elevated anxiety/depressive, anxiety or depressive symptoms
Anxiety/depressive 
symptomsI n = 177
Anxiety 
symptomsII
n = 166
Depressive 
symptoms III
n = 70
or 95% cI p or 95% cI p or 95% cI p
Age (years) - 0.82 0.64-1.05 0.121 0.72 0.56-0.92 0.010 1.41 1.00-2.00 0.049
Gender Male
Female 1.72 1.09-2.73 0.021 1.81 1.13-2.88 0.013 1.61 0.86-3.01 0.138 
Socioeconomic 
status
Low
Middle 0.88 0.45-1.71 0.707 1.01 0.52-1.98 0.971 1.47 0.62-3.49 0.382 
High 0.69 0.36-1.33 0.268 0.80 0.41-1.56 0.512 0.66 0.27-1.63 0.364 
Disease type CD
UC 1.12 0.56-2.26 0.745 1.17 0.58-2.36 0.663 2.14 0.85-5.41 0.108 
IBD-U 0.74 0.24-2.25 0.597 0.85 0.28-2.60 0.776 0.85 0.18-3.97 0.837 
Disease 
duration (years)
- 0.75 0.58-0.97 0.027 0.82 0.64-1.07 0.144 0.72 0.50-1.03 0.075
Disease activity Remission
Active disease 1.87 1.10-3.21 0.023 1.90 1.11-3.24 0.019 4.58 2.38-8.80 <0.001 
Perianal disease 0.93 0.45-1.90 0.835 0.78 0.37-1.62 0.497 1.29 0.49-3.39 0.606
Previous Bowel 
surgery
1.16 0.44-3.09 0.767 1.14 0.44-2.98 0.791 0.97 0.27-3.48 0.960
Current 
medication
5-ASA 0.81 0.38-1.71 0.573 0.82 0.38-1.75 0.606 0.40 0.14-1.10 0.075
Immunomodulators 0.84 0.49-1.44 0.519 0.88 0.51-1.51 0.632 0.69 0.33-1.45 0.330
Biologicals 1.10 0.59-2.05 0.759 1.29 0.69-2.40 0.429 0.62 0.27-1.45 0.269
Corticosteroids 1.65 0.57-4.80 0.361 1.75 0.60-5.14 0.308 0.83 0.24-2.87 0.769
Enemas 0.76 0.27-0.19 0.616 0.87 0.30-2.49 0.795 1.45 0.43-4.90 0.554
No Medication 0.58 0.19-1.77 0.339 0.77 0.25-2.35 0.644 0.63 0.15-2.60 0.520
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DIScuSSIon
This study is unique in describing the prevalence, severity and risk factors of symp-
toms of anxiety and depression, in Europe’s largest cohort of pediatric and young 
adult patients with IBD. In the current study, the prevalence of anxiety/depressive 
symptoms was high, almost 50%. This is almost three times higher than reported in 
a community sample of Dutch adolescents [63]. Anxiety symptoms where far more 
figure 2a (left) | Patients with severe anxiety/
depressive symptoms had more relapse pre-
ceding year compared to patients with mild or 
no anxiety/depressive symptoms
Note: * p<0.05
figure 2b (right) | A higher percentage of ac-
tive disease was found patients with severe 
anxiety/depressive symptoms compared to 
patients with mild or no anxiety/depressive 
symptoms
Note: * p<0.05
table 4 | Factors associated with elevated anxiety/depressive, anxiety or depressive symptoms (continued)
Anxiety/depressive 
symptomsI n = 177
Anxiety 
symptomsII
n = 166
Depressive 
symptoms III
n = 70
or 95% cI p or 95% cI p or 95% cI p
Relapse 
preceding year
No relapse
1 relapse 1.05 0.63-1.75 0.850 1.08 0.65-1.80 0.777 1.33 0.69-2.56 0.391 
≥2 relapses 1.12 0.39-3.17 0.836 1.04 0.37-2.95 0.938 1.44 0.45-4.64 0.539 
Disease 
extension
Limited
extensive 0.66 0.39-1.14 0.140 0.64 0.37-1.11 0.110 1.00 0.50-1.98 0.994 
Steroid use < 3 
months
0.84 0.35-2.01 0.701 0.79 0.33-1.92 0.602 1.41 0.49-4.09 0.524
Abbreviations: or= odds ratio, CI= confidence interval, CD= Crohn’s disease, UC= ulcerative coli-
tis, IBD-U= indeterminate colitis, 5-ASA= 5-aminosalicylic acid.
Notes. I 2 missing, total 372; II 1 missing, total 373; III 2 missing, total 372
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prevalent than depressive symptoms (28.3% vs 2.9%), but they also often occurred 
concomitantly (15.8%). It is well known that anxiety and depressive symptoms can 
coexist [18], but few studies investigated the presence of both anxiety and depressive 
symptoms in young patients with IBD. Compared to previous studies, our cohort has 
a higher prevalence of anxiety symptoms [9-11], whereas prevalence of depressive 
symptoms seems to be lower [5, 10, 64]. We expect that the prevalence rates vary 
depending on the activity and severity of disease. For example, a prevalence of ±5% 
was reported in a study cohort of mild and uncomplicated disease (only patients in 
remission, oral medication [no steroids] and IBD diagnosis >1 year; 13). The most 
prevalent anxiety domains found in our study were social phobia, generalized anxiety 
and specific phobia, which is similar to other studies [11, 12]. The low prevalence of 
depressive symptoms in our cohort can be explained by the low CDI total cutoff score 
used in the other studies, using cutoff points of 9 [5] or 10 [12], which correspond to 
(T-)scores within the average range [64, 65]. It could have been that patients in those 
studies were labeled as having depressive symptoms, where in fact their scores might 
have been in the normal range. Secondly, the higher percentage of patients with 
active disease in the other studies could also explain the higher rates of depressive 
symptoms.
A major strength of our study is that we studied the severity of anxiety/depressive 
symptoms, based on severity scores given during the psychiatric interview. Of the 
177 patients with elevated anxiety/depressive symptoms, 134 patients agreed to this 
interview. 46 patients were diagnosed with severe symptoms and where referred for 
psychological consultation and treatment (12.2% of the total sample). Exploratory 
analysis showed that patients with severe symptoms had significantly higher disease 
activity, used steroids more frequently, experienced more relapses in the preceding 
year and had a lower quality of life than patients with mild or no symptoms. It is 
important to note that, relapses in the preceding year, as an indicator for disease 
severity, were associated with severity of anxiety/depressive symptoms. In addition, 
disease duration was also significantly shorter in the group with mild and severe 
anxiety/depressive symptoms, which may indicate that patients with a longer dis-
ease duration have more time to adapt and build adaptive coping strategies. This is 
supported by the study from Walter et al. [13], that included only patients with a 
longer that one year prior diagnosis of IBD and found a 13% prevalence of anxiety and 
depressive symptoms. It is not likely that patients in the mild and severe group suf-
fered from an adjustment disorder due to recent diagnosis of IBD, as the majority of 
patients had a disease duration >3 months. Considering the fact that not all patients 
agreed to the psychiatric interview (24.2% refused), the severe group could well be an 
underestimation, implying that the group with severe anxiety/depressive symptoms 
might even be larger.
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Our findings confirm our hypothesis that clinical disease activity is an important 
risk factor for anxiety and depression. This corresponds to previous findings [5, 11, 
16, 21, 22, 29] and implies that disease control is important for physical health as 
well as mental health. It also emphasizes that attention should be given to emotional 
health in times of active disease. Studies that have shown an association between 
anxiety/depression and relapse [8], as part of the brain-gut axis, support this recom-
mendation. In addition, in line with previous studies [66], we showed that female 
gender is a significant risk factor for anxiety and depression. This is probably not 
a consequence of an IBD-specific cause, because it parallels the well-known gender 
differences in the general population [67]. We failed to find a significant association 
between steroid use and anxiety and/or depressive symptoms, which is in agreement 
with the finding from Reed-Knight et al. [64] and several studies in adults with IBD 
[66], but in contrast to other pediatric IBD studies [5, 29]. This is likely due to the low 
number of patients using steroids in our cohort (9.6%). Due to these small numbers 
we were not able to take the dosage into account, which most aforementioned studies 
did. Moreover, this study investigated whether the risk factors for anxiety symptoms 
or for depressive symptoms would be different. Analysis showed that age and gender 
were significantly associated with anxiety, but not with depressive symptoms. This 
could reflect the actual situation, but could also be a consequence of the fact that 
the group with depressive symptoms was smaller. Surprisingly, socio economic status 
was not associated with anxiety and/or depression, whereas other studies did find this 
association [29].
Major strengths of this study are that data were collected consecutively and con-
cern a unique study population: pediatric as well as young adult IBD patients from 
regional as well as tertiary medical centers, which makes the results generalizable. In 
addition, and contrary to other studies [5, 11, 27, 29], we assessed anxiety and depres-
sion concomitantly as this has implications for subsequent psychological treatment. 
Furthermore, to the best of our knowledge, we are the first to address the severity 
of the anxiety and depressive symptoms and show that 12.2% of our cohort suffers 
from severe anxiety/depressive symptoms. Moreover, our large cohort has few missing 
values, allowing us to directly perform multiple regression analysis, which does not 
introduce the (multiple testing) bias which is applied in studies that first perform uni-
variate analysis to select significant variables for the multiple or multivariate analysis.
This study has several limitations. Firstly, considering that most patients were in 
clinical remission in our cohort and that the group with active disease mostly con-
sisted of patients with mild disease activity, the prevalence estimates of anxiety and 
depressive symptoms could have been an underestimation. Secondly, because of the 
wide age range (10-25 years) we had to use 2 different validated questionnaires both 
for anxiety and depression and consequently could not work with continuous data. 
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While the use of validated cutoff scores is highly accepted, it does limit options for 
analyses. Furthermore, the BDI-II as well as the CDI contains questions concerning for 
example sleep disturbance, fatigue and reduced appetite. These items are also called 
‘somatic items’ because they can both relate to a physical illness or be an indicator 
of depression. It is suggested that these instruments could overestimate the presence 
of depressive symptoms in physically ill patients. There is ongoing debate about the 
best strategy for this issue: some argue that these items should be removed, but others 
argue the entire screen instrument is more valid because these symptoms do not 
always correlate to disease activity and do respond to psychological treatment [68]. 
Further research is necessary to provide an evidence based strategy regarding the 
use of these instruments in physically ill patients. In addition, we tried to investigate 
differences in risk factors for anxiety and depressive symptoms between the pediatric 
and young adult population. Analysis did not show significant risk factors in the < 18 
age group, which could have reflected the actual situation, but could also be explained 
by low power, or the fact that other predictors, that were not included in the regres-
sion model (for example fatigue or abdominal pain), more strongly influence anxiety/
depressive symptoms in younger patients. Thirdly, not all patients were willing to 
participate in the psychiatric interview and this could have led to and underestima-
tion of the group with severe anxiety/depressive symptoms. Furthermore, the purpose 
of the psychiatric interview was to differentiate severe/clinical from mild/subclinical 
anxiety/depressive symptoms and not to establish the presence of other psychiatric 
disorders. Although this would have been interesting, the study was not designed to 
do so, and there is not much evidence to suspect the presence of other psychiatric 
disorders in youth with IBD [69]. Fourthly, due to logistic constraints inflammatory 
markers (e.g. C-Reactive protein, fecal calprotectin) were not available for all patients 
and could not be used in the regression models, but have shown to be different be-
tween the severe and no anxiety/depressive symptoms group. Although the validated 
clinical disease activity indices are frequently used in research, there is debate about 
the actual correlation to intestinal inflammation. Finally, our study did not encompass 
validated measures of abdominal pain, irritable bowel syndrome and fatigue, while 
these factors are shown to be correlated with anxiety and depression [28]. Including 
these measures would have increased the length of our questionnaire and the risk of 
non-completion, therefore we chose not to include them in this study.
Despite these limitations, this study provides valuable information about the 
prevalence and risk factors of anxiety and/or depression in adolescents and young 
adult patients with IBD. We report a high prevalence of anxiety/depressive symptoms 
of almost 50%. Analyses showed active disease and female gender to be the most 
important predictors. In conclusion, we have shown that the prevalence of anxiety 
and depressive symptoms is high in adolescent and young adult IBD patients. These 
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psychological problems can have a significant impact on the burden of disease and can 
lead to increased health care costs. Therefore we recommend psychological screening 
in adolescent and young adult IBD patients. Screening facilitates early recognition and 
early psychological treatment, in order to improve psychological well-being and clini-
cal course of disease. Physicians should be aware that female patients and patients 
with active disease are the most vulnerable.
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ABStrAct
Background In youth with inflammatory bowel disease (IBD), health-related quality 
of life (HRQOL) has been shown to be affected by individual disease factors and spe-
cific psychological factors. The innovative aim of this study is to examine the combined 
impact of psychological factors (illness perceptions, cognitive coping, anxiety, and 
depression) on HRQOL, over and above the associations of demographic and disease 
factors with HRQOL in youth with IBD.
methods Data on clinical disease activity, illness perceptions, cognitive coping, anxi-
ety, depression, and HRQOL were prospectively collected in 262 consecutive youth 
(age 10-20, 46.6% male) with confirmed IBD. Multiple linear regression analyses tested 
the associations of demographic, disease, and psychological variables with HRQOL in 
separate groups for Crohn’s disease (CD; N=147) and ulcerative colitis and IBD unclas-
sified (UC/IBD-U; N=115), using age-specific validated instruments.
results In both disease groups more negative illness perceptions (ß = -.412; ß = -.438, 
p < .001) and more depression (ß = -.454; ß = -.279 , p < .001) were related to lower 
HRQOL. In the UC/IBD-U group, more anxiety was related to lower HRQOL (ß = -.201, p 
= .001). The model with the psychological variables explained a large and significant 
amount of variance in both groups: 74%; 83%; respectively (p < .001).
conclusions In 10-20-year-old IBD patients, negative illness perceptions and depres-
sion were significantly and more strongly associated with lower HRQOL than demo-
graphic and disease factors. Thus, it is important to integrate psychological factors in 
the treatment for IBD patients. To improve HRQOL in young IBD patients, psychologi-
cal interventions should be targeted at negative illness perceptions and depression.
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IntroDuctIon
Inflammatory bowel disease (IBD) is a disabling chronic gastrointestinal condition, 
with two predominant subtypes: Crohn’s disease (CD) and ulcerative colitis (UC). In up 
to 25% of patients, IBD starts in late childhood or adolescence [1-3]. The designation 
IBD unclassified (IBD-U) is used for patients in which it is not (yet) possible to make 
a distinction between CD and UC. IBD is characterized by periods of clinical disease 
activity and remission, and presents with symptoms such as abdominal pain, bloody 
diarrhea, fatigue and weight loss [4]. In adolescence, growth failure and delayed pu-
bertal development is common, specifically in Crohn’s disease. The adolescent life 
phase is characterized by development on several domains (biological, psychological, 
social, cognitive, academic). Having a chronic disease such as IBD can affect all these 
domains, for example not only becoming more independent from parents, developing 
long-term friendships, starting secondary education, forming an own identity, but 
also experimenting with alcohol and drugs, seeking and finding a (side) job and hav-
ing romantic relationships. The teenage years are a crucial period of transition from 
childhood to young adulthood [5]. IBD and its medical treatment may severely impact 
psychosocial functioning: health-related quality of life (HRQOL) in children and ado-
lescents (further referred to as youth) with IBD is significantly lower than in healthy 
peers [6, 7]. Furthermore, high prevalence rates varying from 20-50% for anxiety and 
depression are found in these patients [8-11]. A recent meta-analysis in children and 
adolescents showed pooled prevalence rates for anxiety and depressive symptoms of 
15%, and for anxiety and depressive disorders of 3-4% [12].
Other psychological factors are also important to consider in patients with IBD, 
such as illness perceptions and coping, because these have been shown to be related 
to psychosocial outcomes (such as HRQOL, general functioning or adjustment to IBD). 
Illness perceptions refer to the cognitive and emotional representations a patients 
forms about his or her disease [13]. These representations cover several dimensions, 
i.e. consequences (the expected effects of the disease), timeline (expectations about 
the duration of the disease), cause (thoughts about the cause of the disease), control-
lability (the extent to which the individual believes he or she can control the disease 
with or without treatment), identity (how the individual describes the symptoms and 
perceives as part of the disease), concern (worries about the disease), and emotions 
(the emotional response to the disease) [13, 14]. Coping refers to intentional efforts to 
regulate negative emotions in response to harm, threat or challenges [15, 16], in this 
study dealing with IBD. Coping encompasses both cognitive and behavioral regula-
tion. Cognitive coping is implicated in the etiology and the maintenance of anxiety 
and depression [17, 18], and is therefore important as well in studying youth with IBD.
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The Common Sense Model (CSM) is a model to describe the relationships between 
disease characteristics, illness perceptions, coping, and anxiety, depression and 
HRQOL, originally developed by Leventhal and Diefenbach [13]. In this model, illness 
characteristics (such as clinical disease activity) lead to certain thoughts about the ill-
ness, the so-called illness perceptions of a patient. These illness perceptions influence 
the type of coping the patient uses to deal with his/her symptoms. Together, these 
factors lead to positive or negative illness outcomes, for example anxiety, depression, 
or HRQOL. In patients with IBD, several relationships have been found between these 
variables, mostly in adults. Below it will be explicitly mentioned if studies were con-
ducted in youth with IBD. For example, more clinical disease activity has been found 
to be associated with more anxiety and depression separately [20, 21]. Previous studies 
have also demonstrated a relationship between clinical disease activity and HRQOL, 
with a mediating role for anxiety and depressive symptoms [20, 22]. Furthermore, 
negative illness perceptions are associated with lower HRQOL in adults with IBD [25] 
and also with more psychological problems in youth with IBD [26]. Coping was associ-
ated with anxiety and depression [23] or adjustment to IBD [27] in adults, and found as 
predictor of depression in youth with IBD as well [28].
Unfortunately, very little is known on how all the factors described above together 
affect health outcomes, more specifically HRQOL in young IBD patients. Only a few 
studies examined several psychological factors simultaneously. In adults, illness per-
ceptions [24] and coping [23] have been reported to impact the relationship between 
clinical disease activity on HRQOL. Recently, Van Tilburg et al. [29] showed in adoles-
cents with IBD that patient-reported disability (as outcome) was associated not only 
with clinical disease activity, but also with a combined latent construct ‘psychological 
factors’ (including coping, pain beliefs, anxiety, and depression). However, they did 
not control for demographic factors (gender, age, socioeconomic status), and did not 
include other disease factors, such as disease type, and disease duration. In addition, 
there is some evidence that these disease factors are associated with HRQOL [21, 30, 
31], and with anxiety and/or depression as well [26, 32]. Moreover, because the authors 
used a combined psychological construct, their findings provide no insight on which 
psychological factors in particular psychological interventions for youth with IBD 
should focus.
The complex interplay between clinical disease activity, illness perceptions, cop-
ing, anxiety, and depression makes it challenging to attune both the medical and 
psychological treatment to the individual needs of IBD patients to improve their 
HRQOL. The surplus value of the present study in a cohort of youth with IBD is that 
it aims to clarify the association of a combination of psychological factors (illness 
perceptions, cognitive coping, anxiety, and depression) with HRQOL, over and above 
demographic and disease factors. By selecting the 10-20-year age range, we cover the 
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period of transition from childhood to young adulthood. More specific insight on how 
psychological factors are associated with HRQOL in these vulnerable youth, can offer 
guidance on which factors psychological interventions should focus. Ultimately, with 
tailored psychological interventions, the course of the IBD and of possible psychologi-
cal problems may be positively affected. We hypothesize that clinical disease activity 
is negatively associated with HRQOL. Furthermore, we hypothesize that psychologi-
cal factors (i.e. illness perceptions, cognitive coping, anxiety, and depression), when 
tested simultaneously, are associated with HRQOL, even after controlling for clinical 
disease activity and other demographic and disease factors.
mAterIAlS AnD metHoDS
Design
The present cross-sectional cohort study is based on a large patient sample (N=374), 
completing the baseline assessment of a multicenter randomized controlled trial 
(RCT), investigating a disease-specific cognitive behavioral therapy in youth with IBD 
and symptoms of anxiety and/or depression (trial registration number: NCT02265588, 
see also Van den Brink & Stapersma et al. [33]). In the current study only data from 
patients aged 10-20 years were used (N=262).
Inclusion criteria were: 1) age 10 to 20 years and 2) diagnosis of IBD, according to the 
consensus criteria [34] [35, 36].
Exclusion criteria were: 1) intellectual disability, 2) current treatment for mental health 
problems (pharmacological and/or psychological), 3) insufficient mastery of the Dutch 
language, 4) a diagnosis of selective mutism, bipolar disorder, schizophrenia, autism 
spectrum disorder, obsessive-compulsive disorder, posttraumatic or acute stress-disor-
der, or substance use disorder, 5) cognitive behavioral therapy in the past year (at least 
8 sessions), and 6) participation in another intervention study.
Procedure
Consecutive patients and their parents were recruited between October 2014 and 
September 2016 from the outpatient clinic in two academic hospitals and four com-
munity hospitals in the Southwest region of the Netherlands. Patient information was 
given and written informed consent was requested in all patients and, if applicable 
their parents or caregivers. Patients (and parents), who consented to participate, 
received an e-mail with a link to online questionnaires. Clinical disease activity was 
scored by the (pediatric) gastroenterologist around the time of inclusion (i.e. within 
approximately a month around the time of inclusion, median = 3.42 weeks).
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measures
control variables
Gender, age, disease type, and disease duration of the patients were derived from 
their medical record. Socioeconomic status (SES) was determined using the occu-
pational level from the parents or, if they lived on their own, patients themselves. 
Using the standard coding system of Statistics Netherlands ([37]), occupations were 
categorized in low, middle and high. For gender and SES dummy variables were cre-
ated to use in the analyses.
clinical disease activity was assessed by two validated clinical disease activity 
instruments. For CD the short Pediatric Crohn’s Disease Activity Index (sPCDAI) and 
for UC the Pediatric Ulcerative Colitis Activity Index (PUCAI) was used. The sPCDAI 
comprises six items on medical history (abdominal pain, stools), well-being, physical 
examination (abdomen), weight and extra-intestinal manifestations [38]. Scores range 
from 0-90. [39]. The PUCAI comprises six items on abdominal pain, rectal bleeding, 
stool frequency and consistency, and activity level. Scores range from 0-85.
Psychological factors
Illness perceptions were assessed by the Brief Illness Perceptions Questionnaire (B-
IPQ; [14, 44]). This 9-item self-report questionnaire assesses cognitive and emotional 
representations of illness, covering eight dimensions: consequences, timeline, per-
sonal control, treatment control, identity, concern, emotions, and understanding. 
All dimensions are scored on an 11-point Likert-scale (0: not at all – 10: very much/
severely). A higher score represents more negative illness perceptions. Good test-retest 
reliability and concurrent validity has been found [14], and the B-IPQ has been used 
before in adolescents with IBD [45]. Internal consistency (Cronbach’s alpha) for the 
current sample was .81 in the CD group and .81 in the UC/IBD-U group.
cognitive coping was measured with the Cognitive Emotion Regulation Question-
naire (CERQ). This self-report scale consists of 36 items, scored 1-5, with nine subscales 
(e.g. self-blame, acceptance, putting into perspective, positive refocusing, positive 
reappraisal, and catastrophizing). These scales are divided into two domains: adaptive 
cognitive coping (e.g. positive reappraisal, putting in perspective) and maladaptive 
cognitive coping (e.g. self-blame, catastrophizing). A higher score indicates more use 
of a particular coping style. Good reliability and construct validity has been found [46]. 
Both adaptive coping and maladaptive coping were used as variable in the analyses. 
For adaptive cognitive coping, internal consistency was .90 in the CD group and .93 in 
the UC/IBD-U group. For maladaptive cognitive coping, internal consistency was .88 in 
the CD group and .90 in the UC/IBD-U group.
Anxiety was assessed using the 69-item self-report questionnaire Screen for Child 
Anxiety Related Disorders (SCARED). The SCARED contains five subscales: general 
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anxiety disorder, separation anxiety disorder, specific phobia, panic disorder, and 
social phobia, rated on a 3-point scale (0-2: total score 0-138). Satisfactory reliability 
and validity has been reported [47]. The cutoffs for elevated anxiety were total score 
≥ 26 for boys, ≥ 30 for girls, or subscale score ≥ 8 [48]. These were only used to decide 
whether patients had elevated anxiety, i.e. could be included in the RCT. Internal con-
sistency for the current sample was .95 in the CD group and .94 in the UC/IBD-U group.
Depression was assessed using the Child Depression Inventory (CDI, for ages 10-17) 
and the Beck Depression Inventory, second version (BDI-II, for ages 18-20). The CDI 
is a 27-item self-report scale (0-2, total score 0-54). Good reliability and validity have 
been established. A CDI score of 13 or higher reflected elevated depression [50]. The 
BDI-II is a 21-item self-report scale (0-3, total score 0-63). It has excellent reliability and 
good to excellent validity. A BDI-II score of 14 or higher reflected elevated symptoms 
of depression [51]. The cutoffs for the CDI and BDI-II were only used to decide whether 
patients had elevated depression, i.e. could be included in the RCT. For the CDI, inter-
nal consistency was .85 in the CD group and .86 in the UC/IBD-U group. For the BDI-II, 
internal consistency was .91 in the CD group and .84 in the UC/IBD-U group. To be 
able to combine patients of all ages within the disease groups, depression scores were 
created a Z-score for depression using either the CDI or the BDI-II (depending on age).
Health-related quality of life was assessed by the IBD-disease specific self-report 
IMPACT-III, which covers six domains: IBD-related symptoms, systemic symptoms, 
emotional functioning, social functioning, treatment related concerns, and body im-
age [52]. The 35 items are scored (1-5; total score 35-175). Good psychometric properties 
have been found [53]. The total score was used, and a higher total score indicates better 
HRQOL. Although the IMPACT-III originally was designed for youth up to 18 years, we 
also used it for the patients of 19 and 20 years. This allowed us to combine all patients 
in to one group for each disease type. This was substantiated by excellent internal 
consistency in both disease groups: .93 in the CD group and .94 in the UC/IBD-U group.
Statistical analyses
To test whether the associations of demographic, disease and psychological factors 
with HRQOL are different for CD than for UC/IBD-U, multiple linear regression analy-
ses were performed for the two disease groups separately: CD (N=147) and UC/IBD-U 
(N=115). UC and IBD-U were combined, since the group with IBD-U patients was quite 
small (N=18), IBD-U often resembles UC more than CD [55], and IBD-U has often a 
similar treatment approach as UC [56]. All variables were continuous, except for gen-
der and SES. For these variables dummy variables were included in the analyses. The 
abovementioned cutoffs for the SCARED, CDI, and BDI-II were only used to determine 
the proportion of patients with elevated anxiety or depressive symptoms. For the 
remaining questionnaires no cutoffs were used.
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The multiple linear regression analyses were run with two blocks/models, using 
HRQOL as outcome. In the first block, the demographic and disease variables (gender, 
age, disease duration, SES, and clinical disease activity) were entered simultaneously 
in the first regression model. In the second block, the psychological factors (illness 
perceptions, cognitive coping, anxiety, and depression) were added simultaneously 
to the variables entered in the first block. To account for missing values, multiple 
imputation with chained equations was applied using SPSS (m =15 for approximately 
15% of missing data; [57]). As a sensitivity analysis we also performed a complete case 
analysis (N=116; N=104 for the CD and UC/IBD-U groups respectively), to see whether 
the multiple imputations had an effect on the results. A p-value of < .05 was consid-
ered significant. SPSS Version 24 was used for the analyses (IBM Corp. Released 2016. 
IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp). A statistician 
(JE) supported and advised in analyzing and interpreting the data and results.
ethical considerations
This study was performed conform the Declaration of Helsinki and approved by the 
Institutional Review Board of the Erasmus MC and of each participating center.
reSultS
Patient characteristics
In total 552 patients (aged 10-25 years) were invited for a randomized controlled trial 
(RCT) and 382 agreed to participate (response rate = 69%). Eight patients had incomplete 
data. From the final 374 youth, 262 were aged 10-20 years and were included in the 
current study. Demographic, disease and psychological characteristics are presented 
in Table 1. In disease groups (CD and UC/IBD-U), the percentage of patients with active 
disease (mild-moderate-severe) was 31.3% and 30.4%, respectively. Overall, 50% of the 
patients had elevated anxiety, 17.9% had elevated depression, and 16.8% had both. For 
HRQOL, illness perceptions, and cognitive coping no cutoffs are available, so means 
with ranges are provided in Table 1.
Influence of demographic, disease and psychological variables on 
HrQol; results of multiple linear regression analyses per disease group
In Table 2-3, the standardized estimates, their significance, and the proportion of 
explained variance for each regression model (model 1 with demographic and disease 
factors and model 2 with psychological factors added) in the two disease groups are 
provided. Results are presented from the analyses on the imputed datasets. Results 
from the complete case analyses were similar (data not shown).
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As is seen in Table 2, in the CD group (N=147), female gender and clinical disease 
activity were significantly associated with HRQOL in the first model, explaining 37% 
of the variance in HRQOL. After adding the psychological factors, clinical disease 
activity (ß = -.170, p = .001), more negative illness perceptions (ß = -.412, p < .001), and 
more depressive symptoms (ß = -.454, p < .001) were associated with lower HRQOL. 
The second model explained 74% of the variance in HRQOL, with a significant change 
in explained variance (R2 change = 37%, p < .001).
table 1 | Demographic and disease characteristics of total sample of IBD patients (10-20 years)
Group
cD uc/IBD-u total
N=147 N=115 N=262
Demographic characteristics
Age (years), mean (SD) 17.19 (2.52) 16.15 (2.98) 16.74 (2.77)
Male (%) 50.3 41.7 46.6
SES (%)a Low 17.7 13.0 15.6
Middle 32.7 40.9 36.3
High 38.1 43.5 40.5
Disease characteristics
Disease type (%) CD 100 0 56.1
UC 0 84.3 37.0
IBDU 0 15.7 6.9
Age at diagnosis (years), mean (SD) 14.25 (3.02) 13.18 (3.97) 13.78 (3.50)
Disease duration (years), median (IQR) 2.26 (0.97-4.39) 1.90 (0.62-4.73) 2.03 (0.81-4.56)
Active disease (%)b 31.3 30.4 30.9
Psychological characteristics
Elevated anxiety symptoms (%)c 49.7 50.4 50.0
Elevated depressive symptoms (%)c 15.6 20.9 17.9
Elevated anxiety and depression (%)c 14.3 20.0 16.8
HRQOL, mean (range) 143.36 (76-174) 141.91 (82-173) 142.72 (76-174)
Illness perceptions, mean (range) 34.75 (3-69) 36.69 (9-70) 35.63 (3-70)
Adaptive cognitive coping, mean (range) 57.67 (20-92) 55.72 (21-97) 56.78 (20-97)
Maladaptive cognitive coping, mean (range) 25.05 (16-59) 25.12 (16-56) 25.08 (16-59)
Abbreviations: SD= standard deviation, SES= socio-economic status, CD= Crohn’s Disease, UC= ulcer-
ative colitis, IBDU= inflammatory bowel disease unclassified, IQR= Inter Quartile Range, HRQOL= 
health-related quality of life, sPCDAI= short Pediatric Crohn’s Disease Activity Index, PUCAI= Pedi-
atric Ulcerative Colitis Activity Index, SCARED= Screen for Child Anxiety Related Emotional Disor-
ders, CDI= Child Depression Inventory, BDI-II= Beck Depression Inventory, Second edition
Notes: a Not for all patients SES was available: CD N=130, UC/IBD-U N=112. Total group N=242. b 
Scored above cutoff for active disease on sPCDAI (≥10 points) or PUCAI (≥10 points). c Scored above 
cutoff on SCARED (anxiety), CDI (depression; 10-17 year) and/or BDI-II (depression 18-20 year).
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table 3 | Influence of demographic, disease, and psychological variables on HRQOL; results of multiple linear 
regression analysis – UC/IBD-U group (N=115)
model 1 model 2
ß Se ß p-value ß Se ß p-value
Block 1
Gender Male
Female -.276 .081 .001* -.101 .044 .022*
Age -.298 .082 <.001* -.193 .045 <.001*
SES Low
Middle -.130 .126 .302 -.033 .066 .619
High -.101 .126 .424 -.047 .067 .483
Disease duration .201 .083 .015* .087 .044 .045*
Clinical disease activity -.289 .081 <.001* -.066 .046 .156
Block 2
Illness perceptions -.438 .056 <.001*
Adaptive cognitive coping .036 .046 .156
Maladaptive cognitive coping -.029 .052 .584
Anxiety -.201 .060 .001*
Depression -.279 .061 <.001*
R2 (CI), p-value .32 (.18-.46), p < .001* .83 (.76-.88), p < .001
Abbreviations: SE= standard error, SES= socioeconomic status, CI= confidence interval
Note: * significant with p < .05
table 2 | Influence of demographic, disease, and psychological variables on HRQOL; results of multiple linear 
regression analysis – CD group (N=147)
model 1 model 2
ß Se ß p-value ß Se ß p-value
Block 1
Gender Male
Female -.230 .072 .002* -.055 .051 .283
Age -.075 .077 .330 -.054 .056 .330
SES Low
Middle .029 .098 .768 .070 .069 .315
High .051 .097 .600 -.042 .067 .533
Disease duration .123 .072 .086 .064 .049 .193
Clinical disease activity -.482 .071 < .001* -.170 .053 .001*
Block 2
Illness perceptions -.412 .063 <.001*
Adaptive cognitive coping .012 0.49 .803
Maladaptive cognitive coping .018 .058 .759
Anxiety .019 .077 .801
Depression -.454 .077 <.001*
R2 (CI), p-value .37 (.24-.49), p < .001* .74 (.65-.80), p < .001*
Abbreviations: SE= standard error, SES= socioeconomic status, CI= confidence interval
Note: * significant with p < .05
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In the UC/IBD-U group (N=115), female gender, age, disease duration, and clinical 
disease activity were significantly associated with HRQOL in the first model, explain-
ing 32% of the variance in HRQOL. After adding the psychological factors, female 
gender (ß = -.101, p = .022), lower age (ß = -.193, p < .001), shorter disease duration (ß 
= .087, p = .045), more negative illness perceptions (ß = -.438, p < .001), more anxiety 
symptoms (ß = -.201, p = .001), and more depressive symptoms (ß = -.279, p < .001) 
were associated with lower HRQOL. The second model explained 83% of the variance, 
with a significant change in explained variance (R2 change = 51%, p < .001).
DIScuSSIon
This study examined the influence of psychological factors on HRQOL over and above 
the influence of demographic and disease factors in youth with IBD, and analyzed 
the results separately for CD and UC/IBD-U. Partly in line with our first hypothesis, 
in the first model, without the psychological factors included, female gender and 
clinical disease activity were significantly associated with HRQOL, as were age and 
disease duration only in the UC/IBD-U group. However, when adding a combination 
of all psychological factors simultaneously in the second model, the influence of 
demographic and disease factors was reduced. Subsequently, illness perceptions and 
depression were associated with HRQOL in youth with IBD, even when controlling 
for demographic and disease factors. More negative illness perceptions and more 
depression were associated with a lower HRQOL, in both the CD group and the UC/
IBD-U group. A difference between the disease groups was that, in the UC/IBD-U group, 
anxiety was associated with HRQOL as well. Most importantly, adding the psychologi-
cal factors resulted in a significant increase in the proportion of explained variance, 
from approximately 35% by the first model to 74-83% by the second model, in both 
groups. This high proportion of explained variance underlines the importance of 
psychological factors contributing to HRQOL in patients with IBD.
These results provide insight in which psychological factors play a role in youth with 
IBD. Consistently in the two disease groups, negative illness perceptions and depres-
sion in particular prove their significant role, whereas cognitive coping and was not 
associated with HRQOL. This was also found in previous studies, which reported that 
illness perceptions and depression were associated with disease outcomes [25, 29]. 
Therefore, we recommend to pay attention to these factors when treating patients. 
Our results suggest that in youth with UC/IBD-U, anxiety should be considered as well.
There are several explanations for only finding an association between anxiety 
and HRQOL in youth with UC/IBD-U. Firstly, the nonsignificant relationship between 
anxiety and HRQOL in youth with CD cannot be explained by a difference in the 
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prevalence of elevated anxiety symptoms between the CD and UC/IBD-U groups (49.7% 
versus 50.4%). Secondly, one might postulate that anxiety is not strongly related to 
HRQOL in youth with IBD. Although we found a high prevalence of anxiety symptoms 
in the current sample (see Table 1 and [32]), presence of anxiety symptoms as such 
may not have to impact the HRQOL of youth with CD. In children and adolescents 
the available studies did not show evidence for differences between CD and UC [26], 
but Sarid et al. [58] showed worse psychosocial outcomes in patients with UC [24, 
59]. Thirdly, anxiety and depression are highly comorbid, have overlapping symptoms 
and anxiety is considered a precursor of depression [60, 61]. So anxiety may have 
played a role in preceding depressive symptoms in these patients. It is possible that 
anxiety and depression both explained variance in HRQOL, but that depression is 
more strongly related to HRQOL, and therefore diminished the relationship between 
anxiety and HRQOL in the patients with CD. More research is needed to unravel the 
interplay between anxiety and depression in youth with IBD. In their benchmark 
review, Cummings et al. [62] describe several pathways for the anxiety and depression 
comorbidity in children and adolescents. They also stress the importance of studying 
specific anxiety disorders for their comorbidity with depression. In IBD, very few stud-
ies tested specific anxiety problems (e.g. [11]). As a result, to our knowledge, there are 
no studies that investigated how specific anxiety problems are related to depressive 
symptoms in patients with IBD. Fourthly, in adults, several studies reported on the 
relationship between anxiety and HRQOL in both patients with CD and UC [63, 64]. 
Anxiety might be more impairing for adults with IBD than for youth with IBD, since 
adults may have to deal with more disease-related anxieties and worries concerning 
their daily and social functioning (impact of IBD on employment, career perspectives, 
income, finding a sexual partner, starting a family, etc.). Lastly, anxiety symptoms may 
be IBD-specific, i.e. anxiety or worries surrounding their IBD symptoms (e.g. bloody 
stools, the necessity of a stoma or surgery). These worries are often exorbitant to 
the actual context, but can have a negative impact [65, 66]. More specifically, higher 
IBD-specific anxiety was associated with lower HRQOL in youth with both CD and UC 
[65]. However, we are not aware of studies that examined differences between CD and 
UC with respect to IBD-specific anxiety in youth. Perhaps, youth with UC/IBD-U experi-
ence different IBD-specific worries than youth with CD, for example since youth with 
UC/IBD-U more often have alarming bloody stools than youth with CD.
Although the CSM postulates that coping is an important factor, in our study, cogni-
tive coping was not significantly related to HRQOL, when simultaneously added to 
the model with the other psychological factors. Cognitive coping may not be related 
to HRQOL in IBD patients, as was also found in earlier studies examining individual 
psychological factors [24, 59]. This is in contrast with the results of a review including 
a wide range of illnesses in adults, that found that coping was a stronger predictor 
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for health outcomes than illness perceptions [67]. Perhaps, coping plays a different 
role in IBD than in other illnesses. On the other hand, the type of coping may be 
of importance , since we only tested cognitive coping styles (and not for example 
behavioral). However, the results of two adult IBD studies including problem-focused 
and emotion-focused coping are mixed [68, 69], and therefore do not support this 
explanation completely.
Comparing the results between patients with CD and UC/IBD-U, showed differences 
in the second model: a significant association of clinical disease activity with HRQOL 
in the CD group, and a significant association of gender, age and disease duration 
with HRQOL in de UC/IBD-U group. Most likely, these differences cannot be explained 
by differences between the two groups, since the groups were similar with respect to 
the percentages of active disease, males versus females and the disease duration (see 
Table 1). Only in the CD group, clinical disease activity was associated with HRQOL, 
even after adding the psychological factors to the model. To our knowledge, in youth, 
no studies have specifically examined differences between CD and UC with respect 
to the relationship between clinical disease activity and HRQOL. Patients with CD 
have a more heterogeneous clinical presentation and are affected by growth failure, 
more often than patients with UC and IBD-U [1]. The heterogeneous clinical presenta-
tion and growth failure can lead to a lower HRQOL. A recent review of Knowles et 
al. [70] showed that HRQOL was significantly lower for patients with active disease, 
although no information was provided about differences between CD and UC/IBD-U. 
In children and adolescents with IBD (both CD and UC), some studies have shown 
that clinical disease activity remained associated with HRQOL, even when anxiety/
depression [20] [22] [71], and parental stress [71, 72] were included as mediators. It was 
therefore not tested, as in our study, what the influence is of demographic, disease, 
and psychological factors on the relationship between clinical disease activity and 
HRQOL. It seems that the relationship between clinical disease activity and HRQOL is 
not a direct relationship as such.
Only in the UC/IBD-U group, gender, age, and disease duration were significantly 
associated with HRQOL, even after adding the psychological factors to the model. For 
gender, previous studies in youth with IBD did not find an association with HRQOL 
[73-75]. These studies all included both CD and UC patients, but the majority of youth 
had CD (>70%), which may have masked the association between gender and HRQOL 
in the UC patients. However, it remains unclear what role gender has in affecting 
HRQOL, especially since gender is associated with more anxiety and depressive 
symptoms in general [76], as well as in our own cohort [32]. Anxiety and depressive 
symptoms are known to affect HRQOL in youth with IBD [22, 71]. For age, our results 
indicated that older age was associated with lower HRQOL in youth with UC/IBD-U. 
This is accordance with Otley et al. [75], who also reported that older age was as-
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sociated with lower HRQOL in the first year after diagnosis of IBD. However, in their 
sample a large majority of youth was diagnosed with CD (77%). Other studies did not 
find association between age and HRQOL [31, 77] or the reversed association (lower 
HRQOL in younger patients; [21]). These mixed findings were confirmed in a review on 
predictors of HRQOL in youth with IBD [6]. Finally, in our study a shorter disease dura-
tion was associated with a lower HRQOL in youth with UC/IBD-U. Previous studies have 
suggested that it seems that disease duration is not associated with HRQOL in general, 
but only within the first months after diagnosis (of both CD and UC/IBD-U) [31, 75]. 
However, these studies included mainly CD patients (77% and 100% respectively) [31, 
75]. In our sample, only 20% had a disease duration of 6 months or shorter. Therefore, 
our results suggest that for youth with CD in the first 6 months after the diagnosis, 
disease duration is not associated with HRQOL. For UC and IBD-U this relationship is 
unclear less clear defined. Although these differences between the disease groups are 
important to notice, the most important finding remains that, overall, in both disease 
groups, illness perceptions and depression were significantly associated with HRQOL.
Strengths
Our sample (N=262) is one of the largest European samples and innovative in studying 
the influence of both disease, demographic and psychological factors in youth with 
IBD. Our large sample covers a broad age range, using internationally validated and 
age-attuned instruments. This age range is an important life phase, as several biologi-
cal and psychosocial changes take place, and a chronic disease such as IBD can have 
negative consequences for the transition to adulthood. In addition, our sample was 
derived from 6 centers (both urban and rural areas), making generalization of our 
findings stronger. In addition, and contrary to other studies that only included either 
anxiety or depression (e.g.[8, 11]), we assessed both anxiety and depression, as this 
had implications for subsequent psychological treatment. Most importantly, whereas 
previous studies mostly examined individual relationships between disease factors, 
psychological factors and HRQOL, we aimed to test the influence of disease, demo-
graphic and psychological factors simultaneously. An advantage of this approach is 
that the current study took into account the interrelationships between all the factors 
in their associations with HRQOL.
limitations
The number of patients with active disease (mostly mild clinical disease activity) 
was low (25%), although this number is often found in population-based cohorts of 
patients with IBD. It may be that the associations between the psychological variables 
and HRQOL are not the same for patients that have more active disease. Nevertheless, 
studies with a higher proportion of patients with active disease reported similar re-
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sults [6, 22, 71, 72]. However, despite these findings, it is still possible that for patients 
with moderate to severe clinical disease activity, the relationships between illness 
perceptions, depression and HRQOL are different. Since evidence has been found for 
a negative impact of clinical disease activity on anxiety, depression and/or HRQOL 
(e.g.[11, 26]), even stronger relationships may be found in patient populations with 
more active disease. Another limitation is that our data were cross-sectional and 
conclusions on causal relationships cannot be drawn. Longitudinal studies are needed 
to examine causal relationships over time. Until now, only few studies have been 
conducted that were able to draw conclusion on causal relationships. For example, a 
recent study in adults with IBD found evidence for a bidirectional and causal relation-
ship between disease activity and anxiety/depression [80]. However, such studies have 
not been conducted investigating HRQOL. A last limitation is that we had a response 
rate of approximately 70%, which can have caused bias, for example if patients with 
a lower HRQOL were more inclined to participate than those with higher HRQOL. 
However, we were not able to compare the HRQOL of responders and non-responders.
clinical implications
These results stress the importance of psychological factors for HRQOL in youth with 
IBD, over and above demographic and disease variables. In our study sample, 75% of 
the patients were in clinical remission. Therefore, treating (pediatric) gastroenterolo-
gists should pay attention to these psychological factors, in all patients and not only 
in patients with active disease. We recommend screening for negative illness percep-
tions and internalizing problems. This can be done either during a medical visit or 
using short (online) questionnaires prior to the medical visit. Our results also have 
implications for psychological treatment of these patients: interventions for improv-
ing HRQOL should focus on negative illness perceptions and depression, and also on 
anxiety for youth with UC/IBD-U. For example, cognitive behavioral therapy (CBT) has 
been proven effective in using techniques to restructure thoughts, such as negative 
illness perceptions [81]. Importantly, at the beginning of a psychological intervention 
disproportionate, unrealistic or incorrect thoughts and ideas should be identified. 
At this phase, it is important to determine whether a patient has disproportionate 
or incorrect negative illness perceptions. These can then be crucial when practicing 
cognitive and behavioral techniques. Naturally, the techniques of CBT can be used to 
improve depression and anxiety as well [82, 83].
In conclusion, our study found that negative illness perceptions and depression 
are negatively associated with HRQOL in youth with IBD, even after controlling for 
several demographic and disease factors, with also other psychological factors (i.e. 
coping, anxiety) taken into account. These factors seriously influence HRQOL, even in 
our cohort with low clinical disease activity, and should be considered by the medical 
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team. Our results indicate that, irrespective of the clinical disease activity, psychologi-
cal treatment should focus on the way these young IBD patients perceive their disease 
and on their depressive symptoms. For youth with UC and IBD-U, anxiety and worries 
should receive attention as well.
compliance with ethical standards
Disclosure of potential conflicts of interest
This work was supported by the Stichting Vrienden van het Sophia [SSWO, grant num-
ber 985 to JCE], and the Stichting Crohn en Colitis Ulcerosa Fonds Nederland [grant 
number 14.307.04 to EMWJU], Fonds NutsOhra [grant number 1303-012 to EMWJU 
and Stichting Theia [grant number 2013201 to EMWJU]. JCE received financial support 
from MSD (research support), Janssen (advisory board) and AbbVie (advisory board). 
EMS received financial support from NIH (grant), Crohn and Colitis Fund America 
(grant), AbbVie (consultancy), Merck (consultancy), IHOPE Network (consultancy) and 
royalties for book editing from APPI. For the remaining authors none were declared.
Informed consent
Informed consent was obtained from all individual participants included in the study.
research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and 
with the 1964 Helsinki declaration and its later amendments or comparable ethical 
standards.
This article does not contain any studies with animals performed by any of the 
authors.
Acknowledgements
We thank our financial supporters Stichting Crohn en Colitis Ulcerosa Fonds Nederland / 
Maag Lever Darm Stichting, Fonds NutsOhra, Stichting Theia, and Stichting Vrienden van het 
Sophia. Furthermore, we are very grateful to the patients and their parents that 
consented, and to the participating hospitals and their professionals that included 
patients: Erasmus Medical Center (coordinating center), Albert Schweitzer Hospital, 
Maasstad Hospital, Haga Hospital, Amphia Hospital, Leiden University Medical Center.
121
5
referenceS
 1. Griffiths AM. Specificities of inflam-
matory bowel disease in childhood. 
Best Pract Res Clin Gastroenterol. 
2004;18(3):509-23.
 2. Adamiak T, Walkiewicz-Jedrzejczak 
D, Fish D, Brown C, Tung J, Khan K, et 
al. Incidence, clinical characteristics, 
and natural history of pediatric IBD in 
Wisconsin: a population-based epide-
miological study. Inflamm Bowel Dis. 
2013;19(6):1218-23.
 3. Ghione S, Sarter H, Fumery M, 
Armengol-Debeir L, Savoye G, Ley D, 
et al. Dramatic Increase in Incidence of 
Ulcerative Colitis and Crohn’s Disease 
(1988-2011): A Population-Based Study 
of French Adolescents. Am J Gastroen-
terol. 2018;113(2):265-72.
 4. Rabizadeh S, Dubinsky M. Update 
in pediatric inflammatory bowel 
disease. Rheum Dis Clin North Am. 
2013;39(4):789-99.
 5. Arnett JJ. Adolescence and emerging 
adulthood: A cultural approach (Inter-
national Edition). Fourth Edition ed. 
Prentice Hall, Upper Saddle River, NJ: 
Pearson; 2010.
 6. Ross SC, Strachan J, Russell RK, Wilson 
SL. Psychosocial functioning and health-
related quality of life in paediatric 
inflammatory bowel disease. J Pediatr 
Gastroenterol Nutr. 2011;53(5):480-8.
 7. Knowles SR, Graff LA, Wilding H, 
Hewitt C, Keefer L, Mikocka-Walus A. 
Quality of Life in Inflammatory Bowel 
Disease: A Systematic Review and Meta-
analyses—Part I. Inflammatory Bowel 
Diseases. 2018;24(4):742-51.
 8. Clark JG, Srinath AI, Youk AO, Kirshner 
MA, McCarthy FN, Keljo DJ, et al. 
Predictors of depression in youth with 
Crohn disease. J Pediatr Gastroenterol 
Nutr. 2014;58(5):569-73.
 9. Szigethy E, Bujoreanu SI, Youk AO, 
Weisz J, Benhayon D, Fairclough D, et 
al. Randomized efficacy trial of two psy-
chotherapies for depression in youth 
with inflammatory bowel disease. J 
Am Acad Child Adolesc Psychiatry. 
2014;53(7):726-35.
 10. Kilroy S, Nolan E, Sarma KM. Quality 
of life and level of anxiety in youths 
with inflammatory bowel disease in 
Ireland. J Pediatr Gastroenterol Nutr. 
2011;53(3):275-9.
 11. Reigada LC, Hoogendoorn CJ, Walsh 
LC, Lai J, Szigethy E, Cohen BH, et al. 
Anxiety symptoms and disease severity 
in children and adolescents with crohn 
disease. J Pediatr Gastroenterol Nutr. 
2015;60(1):30-5.
 12. Stapersma L, van den Brink G, Szigethy 
EM, Escher JC, Utens E. Systematic 
review with meta-analysis: anxiety and 
depression in children and adolescents 
with inflammatory bowel disease. Ali-
ment Pharmacol Ther. 2018;48(5):496-
506.
 13. Diefenbach M, Leventhal H. The 
common-sense model of illness rep-
resentation: Theoretical and practical 
considerations. J Soc Distress Homeless. 
1996;5(1):11-38.
 14. Broadbent E, Petrie KJ, Main J, Wein-
man J. The brief illness perception 
questionnaire. J Psychosom Res. 
2006;60(6):631-7.
 15. Monat AE, Lazarus RS. Stress and cop-
ing: An anthology. 1991.
 16. Compas BE, Connor-Smith JK, Saltzman 
H, Thomsen AH, Wadsworth ME. Cop-
ing with stress during childhood and 
adolescence: problems, progress, and 
potential in theory and research. Psy-
chol Bull. 2001;127(1):87-127.
 17. Compas BE, Jaser SS, Bettis AH, Watson 
KH, Gruhn MA, Dunbar JP, et al. Cop-
122
ing, emotion regulation, and psychopa-
thology in childhood and adolescence: 
A meta-analysis and narrative review. 
Psychol Bull. 2017;143(9):939-91.
 18. Garnefski N, Kraaij V. Specificity of 
relations between adolescents’ cogni-
tive emotion regulation strategies and 
symptoms of depression and anxiety. 
Cogn Emot. 2018;32(7):1401-8.
 19. Gray WN, Denson LA, Baldassano RN, 
Hommel KA. Disease activity, behav-
ioral dysfunction, and health-related 
quality of life in adolescents with 
inflammatory bowel disease. Inflamm 
Bowel Dis. 2011;17(7):1581-6.
 20. Chouliaras G, Margoni D, Dimakou 
K, Fessatou S, Panayiotou I, Roma-Gi-
annikou E. Disease impact on the qual-
ity of life of children with inflammatory 
bowel disease. World J Gastroenterol. 
2017;23(6):1067-75.
 21. Engelmann G, Erhard D, Petersen M, 
Parzer P, Schlarb AA, Resch F, et al. 
Health-related quality of life in adoles-
cents with inflammatory bowel disease 
depends on disease activity and psy-
chiatric comorbidity. Child Psychiatry 
Hum Dev. 2015;46(2):300-7.
 22. Rochelle TL, Fidler H. The importance 
of illness perceptions, quality of life and 
psychological status in patients with 
ulcerative colitis and Crohn’s disease. J 
Health Psychol. 2013;18(7):972-83.
 23. Brooks AJ, Rowse G, Ryder A, Peach EJ, 
Corfe BM, Lobo AJ. Systematic review: 
psychological morbidity in young 
people with inflammatory bowel dis-
ease - risk factors and impacts. Aliment 
Pharmacol Ther. 2016;44(1):3-15.
 24. McCombie AM, Mulder RT, Gearry RB. 
How IBD patients cope with IBD: A 
systematic review. Journal of Crohn’s 
and Colitis. 2013;7(2):89-106.
 25. van Erp SJH, Brakenhoff LKMP, Voll-
mann M, van der Heijde D, Veenendaal 
RA, Fidder HH, et al. Illness Perceptions 
and Outcomes in Patients with Inflam-
matory Bowel Disease: Is Coping a Me-
diator? Int J Behav Med. 2017;24(2):205-
14.
 26. van Tilburg MA, Claar RL, Romano JM, 
Langer SL, Walker LS, Whitehead WE, 
et al. Role of Coping With Symptoms in 
Depression and Disability: Comparison 
Between Inflammatory Bowel Disease 
and Abdominal Pain. J Pediatr Gastro-
enterol Nutr. 2015;61(4):431-6.
 27. van der Have M, Minderhoud IM, 
Kaptein AA, Leenders M, Siersema PD, 
Fidder HH, et al. Substantial impact of 
illness perceptions on quality of life in 
patients with Crohn’s disease. J Crohns 
Colitis. 2013;7(8):e292-301.
 28. van Tilburg MA, Claar RL, Romano JM, 
Langer SL, Drossman DA, Whitehead 
WE, et al. Psychological Factors May 
Play an Important Role in Pediatric 
Crohn’s Disease Symptoms and Dis-
ability. J Pediatr. 2017;184:94-100 e1.
 29. Katz L, Tripp DA, Ropeleski M, Depew 
W, Curtis Nickel J, Vanner S, et al. 
Mechanisms of Quality of Life and 
Social Support in Inflammatory Bowel 
Disease. Journal of Clinical Psychology 
in Medical Settings. 2016;23(1):88-98.
 30. Hill R, Lewindon P, Muir R, Grange I, 
Connor F, Ee L, et al. Quality of life in 
children with Crohn disease. J Pediatr 
Gastroenterol Nutr. 2010;51(1):35-40.
 31. van den Brink G, Stapersma L, Vlug 
LE, Rizopolous D, Bodelier AG, van 
Wering H, et al. Clinical disease 
activity is associated with anxiety and 
depressive symptoms in adolescents 
and young adults with inflammatory 
bowel disease. Aliment Pharmacol Ther. 
2018;48(3):358-69.
 32. van den Brink G, Stapersma L, El 
Marroun H, Henrichs J, Szigethy 
EM, Utens EM, et al. Effectiveness of 
disease-specific cognitive-behavioural 
therapy on depression, anxiety, quality 
123
5
of life and the clinical course of disease 
in adolescents with inflammatory 
bowel disease: study protocol of a mul-
ticentre randomised controlled trial 
(HAPPY-IBD). BMJ Open Gastroenterol. 
2016;3(1):e000071.
 33. Levine A, Koletzko S, Turner D, Escher 
JC, Cucchiara S, de Ridder L, et al. ESP-
GHAN revised porto criteria for the di-
agnosis of inflammatory bowel disease 
in children and adolescents. J Pediatr 
Gastroenterol Nutr. 2014;58(6):795-806.
 34. Magro F, Gionchetti P, Eliakim R, Ardiz-
zone S, Armuzzi A, Barreiro-de Acosta 
M, et al. Third European Evidence-
based Consensus on Diagnosis and 
Management of Ulcerative Colitis. 
Part 1: Definitions, Diagnosis, Extra-
intestinal Manifestations, Pregnancy, 
Cancer Surveillance, Surgery, and Ileo-
anal Pouch Disorders. J Crohns Colitis. 
2017;11(6):649-70.
 35. Gomollon F, Dignass A, Annese V, Tilg 
H, Van Assche G, Lindsay JO, et al. 3rd 
European Evidence-based Consensus 
on the Diagnosis and Management of 
Crohn’s Disease 2016: Part 1: Diagnosis 
and Medical Management. J Crohns 
Colitis. 2017;11(1):3-25.
 36. Statistics Netherlands. Standaard 
Beroepen Classificatie 2010. The Hague: 
Statistics Netherlands; 2010.
 37. Kappelman MD, Crandall WV, Colletti 
RB, Goudie A, Leibowitz IH, Duffy L, 
et al. Short pediatric Crohn’s disease 
activity index for quality improvement 
and observational research. Inflamm 
Bowel Dis. 2011;17(1):112-7.
 38. Turner D, Griffiths AM, Walters TD, 
Seah T, Markowitz J, Pfefferkorn M, 
et al. Mathematical weighting of the 
pediatric Crohn’s disease activity index 
(PCDAI) and comparison with its other 
short versions. Inflamm Bowel Dis. 
2012;18(1):55-62.
 39. de Raaij EJ, Schröder C, Maissan FJ, Pool 
JJ, Wittink H. Cross-cultural adaptation 
and measurement properties of the 
Brief Illness Perception Questionnaire-
Dutch Language Version. Manual 
Therapy. 2012;17(4):330-5.
 40. Szigethy EM, Youk AO, Benhayon D, 
Fairclough DL, Newara MC, Kirshner 
MA, et al. Depression subtypes in 
pediatric inflammatory bowel dis-
ease. J Pediatr Gastroenterol Nutr. 
2014;58(5):574-81.
 41. Garnefski N, Legerstee J, Kraaij V, Van 
Den Kommer T, Teerds JAN. Cognitive 
coping strategies and symptoms of 
depression and anxiety: A comparison 
between adolescents and adults. Jour-
nal of adolescence. 2002;25(6):603-11.
 42. Muris P, Bodden D, Hale W, Birmaher 
B, Mayer B. SCARED-NL. Handleiding 
bij de gereviseerde Nederlandse versie 
van de Screen for Child Anxiety Re-
lated Emotional Disorders. Amsterdam: 
Boom test uitgevers; 2011.
 43. Bodden DHM, Bögels SM, Muris P. 
The diagnostic utility of the Screen 
for Child Anxiety Related Emotional 
Disorders-71 (SCARED-71). Behaviour 
Research and Therapy. 2009;47(5):418-
25.
 44. Timbremont B, Braet C, Roelofs J. 
Handleiding Children’s Depression In-
ventory (herziene versie). Amsterdam: 
Pearson Assessment and Information 
B.V.; 2008.
 45. Van der Does AJW. BDI-II-NL Handlei-
ding. De Nederlandse versie van de 
Beck Depression Inventory-2nd edition. 
Lisse: Harcourt Test Publishers; 2002.
 46. Otley A, Smith C, Nicholas D, Munk M, 
Avolio J, Sherman PM, et al. The IM-
PACT questionnaire: a valid measure of 
health-related quality of life in pediatric 
inflammatory bowel disease. J Pediatr 
Gastroenterol Nutr. 2002;35(4):557-63.
124
 47. Loonen HJ, Grootenhuis MA, Last 
BF, Haan RJd, Bouquet J, Derkx BHF. 
Measuring Quality of Life in Children 
with Inflammatory Bowel Disease: 
The Impact-II (NL). Qual Life Res. 
2002;11(1):47-56.
 48. Birimberg-Schwartz L, Zucker DM, 
Akriv A, Cucchiara S, Cameron FL, 
Wilson DC, et al. Development and 
Validation of Diagnostic Criteria for IBD 
Subtypes Including IBD-unclassified in 
Children: a Multicentre Study From the 
Pediatric IBD Porto Group of ESPGHAN. 
J Crohns Colitis. 2017;11(9):1078-84.
 49. Turner D, Ruemmele FM, Orlanski-
Meyer E, Griffiths AM, Carpi JM, Bron-
sky J, et al. Management of Paediatric 
Ulcerative Colitis, Part 1: Ambulatory 
Care- an Evidence-Based Guideline from 
ECCO and ESPGHAN. J Pediatr Gastro-
enterol Nutr. 2018.
 50. White IR, Royston P, Wood AM. Multiple 
imputation using chained equations: 
Issues and guidance for practice. Stat 
Med. 2011;30(4):377-99.
 51. Sarid O, Slonim-Nevo V, Schwartz D, 
Friger M, Sergienko R, Pereg A, et al. 
Differing Relationship of Psycho-Social 
Variables with Active Ulcerative Colitis 
or Crohn’s Disease. Int J Behav Med. 
2018;25(3):341-50.
 52. Dorrian A, Dempster M, Adair P. Adjust-
ment to inflammatory bowel disease: 
The relative influence of illness percep-
tions and coping. Inflammatory Bowel 
Diseases. 2009;15(1):47-55.
 53. Axelson DA, Birmaher B. Relation be-
tween anxiety and depressive disorders 
in childhood and adolescence. Depres-
sion Anxiety. 2001;14(2):67-78.
 54. Garber J, Weersing VR. Comorbidity 
of Anxiety and Depression in Youth: 
Implications for Treatment and Preven-
tion. Clinical Psychology: Science and 
Practice. 2010;17(4):293-306.
 55. Cummings CM, Caporino NE, Kendall 
PC. Comorbidity of Anxiety and De-
pression in Children and Adolescents: 
20 Years After. Psychological Bulletin. 
2014;140(3):816-45.
 56. Iglesias-Rey M, Barreiro-de Acosta M, 
Caamano-Isorna F, Rodriguez IV, Fer-
reiro R, Lindkvist B, et al. Psychological 
factors are associated with changes 
in the health-related quality of life in 
inflammatory bowel disease. Inflamm 
Bowel Dis. 2014;20(1):92-102.
 57. Luo XP, Mao R, Chen BL, Qiu Y, Zhang 
SH, He Y, et al. Over-reaching beyond 
disease activity: the influence of anxi-
ety and medical economic burden on 
health-related quality of life in patients 
with inflammatory bowel disease. Pa-
tient Prefer Adherence. 2017;11:23-31.
 58. Reigada LC, Moore MT, Martin CF, Kap-
pelman MD. Psychometric Evaluation 
of the IBD-Specific Anxiety Scale: A 
Novel Measure of Disease-Related Anxi-
ety for Adolescents With IBD. J Pediatr 
Psychol. 2017.
 59. Reigada LC, Bruzzese JM, Benkov KJ, 
Levy J, Waxman AR, Petkova E, et al. 
Illness-specific anxiety: implications for 
functioning and utilization of medical 
services in adolescents with inflamma-
tory bowel disease. J Spec Pediatr Nurs. 
2011;16(3):207-15.
 60. Dempster M, Howell D, McCorry NK. 
Illness perceptions and coping in physi-
cal health conditions: A meta-analysis. 
Journal of Psychosomatic Research. 
2015;79(6):506-13.
 61. Knowles SR, Wilson JL, Connell WR, 
Kamm MA. Preliminary examination of 
the relations between disease activity, 
illness perceptions, coping strategies, 
and psychological morbidity in Crohn’s 
disease guided by the common sense 
model of illness. Inflamm Bowel Dis. 
2011;17(12):2551-7.
125
5
 62. Zhang M, Hong L, Zhang T, Lin Y, Zheng 
S, Zhou X, et al. Illness perceptions 
and stress: mediators between disease 
severity and psychological well-being 
and quality of life among patients with 
Crohn’s disease. Patient Prefer Adher-
ence. 2016;10:2387-96.
 63. Knowles SR, Keefer L, Wilding H, 
Hewitt C, Graff LA, Mikocka-Walus A. 
Quality of Life in Inflammatory Bowel 
Disease: A Systematic Review and Meta-
analyses—Part II. Inflammatory Bowel 
Diseases. 2018;24(5):966-76.
 64. Reed-Knight B, Lee JL, Greenley RN, 
Lewis JD, Blount RL. Disease Activity 
Does Not Explain It All: How Internal-
izing Symptoms and Caregiver Depres-
sive Symptoms Relate to Health-related 
Quality of Life Among Youth with 
Inflammatory Bowel Disease. Inflamm 
Bowel Dis. 2016.
 65. Gray WN, Boyle SL, Graef DM, Janicke 
DM, Jolley CD, Denson LA, et al. Health-
related quality of life in youth with 
Crohn disease: role of disease activity 
and parenting stress. J Pediatr Gastro-
enterol Nutr. 2015;60(6):749-53.
 66. Kunz JH, Hommel KA, Greenley RN. 
Health-related quality of life of youth 
with inflammatory bowel disease: 
A comparison with published data 
using the PedsQL 4.0 generic core 
scales. Inflammatory Bowel Diseases. 
2010;16(6):939-46.
 67. De Boer M, Grootenhuis M, Derkx 
B, Last B. Health-related quality of 
life and psychosocial functioning of 
adolescents with inflammatory bowel 
disease. Inflammatory Bowel Diseases. 
2005;11(4):400-6.
 68. Otley AR, Griffiths AM, Hale S, Kugath-
asan S, Pfefferkorn M, Mezoff A, et al. 
Health-related quality of life in the 
first year after a diagnosis of pediatric 
inflammatory bowel disease. Inflamm 
Bowel Dis. 2006;12(8):684-91.
 69. Altemus M, Sarvaiya N, Epperson CN. 
Sex differences in anxiety and depres-
sion clinical perspectives. Frontiers in 
neuroendocrinology. 2014;35(3):320-30.
 70. Gallo J, Grant A, Otley AR, Orsi M, 
MacIntyre B, Gauvry S, et al. Do 
parents and children agree? Quality-
of-life assessment of children with 
inflammatory bowel disease and their 
parents. J Pediatr Gastroenterol Nutr. 
2014;58(4):481-5.
 71. Gracie DJ, Guthrie EA, Hamlin PJ, Ford 
AC. Bi-directionality of Brain-Gut In-
teractions in Patients With Inflamma-
tory Bowel Disease. Gastroenterology. 
2018;154(6):1635-46 e3.
 72. Christensen SS, Frostholm L, Ornbol E, 
Schroder A. Changes in illness percep-
tions mediated the effect of cognitive 
behavioural therapy in severe func-
tional somatic syndromes. J Psychosom 
Res. 2015;78(4):363-70.
 73. Weisz JR, Kuppens S, Ng MY, Eckshtain 
D, Ugueto AM, Vaughn-Coaxum R, et al. 
What five decades of research tells us 
about the effects of youth psychological 
therapy: A multilevel meta-analysis and 
implications for science and practice. 
Am Psychol. 2017;72(2):79-117.
 74. Compton SN, March JS, Brent D, Albano 
AM, Weersing VR, Curry J. Cognitive-
Behavioral Psychotherapy for Anxiety 
and Depressive Disorders in Children 
and Adolescents: An Evidence-Based 
Medicine Review. Journal of the Ameri-
can Academy of Child & Adolescent 
Psychiatry. 2004;43(8):930-59.

6
Effectiveness of disease-specific cognitive 
behavioral therapy on anxiety, depression and 
quality of life in youth with inflammatory bowel 
disease: a randomized controlled trial
Luuk Stapersma, Gertrude van den Brink, Jan van der Ende, 
Eva M. Szigethy, Ruud Beukers, Thea A. Korpershoek, 
Sabine D.M. Theuns-Valks, Manon H.J. Hillegers, Johanna C. Escher, 
Elisabeth M.W.J. Utens
Journal of Pediatric Psychology; 2018, 1-14. doi:10.1093/jpepsy/jsy029.
128
ABStrAct
objective To evaluate the effectiveness of a disease-specific cognitive behavioral 
therapy (CBT) protocol on anxiety and depressive symptoms, and health-related qual-
ity of life (HRQOL) in adolescents and young adults with inflammatory bowel disease 
(IBD).
methods A parallel group randomized controlled trial, conducted in 6 centers of (pe-
diatric) gastroenterology. Included were 70 adolescents and young adults (10-25 years) 
with IBD and subclinical anxiety and/or depressive symptoms. Patients were random-
ized into two groups, stratified by center: a) standard medical care (care-as-usual; CAU) 
plus disease-specific manualized CBT (Primary and Secondary Control Enhancement 
Therapy for Physical Illness; PASCET-PI), with 10 weekly sessions, 3 parent sessions 
and 3 booster sessions (n=37) or b) CAU only (n=33). Primary analysis concerned the 
reliable change in anxiety and depressive symptoms after 3 months (immediate post-
treatment assessment). Exploratory analyses concerned 1) the course of anxiety and 
depressive symptoms and HRQOL in subgroups based on age, and 2) the influence of 
age, gender, and disease type on the effect of the PASCET-PI.
results Overall, all participants improved significantly in their anxiety and depressive 
symptoms and HRQOL, regardless of group, age, gender, and disease type. Primary chi-
square tests and exploratory linear mixed models showed no difference in outcomes 
between the PASCET-PI (n=35) and the CAU group (n=33).
conclusions In youth with IBD and subclinical anxiety and/or depressive symptoms, 
preliminary results of immediate post-treatment assessment indicated that a disease-
specific CBT added to standard medical care did not perform better than standard 
medical care in improving psychological symptoms or HRQOL. ClinicalTrials.gov: 
NCT02265588.
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IntroDuctIon
Crohn’s disease (CD) and ulcerative colitis (UC) are two types of inflammatory bowel 
disease (IBD). IBD is a chronic disease, that is characterized by episodes of exacerba-
tion (with increased clinical symptoms) and clinical remission. Symptoms are ab-
dominal pain, (bloody) diarrhea, fatigue, fever, and weight loss [1]. In pediatric IBD 
(especially CD) malnutrition, resulting in delay of growth and puberty is common [2]. 
Adolescents and young adults (also referred to as youth) with IBD have a high risk 
for anxiety and/or depression [3], possibly related to the unpredictable disease course 
and embarrassing symptoms [4]. Moreover, the inflammation-depression(-/anxiety) hy-
pothesis is thought to explain the bidirectional association between inflammation in 
IBD and anxiety and/or depression. This hypothesis states that inflammation increases 
vulnerability for emotional symptoms and that treating these symptoms can decrease 
inflammation and thus improve disease course [5].
In general, prevalence studies show elevated levels of anxiety and depressive symp-
toms in respectively 39-50% [6, 7], and in 38-55% [8, 9] of adolescents with IBD. Only, a 
few studies report lower prevalence rates [10]. Furthermore, a meta-analysis showed 
higher rates of depressive and internalizing disorders in IBD youth, compared to other 
chronic conditions [4].
At present, cognitive behavioral therapy (CBT) is the most effective evidence-based 
psychological treatment for anxiety and depression in youth [11]. Until now, only a 
few studies evaluated CBT for youth with IBD. In a randomized controlled trial (RCT) 
Szigethy et al. [12] found promising results of a disease-specific CBT in reducing depres-
sive symptoms in 41 adolescents with IBD and subclinical depression. Furthermore, 
in a later study (N=178) the same disease-specific CBT was effective in reducing de-
pressive symptoms and improving health-related quality of life. However, supportive 
nondirective therapy (SNDT) had equally favorable outcomes [9]. Reigada et al. [13] 
found improvement in anxiety, pain, and disease activity in 9 adolescents with anxi-
ety disorders receiving CBT. In addition, a large recent trial in pediatric patients with 
IBD (N=185), not selected on the presence of either somatic or psychological symp-
toms at baseline, examined the effect of a social learning and cognitive behavioral 
therapy (SLCBT) of only three sessions versus educational support. Although SLCBT 
outperformed educational support in improving IBD-related quality of life and school 
attendance, the authors found no difference between the two groups on anxiety and 
depression. The authors proposed low levels of disease activity and the short duration 
of the psychological treatment as possible explanations [14].
Taken together, CBT for youth with IBD seems beneficial. The mixed findings 
described above may be due to differences in the included patients, since some stud-
ies focused on either anxiety or depression separately [9, 12, 13] or included all IBD 
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patients rather than those selected on anxiety or depression [14]. However, anxiety 
can precede depression, and anxiety and depression often occur together [15, 16], so 
investigating both is important. Moreover, for CBT to be effective for anxiety/depres-
sion, patients have to experience at least elevated levels of anxiety and/or depressive 
symptoms, so selecting patients at baseline may be necessary [17]. Therefore, the 
present multi-center RCT aims to test the effectiveness of a disease-specific CBT on 
symptoms of both anxiety and depression, as well as on health-related quality of life 
(HRQOL) in adolescents and young adults with IBD (age 10-25 years). This age range 
was chosen to cover the clinically relevant phases of adolescence and young adult-
hood, when IBD is often diagnosed [2] and can affect the many psychosocial changes 
that take place (e.g. becoming independent and identity formation).
The primary research question was: Compared to standard medical care only, what 
is the effect of a disease-specific CBT added to standard medical care, on the level of 
anxiety and depressive symptoms, from pre- to post assessment, in adolescents and 
young adults with IBD aged 10-25 years?
Additional research questions were: 1) What is the course of anxiety and depressive 
symptoms and HRQOL in subgroups based on age, regarding the effect of CBT? And 
2) What is the influence of age, gender, and disease type on the course of anxiety 
and depressive symptoms and HRQOL, regarding the effect of CBT? By these ques-
tions we aim to examine which patients may benefit most from the disease-specific 
CBT. We hypothesized that patients in the disease-specific CBT group would improve 
more on anxiety and/or depressive symptoms and HRQOL compared to patients who 
received only standard medical care. In addition, we expected to find more effect 
of CBT in young adult patients (as they already face more life challenges, and could 
benefit more from the CBT skills than children), in women (as they often experience 
more anxiety and/or depressive symptoms than men) and in patients with CD (as the 
systemic symptoms in CD increase the burden of disease). We also investigated how 
patients (and parents) evaluate the disease-specific CBT (i.e. what is the social validity 
of the disease-specific CBT).
metHoDS
Design and procedure
This multi-center parallel group randomized controlled trial was designed according 
to the CONSORT guidelines for trials of non-pharmacologic treatments [18]. The trial 
had two arms. Patients in the experimental group received a disease-specific CBT 
protocol (Primary and Secondary Control Enhancement Training for Physical Illness; 
PASCET-PI) [12] added to standard medical care. The control group received standard 
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medical care (care-as-usual, CAU) only, as this resembles the current care best. Ini-
tially, only patients aged 10-20 years were included. A few months after the start of 
the recruitment, patients of 21-25 years were also included, to include more patients 
in young adulthood as well, to cover the transition phase. The research protocol was 
approved by the Medical Ethics Committee of the Erasmus MC and confirmed by the 
ethical boards of all participating hospitals. The study was registered with ClinicalTri-
als.gov as study number NCT02265588.
After having provided written informed consent, patients (and parents) completed 
validated psychological instruments at 2 points in time (see Outcome measures). At 
baseline, patients completed online questionnaires (at home) and a clinical interview 
(by phone) (no longer than 2 weeks before the start of the PASCET-PI). The immediate 
post(-treatment) assessment was similar to the baseline and was performed approxi-
mately 3 months after baseline, no later than 2 weeks after completing the PASCET-PI. 
Timing and method of assessments were the same in the experimental and control 
group.
recruitment (see also figure 1)
Step 1: Inclusion baseline screening
Included for baseline screening for symptoms of anxiety and depression were adoles-
cents and young adults aged 10-25 years with a confirmed diagnosis of IBD (Crohn’s 
disease, ulcerative colitis or inflammatory bowel disease unclassified). Between Octo-
ber 2014 and October 2016, patients were consecutively recruited from the pediatric 
or (pediatric) gastroenterology departments of 2 academic hospitals and 4 community 
hospitals. The centers were medium sized to large hospitals from mixed rural and 
urban regions. Parents participated for all patients aged 17 years or younger, parental 
participation for patients aged 18-20 was voluntary. Exclusion criteria were 1) intel-
lectual disability, 2) current treatment for mental health problems (pharmacological 
and/or psychological), 3) insufficient mastery of the Dutch language, 4) a diagnosis 
of selective mutism, bipolar disorder, schizophrenia/psychotic disorder, autism spec-
trum disorders, obsessive-compulsive disorder, posttraumatic or acute stress-disorder, 
or substance use disorder (parent- or self-reported or from medical file), 5) CBT in the 
past year (at least 8 sessions), and 6) participation in another interventional study, 
all assessed by the treating physician using medical files (unless otherwise specified).
Step 2: Inclusion rct
Only youth with subclinical anxiety and/or depressive symptoms were included in the 
RCT. Patients with clinical anxiety and/or depression were excluded since we deemed 
it unethical to randomize them.
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Subclinical anxiety and/or depressive symptoms were defined as a score equal or 
above the cutoff of age-appropriate questionnaires, but not meeting criteria for clini-
cal anxiety and/or depression (see below). For anxiety the Screen for Child Anxiety 
Related Emotional Disorders (SCARED; 10-20 years; cutoff ≥26 for boys and ≥30 for 
girls) [19] and the Hospital Anxiety and Depression Scale – Anxiety Scale (HADS-A; 
21-25 years; cutoff ≥8) [20] were used. For depression the Child Depression Inventory 
(CDI; 10-17 years; cutoff ≥13) [21] and the Beck Depression Inventory – second edition 
(BDI-II; 18-25 years; cutoff ≥14) [22] were used.
Clinical anxiety and/or depression was defined as follows: for patients who scored 
on or above the cutoffs for elevated symptoms of anxiety and/or depression, the 
psychologist-investigator (LS) administered a clinical interview. The Anxiety Disorders 
Interview Schedule for Children (ADIS-C) [23] was delivered by telephone to patients, 
and if applicable, parents. In the ADIS-C, if a patient meets criteria for a clinical disor-
der a Clinician’s Severity Rating (CSR, a 0-8 rating of symptom severity and functional 
impairment) is assigned by the interviewer. In addition, severity of anxiety and/or de-
pressive symptoms was rated by the interviewer using age-appropriate rating scales. 
For anxiety the Pediatric Anxiety Rating Scale (PARS; 10-20 years; cutoff ≥18) [24] and 
Hamilton Anxiety Rating Scale (HAM-A; 21-25 years; cutoff ≥15) [25, 26] were used. 
For depression the Child Depression Rating Scale Revised (CDRS-R; 10-12 years; cutoff 
≥40) [27], Adolescent Depression Rating Scale (ADRS; 13-20 years; cutoff ≥20) [28], and 
the Hamilton Depression Rating Scale (HAM-D; 21-25 years; cutoff ≥17) [29, 30] were 
used. If patients met criteria for an anxiety or depressive disorder on the ADIS-C (i.e. 
a CSR of at least 4) and score equal to or above the clinical cutoff on the rating scale 
this indicates a clinical anxiety or depressive disorder. These patients were excluded 
and received immediate referral to mental health care. Within the group of patients 
included in the RCT (all with subclinical anxiety and/or depressive symptoms, n = 70) 
a subdivision was made based on the ADIS-C. If patients had one or more CSR’s of at 
least 4 (but scored below the cutoff on either the CDRS, ADRS, HAM-D, PARS or HAM-A) 
they were considered ‘high’ subclinical, if not they were considered ‘low’ subclinical.
randomization
Patients with subclinical anxiety and/or depressive symptoms (but not clinical anxiety 
and/or depression) were randomized to PASCET-PI and CAU versus CAU alone, with a 
ratio of 1:1 An independent biostatistician provided a computer-generated blocked 
randomization list with randomly chosen block sizes (with a maximum of 6) and 
stratification by center using the blockrand package in the R software package 
thereby providing numbered envelopes per center. Patients were enrolled by one of 
the investigators (GB). To prevent drop-out, before randomization it was thoroughly 
checked with the patients whether they would be motivated enough to complete the 
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CBT. For example, they were asked about their motivation and concerns regarding 
traveling and time investment, or regarding discussing private information.
Intervention
The PASCET-PI is a disease-specific CBT protocol, developed for adolescents with IBD 
and depression. Disease-specific components encompass the illness narrative (i.e. per-
ceptions and experience of having IBD), disease-specific psycho-education, techniques 
for pain and immune functioning, social skills training and emphasis on IBD related 
cognitions and behavior [12]. Parents receive psycho-education about coaching their 
child to cope with IBD.
In the current study the PASCET-PI contained ten weekly individual sessions, 
delivered in three months. Conform the protocol, six of these sessions were face-to-
face, the remaining 4 sessions were by phone at a pre-arranged moment (to advance 
adherence and lower the treatment burden). In addition, 3 family sessions (for pa-
tients and their parents) were held (only for patients ≤ 20 years), and following the 
weekly sessions, 3 monthly individual booster sessions were held by telephone (this 
was after the immediate post[-treatment] assessment). As the original PASCET-PI was 
developed for depression, therapists were instructed how to make the exercises more 
anxiety-tailored, an anxiety hierarchy and step-by-step exercise was added, and an 
extra anxiety hand-out was provided to the patients. For patients 21-25 years of age 
the practice book was made more age-appropriate. See Van den Brink & Stapersma et 
al. [31] or Appendix 1 for a more detailed description of this Dutch modification of the 
PASCET-PI. The therapy was provided by all licensed (healthcare/CBT) psychologists, 
who received onsite training from the developer (EMS) and performed the therapy in 
their own hospital or center. To ensure treatment integrity, monthly supervision was 
provided by EMWJU (clinical psychologist/professor) and audiotaped sessions were 
rated by EMWJU and five master level Psychology students. Of all sessions, 30% was 
rated on adherence by at least one rater, and of that 30% half was evaluated by at least 
2 raters (i.e. 15% of all sessions). Audiotapes were randomly selected to be rated by two 
of the raters. However, which pair of two raters rated the sessions varied strongly, so 
there were too few standardized pairs of raters to use for example intraclass correla-
tion [32]. Therefore, interrater agreement was globally calculated using Pearson’s cor-
relation between two data columns with 1) all first ratings and 2) all second ratings for 
all patients and sessions combined. CAU consisted of regular medical appointments 
with the (pediatric) gastroenterologist every 3 months, consisting of a 15 minute 
consultation discussing overall wellbeing, disease activity, results of diagnostics tests, 
medication use, and future diagnostic/treatment plans.
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outcome measures (online questionnaires)
Demographic data were assessed with a general questionnaire, based on a semi-
structured interview [33]. Socioeconomic status was based on occupational level 
from parents or, if they lived on their own, patients themselves. It was divided into 
low, middle, and high [34]. Ethnicity was based on mother’s country of birth or if 
the mother was born in the Netherlands, the father’s country of birth [35]. Disease 
characteristics were extracted from the medical charts.
Symptoms of anxiety were assessed with the SCARED (for 10-20 years), and the 
anxiety scale of the HADS (for 21-25 years). Both are self-report questionnaires. The 
SCARED has 69-items with 3 response categories (0-2; total score 0-138). It contains 
five subscales: general anxiety disorder, separation anxiety disorder, specific phobia, 
panic disorder, and social phobia [19, 36]. The anxiety scale of the HADS has 7-items 
with 4 response categories (0-3, total score 0-21) [20]. Internal consistency was .86 
and .92 for the SCARED and .54 and .77 for the HADS-A at baseline and follow-up, 
respectively (Cronbach’s α).
Symptoms of depression were assessed using the CDI (for 10-17 years) and the BDI-
II (for 18-25 years) self-report symptom scales. The CDI has 27-items with 3 response 
categories (0-2, total score 0-54) [21]. The BDI-II has 21-items with 4 response categories 
(0-3, total score 0-63) [22]. Internal consistency was .70 and .77 for the CDI and .54 and 
.83 for the BDI-II at baseline and follow-up, respectively.
Health-related quality of life was assessed with the self-reports IMPACT-III (10-
20 years) and Inflammatory Bowel Disease Questionnaire (IBDQ; 21-25 years). The 
IMPACT-III has 35 items, scored 1-5 (total score 35-175) [37]. The IBDQ contains 32 
items, scored 1-5 (total score 32-160) [38]. A higher score of both instruments indicates 
better quality of life. Internal consistency was .86 and .89 for the IMPACT-III and .71 
and .92 for the IBDQ at baseline and follow-up, respectively.
clinical disease activity was assessed with four validated clinical disease activity 
measures. For patients of 10-20 years with CD the short Pediatric Crohn’s Disease 
Activity Index (sPCDAI) [39] was used, whereas for patients with UC and IBD-U the 
Pediatric Ulcerative Colitis Activity Index was used (PUCAI) [40]. For patients of 21-25 
years with CD the Crohn’s Disease Activity Index (CDAI) [41] was used, whereas for 
patients with UC and IBD-U the partial Mayo score [42] was used. All indices were 
scored by the physician during the medical visit and provide four categories of clinical 
disease activity: remission, mild, moderate, and severe.
Social validity questions were included in the online questionnaire to gain insight 
in how the patients in the CBT group (and if applicable parents) evaluated the PASCET-
PI. For this study we chose to assess three relevant aspects of social validity: satisfac-
tion, usefulness, and recommendation. Patients and/or parents awarded 3 items with 
0-10 points (0 = ”Not at all” to 10 = “Very much”) regarding 1) their satisfaction with 
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the protocol, 2) how useful it was for them, and 3) whether they would recommend 
it to other patients.
Blinding
The interviewer (LS) and treating physicians were blinded for the result of randomiza-
tion (they were not informed and had no access to files containing this information). 
Patients could not be blinded. They were explicitly asked not to discuss the group they 
were randomized into with their physician.
Statistical analysis
Descriptive statistics were computed for demographic and disease characteristics. 
Independent t-tests and chi-square tests were used to assess differences between these 
variables in the two groups at baseline. An intention-to-treat principle was applied in 
the analyses.
For each participant we calculated a Reliable Change Index (RCI) [43] value for 
anxiety and depression (but not for HRQOL, since no data on test-retest reliability 
was available for the HRQOL instruments, which is necessary to calculate the RCI). By 
calculating RCI’s, we were able to combine all participants in one analysis. The RCI is 
calculated using the standard error of measurement (SEM) of the pretest and the test-
retest reliability of the instrument. The RCI can have three possible values: reliably 
improved, no reliable change, and reliably deteriorated. See Appendix 2 for the details 
of calculating the RCI variable. A chi-square test was used to compare the RCI values 
between the two groups, using complete cases (n = 68). For exploratory analyses we 
first used six linear mixed models (which take into account missing data) to compare 
change between the groups from baseline to directly after CBT for anxiety (SCARED 
or HADS-A), depression (CDI or BDI-II), and HRQOL (IMPACT-III or IBDQ). Time, group 
(PASCET-PI vs. CAU) and the interaction between time and group were included as 
fixed factors. We repeated these linear mixed models in subgroups to examine the 
influence of gender, and disease type. The influence of age is incorporated in the 
first set of linear mixed models, as the questionnaires for the specific age-group were 
used. Using an Identity covariance structure, random intercepts were estimated for 
each participant. No random slopes could be specified, because we only had two time 
points. Restricted maximum likelihood (REML) was applied as estimation method. 
A p-value of less than .05 was considered statistically significant. Reported Cohen’s 
d’s represent the effect size between groups at follow-up. For the SCARED, HADS-A, 
CDI, and BDI-II a negative effect size is in favor of CBT, for the IMPACT-III and IBDQ a 
positive effect size is in favor of CBT. Data were analyzed using SPSS version 21.
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Sample size and power
Considering literature regarding effectiveness of CBT for anxiety and depressive 
symptoms in youth without a somatic disease, as well as earlier studies of CBT in 
youth with IBD [9], we expected medium to large effects on anxiety symptoms [44] 
and medium effects for depressive symptoms [45]. This corresponds to j >0.40 for 
anxiety symptoms, and to j >0.30 for depressive symptoms. For the chi-square tests 
for anxiety and depressive symptoms this means that a total of 70 patients provides 
us with sufficient power for the anxiety outcomes (>85%) and with medium power for 
the depression outcomes (>60%).
reSultS
Demographic, disease and intervention characteristics
Figure 1 displays the patient flow throughout the study. In total, 70 patients were 
randomized (10-20 years n = 50, 21-25 years n = 20). In Table 1 demographic and 
disease characteristics are displayed for both groups. No significant differences were 
found between the PASCET-PI group and the CAU group on demographics (e.g. gender, 
age) and disease characteristics (disease type, duration, activity), neither as to whether 
patients were included based on anxiety, depression or both.
Regarding treatment integrity, in the PASCET-PI group 33 (89.2%) patients followed 
all 10 treatment sessions, 1 patient (2.7%) followed 8 sessions, 1 patients (2.7%) fol-
lowed 5 sessions, 1 patient (2.7%) followed 3 sessions and 1 patient (2.7%) followed 1 
session. The mean number of treatment sessions followed was 9.38. In the 21 patients 
of whom parents participated as well, 76.2% of the parents followed all three family 
sessions. The mean number of family sessions was 2.57. In all sessions at least 75%, 
and in 75% of the sessions at least 80% of the required topics were discussed, indicat-
ing good adherence to the protocol (i.e. treatment integrity). A global estimation of 
interrater agreement, over all sessions and patients combined, was calculated. Treat-
ment adherence ratings correlated .41 between the 6 raters [46]. No patients in the 
control group sought mental health care and no study-related adverse events occurred 
during the trial.
effect of disease-specific cBt on symptoms of depression and anxiety, 
HrQol
As some cells in the cross-tabulation were smaller than 5, a Fisher’s exact test was 
performed. In the primary analysis, RCI values did not differ between the two groups 
for both anxiety (χ2 (2) = 1.656, p = .465, j = .159) and depression (χ2 (2) = 1.648, p = 
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.523, j = .161), see Table 2. Overall, patients in both groups either remained stable or 
improved in their symptoms of anxiety and depression.
Excluded  (n=178) 
•Declined to participate – screening (n=169) 
•No screening data (n=9) 
Lost to follow-up (n=0) 
Allocated to Care-As-Usual (n=33) 
11 care providers in 6 centers performed intervention  Number of patients treated by each 
•care provider (median=3, IQR=2, min=1, max=9) 
•center (median=5, IQR=2.5, min=1, max=15)  
Allocated to Cognitive Behavioral Therapy (n=37) 
•Received allocated intervention (n=37) 
•Did not receive allocated intervention (n=0)  
Lost to follow-up (n=2; missing data post assessment) Discontinued intervention (n=2; dropped out intervention, 
but provided post assessment data) 
Allocation  
Follow-Up  
Step 2: Inclusion RCT Randomized (n=70) 
Enrollment  
Analysed  (n=33) 
•Baseline data (n=33) 
•Post assessment data (n=33) 
•Excluded from analysis (n=0)  Analysed •Baseline data (n=37) •Post assessment data (n=35) •Excluded from analysis (n=0)  
Analysis  
Allocation  
Excluded  (n=304) 
•Not meeting inclusion criteria (n=195) 
•Too severe anxiety/depression (n=46) 
•Declined randomisation (n=61) 
•Incomplete screening data (n=2) 
Step 1: Inclusion baseline screening Screened for anxiety/depression (n=374) 
Assessed for eligibility (n=552) 
figure 1 | CONSORT study flow chart
Abbreviations: RCT= randomized controlled trial; IQR= inter quartile range
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table 1 | Baseline demographic and disease characteristics
PAScet-PI 
group (n=37)
cAu group 
(n=33)
p value
Demographic status
Male, n (%) 10 (27.0) 12 (36.4) .401a
Age, mean (SD), years 18.62 (4.27) 17.69 (4.82) .393b
SES, n (%)
Low 8 (21.6) 4 (12.9)
.348aMiddle 15 (40.5) 10 (32.3)
High 14 (37.8) 17 (54.8)
Ethnicity, n (%) (n = 64)
Dutch / Western 30 (81.1) 25 (80.6)
.749a
Other 7 (18.9) 6 (19.4)
Included on, n (%)
Anxiety 30 (81.1) 20 (60.6)
.070a
Depression 0 (0.0) 3 (9.1)
Both 7 (18.9) 10 (30.3)
IBD subtype, n (%) 
Crohn’s disease 18 (48.6) 18 (54.5)
.808aUlcerative colitis 14 (37.8) 12 (36.4)
IBD-U 5 (13.5) 3 (9.1)
Paris classification at diagnosis, n (%)
CD: location† (n = 36)
L1 4 (22.2) 2 (11.1)
.813a
L2 4 (22.2) 4 (22.2)
L3 6 (33.3) 8 (44.4)
+ L4a/L4b 4 (22.2) 4 (22.2)
CD: behavior (n = 36)
Nonstricturing, nonpenetrating 18 (100.0) 16 (88.9)
.243c
Stricturing, penetrating, or both 0 (0.0) 2 (11.1)
UC: extent‡ (n = 34)
Limited: E1 + E2 11 (57.9) 4 (26.7)
.069a
Extensive: E3 + E4 8 (42.1) 11 (73.3)
UC: severity
Never severe 18 (94.7) 11 (73.3)
.104c
Ever severe 1 (5.3) 4 (26.7)
Clinical disease activity, n (%)
Remission 27 (73.0) 26 (78.8)
.571a
Mild 10 (27.0) 7 (21.2)
Disease duration, median, years 2.59 1.17 .039d
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In the exploratory analyses (see Table 3) the same pattern was seen. No significant 
time-group interaction effect was found for anxiety (SCARED n=50: t(47.460) = -0.639, 
p = .526, d = -0.15; HADS-A n=20: t(16.047) = 0.976, p = .343, d = -0.06), depression (CDI 
n=35: t(32.004) = -1.272, p = .212, d = -0,11; BDI-II n=35: t(30.739) = -0.363, p = .719, 
d = -0.47), and HRQOL (IMPACT-III n=50: t(45.363) = 1.033, p = .315, d = 0.23; IBDQ 
n=20: t(18.124) = -0.539, p = .597, d = 0.44). For the SCARED (t(48.059) = -5.709, p < 
.001), HADS-A (t(16.431) = -4.375, p < .001), the BDI-II (t(31.236) = -4.778, p < .001), the 
IMPACT-III (t(45.849) = 4.847, p < .001), and the IBDQ (t(18.738) = 2.367, p < .05) the 
effect of time was significant, for the CDI this was not the case (t(32.525) = -1.554, p 
table 1 | Baseline demographic and disease characteristics (continued)
PAScet-PI 
group (n=37)
cAu group 
(n=33)
p value
IBD Medications, n (%)
Aminosalicylates 18 (48.6) 12 (36.4) .300a
Immunomodulators 16 (43.2) 16 (48.5) .660a
Biologicals 8 (21.6) 12 (36.4) .173a
Corticosteroids§ 2 (5.4) 5 (15.2) .170c
Enemas 3 (8.1) 1 (3.0) .352c
No medication 2 (5.4) 1 (3.0) .543c
Note: all demographic and disease characteristics were not significantly different between 
groups, except disease duration
Abbreviations: PASCET-PI= Primary and Secondary Control Enhancement Training for Physical 
Illness; CAU= care-as-usual; SD= Standard Deviation; IBD= Inflammatory Bowel Disease; IBD-U= 
Inflammatory Bowel Disease Unclassified; SES= Socioeconomic Status
Notes: a chi-square, b ANOVA, c Fisher’s Exact Test | * UC includes IBD-U patients, † L1: ileocecal, 
L2: colonic, L3: ileocolonic, L4a: upper gastrointestinal tract proximal, and L4b distal from Treitz 
ligament ‡ E1: proctitis, E2: left sided colitis distal of splenic flexure, E3: extensive colitis distal of 
hepatic flexure, E4: pancolitis § prednisone (oral and intravenous) and budesonide (oral)
table 2 | Crosstabulation RCI of symptoms of anxiety and depression versus group
no reliable change reliable increase 
of score / 
deterioration
reliable decrease 
of score / 
improvement
total
RCI categories anxiety (SCARED or HADS-A)
CAU 20 (60.6%) 0 (0%) 13 (39.4%) 33
CBT 17 (48.6%) 1 (2.9%) 17 (48.6%) 35
χ2 =1.656, df = 2, p = .465, φ = .159 (95%BI 0.00-0.36). Numbers in parentheses indicate row percentages
RCI categories depression (CDI or BDI-II)
CAU 14 (42.4%) 1 (3.0%) 18 (54.5%) 33
CBT 14 (40.0%) 4 (11.4%) 17 (48.6%) 35
χ2 =1.648, df = 2, p = .523, φ = .161 (95%BI 0.00-0.37). Numbers in parentheses indicate row percentages
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= .130). These findings show that, after three months, all patients improved in their 
symptoms of anxiety and depression, as well as in their HRQOL. Even when these 
analyses were carried out only in patients who showed relatively ‘high’ subclinical 
problems (‘high’ n=40 vs. ‘low’ n=30), no group differences were found on the anxiety 
and depression outcomes (data not shown).
Influence of age, gender, and disease type on effect of disease specific 
cBt on anxiety and depression
In exploratory analyses for the four separate age groups (classified by the four age-
attuned questionnaires: SCARED [10-20 years], HADS [21-25 years], CDI [10-17 years], 
BDI-II [18-25 years)] no differences were found between the groups as to the change 
in anxiety, depression, or HRQOL. As we did not find group differences in all four age 
groups, an age effect seems absent. We explored the possible influence of gender and 
disease type on the effect of the PASCET-PI by conducting linear mixed model analyses 
separately in subgroups (male vs. female and CD vs. UC & IBD-U). Overall, none of 
the subgroup analyses showed a difference between two groups on either anxiety, 
depression, or HRQOL, except for a significant lower score on the BDI-II in the CAU 
group (n=6) than in the CBT group (n=3) for the subgroup analysis in males (data not 
shown). Therefore, gender and disease type do not seem to influence the effect of CBT.
Social validity
With respect to satisfaction, patients reported a mean of 7.82 (out of 10), whereas 
parents reported a mean of 7.50 (out of 10). Mean scores of patients and parents for 
usefulness were 6.82 and 6.06 (out of 10), respectively. Furthermore, patients reported 
a mean of 6.96 (out of 10) for recommending it to other patients, and parents reported 
a mean of 7.25 (out of 10). These results indicate that, in general, patients and their 
parents evaluated the PASCET-PI positively.
table 3 | Estimated Marginal Means at Baseline and after 3 months for Anxiety, Depression and Health-
Related Quality of Life
Variable Baseline 3 months p
(time 
effect)
p
(time x 
group)
cohen’s d (95%cI) 
(after 3 months)
SCARED (0-138) Mean (SE) Mean (SE)
CBT 36.2 (2.7) → 22.9 (2.6)
< .001
CAU 40.5 (2.8) → 25.0 (2.9)
CBT vs. CAU .526 -0.15 (-1.02-0.71)
HADS-A (0-14)
CBT 9.9 (0.7) → 7.1 (0.7)
< .001
CAU 9.1 (0.8) → 7.3 (0.8)
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DIScuSSIon
The current study, which had very low attrition (< 3%), tested the effect of a disease-
specific CBT compared to CAU in reducing subclinical anxiety and/or depressive 
symptoms and in improving HRQOL, in adolescents and young adults with IBD. At 
the immediate post(-treatment) assessment disease-specific CBT added to standard 
medical care did not perform better than standard medical care. Overall, both the 
PASCET-PI and CAU group significantly improved over time, on all three outcomes, 
3 months after baseline (i.e. at the immediate post[-treatment] assessment). Further-
more, in subgroup analyses we did not find indications for differences between age 
groups, boys versus girls, nor between CD and UC/IBD-U regarding the effect of the 
PASCET-PI on anxiety, depression, or HRQOL. Our results are in contrast to results of 
earlier trials with positive findings of CBT treatment for youth with IBD [9], but are in 
accordance with some of the evidence from studies in adults with IBD [47]. There are 
several explanations for our findings.
table 3 | Estimated Marginal Means at Baseline and after 3 months for Anxiety, Depression and Health-
Related Quality of Life (continued)
Variable Baseline 3 months p
(time 
effect)
p
(time x 
group)
cohen’s d (95%cI) 
(after 3 months)
CBT vs. CAU .343 -0.06 (-1.49-1.37)
CDI (0-54)
CBT 8.5 (1.1) → 7.2 (1.1)
.130
CAU 10.8 (1.2) → 7.7 (1.2)
CBT vs. CAU .212 -0.11 (-1.11-1.02)
BDI-II (0-63)
CBT 11.3 (1.1) → 5.9 (1.1)
< .001
CAU 14.2 (1.2) → 8.2 (1.2)
CBT vs. CAU .719 -0.47 (-1.51-0.58)
IMPACT-III (35-175)
CBT 137.1 (2.8) → 148.1 (2.8)
< .001
CAU 137.4 (2.9) → 144.9 (3.0)
CBT vs. CAU .315 0.23 (-1.28-0.49)
IBDQ (32-224)
CBT 164.6 (5.8) → 179.6 (5.8)
< .001
CAU 161.6 (6.4) → 171.2 (6.7)
CBT vs. CAU .597 0.44 (-2.02-0.77)
Note. For the SCARED, HADS-A, CDI, and BDI-II a negative Cohen’s d favors CBT, for the IMPACT-
III and IBDQ a positive Cohen’s d favors CBT.
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First, just by participating in the study, patients in the CAU group did not exactly 
receive standard medical care. They were psychologically assessed at two points in 
time with questionnaires and interviews. This is not done in routine practice and 
therefore it provided additional exposure to attention from professionals. Usually, 
only if psychological problems are obvious, the medical team refers patients for men-
tal health care. CAU was chosen as comparison condition, because it resembles the 
current care for youth with IBD in our institute best. However, mere participation in 
the trial may have had a positive effect on all patients due to increased awareness and 
(unintended) psychoeducation. It has been described before that merely answering 
questions or participate in a trial can influence behavior or emotions. For example, 
McCambridge [48] recently described that the ‘question-behavior effect’ can occur in 
randomized trials. Moreover, Arrindell [49] has described the re-test effect: in patients 
with psychiatric problems mean scores of psychopathology often decrease at follow-
up (without any formal intervention). A first assessment can heighten awareness of 
anxious or depressive symptoms, which can cause an respondent to try to deal with 
these symptoms (by talking more about it or try to think different) or lead to more 
introspection or self-monitoring [49]. The awareness caused by receiving information 
about the study and receiving the psychological assessment may have contributed to 
the fact that all patients improved. It can be perceived as some form of support, like 
in the control conditions of earlier trials in youth with IBD [9, 14].
Second, the overall patient group had a low disease burden, both psychologically 
as well as somatically. Included patients experienced only subclinical anxiety and/
or depressive symptoms, as randomization was not ethical for patients with clinical 
mental health disorders. We mainly included patients in clinical remission, because 
for patients with severe disease activity adherence to the CBT protocol might have 
been complex. For the subclinical anxiety and/or depressive symptoms mere par-
ticipation may have been enough to improve. This raises the question: which IBD-
patients should receive psychological treatment? When we analyzed those patients 
with the highest levels of subclinical anxiety and/or depressive symptoms still no 
differences between CBT and CAU were observed. However, a recent trial showed a 
significant effect of CBT compared to a waiting list on QOL, anxiety, and depression in 
adult IBD patients, of whom 70% met criteria for a psychiatric disorder [50]. This implies 
that IBD patients with severe psychological problems can actually benefit from CBT. 
Furthermore, for adolescents with IBD, when compared to supportive therapy, CBT 
has been shown to improve somatic depressive symptoms as well as clinical disease 
activity and ESR (Erythrocyte Sedimentation Rate), but only in patients with CD and 
moderate clinical disease activity [51]. This suggests that patients with active disease 
can benefit from CBT. For these patients, however, sessions should be delivered with 
great flexibility, as they may not be able to adhere to weekly ‘live’ sessions.
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Third, the PASCET-PI may not be suited enough to improve subclinical anxiety 
and/or depressive symptoms. However, an earlier study using the original PASCET-PI 
protocol in a group of patients selected on elevated depression, did find an effect on 
these subclinical depressive symptoms, and also on comorbid anxiety disorders [12]. 
In our trial patients experienced more anxiety symptoms than depressive symptoms, 
which can have influenced the results. Nevertheless, CBT is the most evidence-based 
psychological therapy for both anxiety and depression [11]. In general, CBT techniques 
do have an effect on both anxiety and depressive symptoms, with even higher effect 
sizes found for anxiety than for depression [52]. This implies that PASCET-PI may be 
effective, as to both anxiety and depressive symptoms. In adults with IBD, mixed 
results are found with respect to the effectiveness of CBT on psychological as well as 
somatic symptoms [47, 53]. Several recommendations are made [17, 47] to focus on 
patients with for example decreased HRQOL or experiencing psychological problems 
and to take into account high attrition rates in power and sample size calculations. 
In our trial these recommendations were covered by selecting patients on anxiety 
and/or depression and by having very low attrition. The mixed findings in IBD are 
consistent with mixed findings on the effect of preventive CBT programs for subclini-
cal anxiety and/or depression in youth [54]. Since our patients experienced subclinical 
psychological and somatic symptoms, the treatment can be considered as preventive 
(for the development of clinical disorders). Further studies are needed to examine this 
type of preventive effects, especially in patients with IBD, as psychological problems 
can also affect the disease course [55, 56].
Fourth, although a sample size of 70 participants should be large enough for the 
expected effect sizes for CBT on anxiety and/or depression, perhaps we would have 
found a significant group difference with a larger sample size. Originally, to take into 
account possible attrition, we aimed to enroll 100 patients [31], which we could not 
achieve. Revised power calculations still indicated that we had sufficient power to 
investigate the effect of the PASCET-PI, using n = 70. With this sample size one would 
expect to see at least a trend towards a difference between the two groups, but this 
was not the case. Moreover, compared to earlier trials, a strength of the present study 
was the very low attrition rate and that almost all (95%) patients completed disease-
specific CBT.
Fifth, it may be possible that the effect of the PASCET-PI sustains on the longer-term, 
whereas the effect of the control group diminishes over time. The course of IBD can 
be fluctuating, and perhaps the knowledge and skills taught in the PASCET-PI can be 
more useful when patients suffer from more disease activity or flares during a longer 
period of follow-up. Patients themselves often expressed that this was a motivation 
to participate in the therapy (“I have no complaints now, but the CBT skills can be 
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useful in the future, when I have a flare”). Data on longer follow-up assessments will 
be available for analyses later.
In summary, strengths of the current study are that we included patients with a 
broad and clinical relevant age, with both anxiety and/or depressive symptoms, and 
that our study had very low attrition. Moreover, no patients in the control group 
sought mental health care. Furthermore, since our study sites encompass both rural 
and urban hospitals, this strengthens the generalizability and external validity of our 
findings. Although the age-specific instruments were most appropriate for the patients 
in our study, statistically it was a limitation that using different instruments made it 
difficult to combine all patients in one analysis and that we could perform the linear 
mixed models only in subgroups. Originally the study was sufficiently powered to 
analyze mean symptom change of anxiety and depression. Due to the fact that finally 
multiple instruments had to be used to cover the age-range, this was not possible. 
However, a revised power calculation for the chi-square analyses with the reliable 
change index indicated that we had enough power with the total of 70 patients in the 
RCT. Another limitation was the relatively small sample size. Therefore, our results 
should be interpreted with caution. We recommend screening for anxiety and/or 
depressive symptoms in youth with IBD, as these symptoms can affect disease course 
[55, 56], and health-related quality of life [57]. Subclinical symptoms may develop into 
more severe psychological disorders which even have a greater impact [58, 59]. CBT 
may be more effective in patients with more severe psychological symptoms or more 
IBD disease activity. This, however, should be examined in studies with a different 
design (i.e. not with standard medical care as comparison condition). Based on our 
clinical experience, we consider PASCET-PI as suited also for patients with more 
severe IBD symptoms, but with great flexibility in delivery (over the phone or in the 
hospital when patients are hospitalized). Yet, future research is needed to find out 
how the PASCET-PI or CBT can be best delivered to those patients, which patients with 
IBD benefit most from psychological treatment, but also how the long-term course of 
disease activity is associated to the long-term course of anxiety/depression.
In conclusion, in our RCT all patients improved in their symptoms of anxiety and 
depression, and their HRQOL over time (3 months). At the immediate post-treatment 
assessment, we found no additional effect for a disease-specific CBT on improving 
subclinical anxiety and depressive symptoms or HRQOL in adolescents and young 
adults with IBD, when compared to CAU. We hypothesize that the awareness the 
study elicited and the possible (unintended educational) support provided may have 
had a strong positive effect on all patients. CBT could be beneficial for patients with 
more severe psychological symptoms or IBD patients with clinical disease activity.
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APPenDIx 1. outlIne of tHe PAScet-PI [12, 31]
APPenDIx 1 | Outline of the PASCET-PI [12, 31]
Session number content of session
Session 1
Live (60 min)
Introduction of Act & tHInk model and PASCET-PI, building work 
alliance, psycho-education about IBD and depression or anxiety, illness 
narrative
Session 2
Live (60 min)
Mood monitoring, explaining link between feelings, thoughts and 
behaviors, discussing feeling good and feeling bad, problem-solving
Session 3
By telephone (30 min)
Link between behavior and feelings: Activities to feel better
Session 4
Live (60 min)
Be calm and Confident: relaxation exercises
Session 5
Live (60 min)
Be Calm and confident: positive self versus negative self, training social 
skills
Session 6
By telephone (30 min)
talents: developing talents and skills makes you feel better
Session 7
Live (60 min)
Social problem solving, discussing the Act skills and introduction of the 
tHInk skills with discussing negative thoughts (think positive)
Session 8
By telephone (30 min)
Help from a friend, Identify the ‘Silver Lining’, and no replaying bad 
thoughts
Session 9
By telephone (30 min)
keep trying – Don’t give up, making several plans to use the Act & 
tHInk skills
Session 10
Live (60 min)
Quiz on Act & tHInk model, discussing use of Act & tHInk skills in the 
future, updating illness narrative
Booster 1
By telephone (30 min)
Several plans to use the Act & tHInk skills, updating illness narrative, 
personalizing Act & tHInk skills
Booster 2
By telephone (30 min)
Several plans to use the Act & tHInk skills, updating illness narrative, 
personalizing Act & tHInk skills
Booster 3
By telephone (30 min)
Several plans to use the Act & tHInk skills, updating illness narrative, 
personalizing Act & tHInk skills
Family 1
Live (60 min)
Parental view on IBD, family situation, psycho-education about IBD and 
depression or anxiety, introduction of Act & tHInk model and PASCET-PI
Family 2
Live (60 min)
Parental view on progress, the Act & tHInk skills that are most 
effective for the patient, expressing emotions within family, family 
communication, family stress game
Family 3
Live (60 min)
Parental view on progress, family communication, parental depression or 
anxiety
Abbreviations: IBD= Inflammatory Bowel Disease; PASCET-PI= Primary and Secondary Control En-
hancement Training for Physical Illness.
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APPenDIx 2. cAlculAtIon of relIABle cHAnGe InDex (rcI) 
VArIABleS
Step 1. Calculating the standard error of difference for each participant, separately for 
anxiety and depression:
�� �
�� 	� ��
�����
����� � ������	 �� � �� � � ���
In which x1 and x2 are the individual’s scores on baseline and at follow up, respec-
tively. S1 is the pre-test variance for that instrument. rxx is the test-retest reliability of 
the instrument as reported in the manual.
	 •	 SCARED	(10-20	years):	rxx = .81 [36]| S1 = 13.389| Sdiff = 8.253
	 •	 HADS-A	(21-25	years):	rxx = .89 [60] | S1 = 2.373| Sdiff = 1.113
	 •	 CDI	(10-17	years):	rxx = .86 [21]| S1 = 4.648| Sdiff = 2.459
	 •	 BDI-II	(18-25	years):	rxx = .93 [22] | S1 = 4.381| Sdiff = 1.639
Step 2. Calculating the difference between the follow up and the baseline for each 
participant, separately for anxiety and depression.
Step 3. Calculating the RC value for each participant, separately for anxiety and 
depression.
Step 4. Determining the RCI value for each participant, separately for anxiety and 
depression. Both for anxiety and depression this leads to a variable with three possible 
values: no reliable change, reliable deterioration, and reliable improvement. An RC 
value of between -1.96 and 1.96 indicates no reliable change (p < .05). When RC is 
higher than 1.96, this indicates a reliable increase in the score (p < .05), i.e. reliable 
deterioration (as for all the instruments applies that a higher score represents more 
symptoms). When RC is lower than -1.96, this indicates a reliable decrease in the score 
(p < .05), i.e. reliable improvement.
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ABStrAct
Youth with inflammatory bowel disease (IBD) often experience psychological difficul-
ties, such as anxiety and depression. This random controlled study tested whether a 
3 month disease-specific cognitive behavioral therapy (CBT) in addition to standard 
medical care versus standard medical care only was effective in improving these 
youth’s psychological outcomes. As this was a preventive study, we included 70 pa-
tients (10-25 years) with subclinical anxiety and/or depression, and measured psycho-
logical outcomes at 6 and 12 months’ follow-up. In general, patients in both groups 
showed improvements in anxiety, depression, health-related quality of life, social 
functioning, coping, and illness perceptions, sustained until 12 months follow-up. 
Overall, we found no differences between those receiving additional CBT and those 
receiving standard medical care only. We assume that this can be explained by the 
perceived low burden (both somatically and psychologically) or heightened awareness 
regarding psychological difficulties and IBD. ClinicalTrials.gov: NCT02265588.
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IntroDuctIon
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastroin-
testinal tract characterized by periods of active inflammation (with increased clinical 
symptoms) followed by periods of clinical remission. The two main types of IBD are 
Crohn’s disease (CD) and ulcerative colitis (UC). Symptoms are abdominal pain, bloody 
diarrhea, fatigue, fever, and weight loss [1, 2]. Pediatric patients may also suffer from 
anorexia/loss of appetite, malnutrition, and experience delayed growth and puberty 
onset – especially those with CD [3, 4].
Adolescents and young adults (hereafter referred to as youth) with IBD may experi-
ence various psychological problems related to the disease and its treatment. Firstly, 
they are at risk for anxiety and depression [5, 6]. More specifically, a large cohort study 
found that these patients have a higher risk for anxiety or depressive disorders [7]. 
Secondly, they are at risk for a lower health-related quality of life (HRQOL) compared 
to healthy peers [8], likely on account of more maladaptive avoidant coping [9, 10]. 
In addition, negative illness perceptions (i.e. negative cognitions on for example the 
consequences of the disease or personal control) are associated with more negative 
outcomes in these patients [11, 12]. Thirdly, youth with IBD also experience sleep 
problems [13], related to anxiety and depression [14]. Lastly, they their social function-
ing is worse than that of healthy controls [6]. In conclusion, youth with IBD are likely 
to experience psychological problems as described above and the interrelationships 
between these problems makes treating this patients somatically and psychologically 
even more complex.
Importantly, psychological problems of youth with IBD can influence medical out-
comes, creating a vicious circle of problems [e.g. 15-17]. There seems to be a reciprocal 
relationship between these psychological difficulties and clinical symptoms due to 
gut inflammation [18]. It has been hypothesized that psychological interventions may 
positively influence the inflammatory disease course [19]. Psychological treatment 
should be focused on decreasing anxiety and depression and addressing other psycho-
logical problems, such as coping or negative illness perceptions, and on improving 
HRQOL and daily functioning. A recent randomized controlled trial (RCT) of Levy et 
al. [20] in pediatric patients with IBD tested the effect of a 3-session social learning 
and cognitive behavioral therapy (SLCBT) versus educational support (ES; focusing on 
the gastrointestinal system, food labels, and nutrition) on a large set of psychological 
outcomes. SLCBT outperformed educational support in improving IBD-related quality 
of life 1 week after treatment and coping and school attendance over the course of 12 
months, but had no effect on anxiety, depression, and functional disability. However, 
patients were not selected on either somatic of psychological symptoms, and there-
fore, many of them did not have psychological problems. Mikocka-Walus et al. [21] 
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have suggested that targeted psychological treatment may be more useful to tackle 
psychological problems such as elevated anxiety and/or depression. Furthermore, Levy 
et al. [20] used an intervention of only 3 sessions, whereas in IBD it has been shown 
that a full 12-session protocol of disease-specific CBT improved depressive symptoms 
and HRQOL [22, 23].
HAPPY-IBD aimed to test the extent to which disease-specific CBT in youth with 
subclinical anxiety and depression is effective to decrease the negative impact of the 
disease and these subclinical psychological symptoms. By providing CBT for these 
specifically subclinical symptoms, we aimed to improve the disease course and to 
prevent the development of clinical anxiety and depressive disorders. So the study 
had a perspective of secondary prevention. To cover the important life phase of tran-
sition from adolescence to adulthood, we included youth aged 10-25 years. In this 
adolescent life phase, IBD can affect the psychological development, such as becom-
ing independent from parents, developing long-term friendships, and forming an own 
(sexual) identity. For teenagers, important changes are starting secondary education, 
making new friends at a new school, becoming more independent from parents, and 
spending more time with peers. For late adolescents these processes continue and 
graduating, experimenting with alcohol or drugs, finding a (side) job and earning 
money, and forming an identity will take place as well. Lastly, young adults face 
developmental challenges such as finding a job, leaving home, having long lasting 
romantic relationships, and becoming financially independent [24]. A diagnosis of IBD 
can involve a sense of loss in for example body image, future plans, self-confidence, 
sense of control, and roles inside and outside the family context [25]. These changes 
and challenges should be considered in the treatment of youth with IBD.
Earlier we have reported the immediate post-treatment assessment of this RCT, 
three months after baseline: patients in both the CBT and the standard medical care 
group improved on anxiety, depression, and HRQOL, but the level of improvement 
did not differ between groups [26]. Considering that IBD has a fluctuating disease 
course, we re-assessed psychological outcomes at 6 and 12 months. We expected that 
patients who had received CBT would be better able to deal with possible flares and 
be better equipped with skills to prevent worsening of their subclinical psychological 
problems. Since CBT in general aims to improve anxiety and depression, these were 
chosen as primary outcomes. In addition, in this study we extended and innovated 
the range of our outcomes and also measured HRQOL, social functioning, coping [27], 
illness perceptions [28], and sleep problems.
In summary, the present study aims to test the effectiveness of a full disease-specific 
CBT protocol in addition to standard medical care), 6 and 12 months after the baseline 
assessment, to improve anxiety and depressive symptoms, and other psychological 
outcomes, in youth with IBD (10-25 years old) and subclinical symptoms of anxiety and 
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depression, compared to standard medical care only. We hypothesized that patients 
who had received CBT would have more sustained improvement on all psychological 
outcomes than those in the standard medical care group.
metHoDS
For details of this RCT and the 3-month outcomes, see Van den Brink & Stapersma et 
al. [29] and Stapersma et al. [26]. This study is a two-armed multi-center parallel group 
RCT, comparing a disease-specific CBT (Primary and Secondary Control Enhancement 
Training for Physical Illness; PASCET-PI) [30] in addition to standard medical care to 
standard medical care only (care-as-usual, CAU). The latter represents the current 
usual care for youth with IBD in the Netherlands, and was therefore chosen as control 
condition. Patients were consecutively recruited between October 2014 and October 
2016 in two academic and four community hospitals in urban and rural regions. The 
trial design adheres to the CONSORT guidelines for non-pharmacological treatments 
[31]. The research protocol was approved by the Medical Ethics Committee of the 
Erasmus MC (approval number NL49147.078.14) and confirmed by the ethics boards 
of all participating hospitals. The study was registered with ClinicalTrials.gov as study 
number NCT02265588.
Participants and Assessment procedure
After patients and/or their parents had provided written informed consent, they were 
included in two steps. Patients from the age of 12 years provided informed consent 
themselves as well, patients of 10 or 11 years provided assent. All patients received a 
small financial reward (25 EUR voucher) for participating.
Step 1 involved baseline screening of anxiety and depression symptoms, for which 
all consecutive youth (aged 10-25 years) with a confirmed diagnosis of IBD (CD, UC 
or inflammatory bowel disease unclassified) recruited in the abovementioned period 
were eligible.
Step 2, the actual RCT, included only youth with subclinical anxiety or depression 
established in step 1, as we aimed to examine whether the disease specific CBT could 
prevent clinical anxiety and/or depression. In addition, it is unethical to withhold 
treatment to patients with clinical anxiety and/or depression.
Subclinical anxiety or depressive symptoms were defined as a score equal or above 
the cutoff of age-appropriate questionnaires, but not meeting criteria for clinical anxi-
ety and depression (see below). Subclinical anxiety symptoms were measured with the 
Screen for Child Anxiety Related Emotional Disorders (SCARED; 10-20 years; cutoff 
≥26 for boys and ≥30 for girls) [32] and the Hospital Anxiety and Depression Scale – 
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Anxiety Scale (HADS-A; 21-25 years; cutoff ≥8) [33]. Subclinical depressive symptoms 
were measured with the Child Depression Inventory (CDI; 10-17 years; cutoff ≥13) [34] 
and the Beck Depression Inventory – second edition (BDI-II; 18-25 years; cutoff ≥14) 
[35].
Patients were assumed to suffer from clinical anxiety or depression if they met DSM-
5 criteria for an anxiety or depressive disorder, as assessed a psychiatric interview 
(Anxiety Disorders Interview Schedule for Children; ADIS-C) [36], and scored equal to 
or above the clinical cutoff on age-specific severity rating scales: the Pediatric Anxiety 
Rating Scale (PARS; 10-20 years; cutoff ≥18) [37] or the Hamilton Anxiety Rating Scale 
(HAM-A; 21-25 years; cutoff ≥15) [38, 39] for anxiety; the Child Depression Rating Scale 
Revised (CDRS-R; 10-12 years; cutoff ≥40) [40], the Adolescent Depression Rating Scale 
(ADRS; 13-20 years; cutoff ≥20) [41], or the Hamilton Depression Rating Scale (HAM-
D; 21-25 years; cutoff ≥17) [42, 43] for depression. All above-mentioned cutoffs only 
served for inclusion of patients and not for analysis purposes.
Patients with clinical anxiety or depression were referred to mental health care. 
Patients with subclinical anxiety or depressive symptoms (but not clinical anxiety or 
depression) were randomized at a ratio 1:1 to receive either PASCET-PI in addition to 
CAU or CAU only.
randomization
An independent biostatistician provided a computer-generated blocked randomiza-
tion list with randomly chosen block sizes (with a maximum of 6) and stratification 
by center using the blockrand package in the R software package, thereby providing 
numbered envelopes per center. Patients were enrolled by a single investigator (GB). 
The interviewer (LS) and treating physicians had no access to the files in which the 
randomization result was described. We requested patients and parents not to reveal 
the trial arm assignment to the interviewer and treating physicians. Patients and 
parents received a link to web-based questionnaires, to be completed at home. They 
completed the same set of questionnaires at baseline (no longer than 2 weeks before 
the start of the PASCET-PI), and at the post-assessments (3, 6 and 12 months after 
baseline). For both groups, assessments were performed at comparable time points 
(i.e. between 11-13 weeks, 25-27 weeks and 51-53 weeks after randomization).
Intervention
The PASCET-PI is a disease-specific CBT protocol for youth with IBD [30], consisting 
of ten weekly individual sessions, delivered in three months. It was provided in a 
‘blended format’: six sessions were face-to-face with a psychologist (in the patient’s 
own hospital), four sessions by telephone. In addition, parents of patients ≤20 years 
were invited for three face-to-face family sessions. Booster sessions were delivered 
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by telephone 4,5 and 6 months after baseline. The authorized Dutch translation of 
the PASCET-PI was used, developed by the research team. Originally, the PASCET-PI 
is targeted at depression. For this study, the treatment content was adjusted to also 
target aspects of anxiety such as anxiety hierarchy, exposure, cognitive restructuring, 
and to also target young adults (with more age-appropriate exercises and lay-out). A 
more detailed description is provided in Appendix 1 or Van den Brink & Stapersma 
et al. [29]. In short, sessions are focused on discussing, in an age-attuned manner, the 
patient’s illness narrative and the link between behavior and feelings, on relaxation, 
on discussing negative thoughts and cognitive restructuring, and on personalizing 
the taught skills. The therapists provided age-appropriate information and exercises. 
In this way, the protocol took into account the patient’s psychological, cognitive and 
social development.
The therapy was provided by licensed (healthcare/CBT) psychologists with ample 
experience working with youth, who had all been trained by the developer (EMS) and 
received monthly supervision by EMWJU (clinical psychologist/professor). Treatment 
integrity was ensured by supervision of the therapists and by rating of audiotaped 
sessions. For details, see Stapersma et al. [26]. CAU consisted of regular medical consul-
tations of 15-30 minutes with the (pediatric) gastroenterologist and/or IBD nurse every 
three months, in which overall wellbeing, disease activity, and future diagnostic/treat-
ment plans were discussed.
outcome measures (online questionnaires)
Demographic data were obtained from a semi-structured questionnaire [44]. Socio-
economic status was based on parents’ occupational level or, for patients living on 
their own, the own occupational level. We classified socioeconomic status into low, 
middle, and high [45]. Ethnicity was based on the mother’s country of birth or if 
the mother was born in the Netherlands, the father’s country of birth [46]. Disease 
characteristics were extracted from the electronic medical charts.
Symptoms of anxiety were assessed with the SCARED (for 10-20 years), and the 
anxiety scale of the HADS (for 21-25 years). Both are self-report questionnaires. The 
SCARED has 69-items with 3 response categories (0-2; total score 0-138) [47]. The 
anxiety scale of the HADS has 7-items with 4 response categories (0-3, total score 0-21) 
[33]. Internal consistency at baseline and the three follow-up assessments was .86, .92, 
.94, respectively, and .94 for the SCARED, and .54, .77, .81, .80, respectively, for the 
HADS-A. Clinical anxiety was defined using a psychiatric interview and severity rating 
scales (as described above in the assessment procedure).
Symptoms of depression were assessed using the CDI (for 10-17 years) and the BDI-
II (for 18-25 years) self-report symptoms scales. The CDI has 27-items with 3 response 
categories (0-2, total score 0-54) [34]. The BDI-II has 21-items with 4 response categories 
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(0-3, total score 0-63) [35]. Internal consistency at baseline and the three follow-up 
assessments was .70, .77, .79, and .81, respectively, for the CDI, and .54, .83, .81, and 
.84, respectively, for the BDI-II. Clinical depression was defined using a psychiatric 
interview and severity rating scales (as described above in the assessment procedure).
Health-related quality of life (including social functioning) was assessed with 
the self-report questionnaires IMPACT-III (10-20 years) and the Inflammatory Bowel 
Disease Questionnaire (IBDQ; 21-25 years). The IMPACT-III has 35 items, scored 1-5 
(total score 35-175) [48]. The IBDQ contains 32 items, scored 1-5 (total score 32-160) 
[49]. For both instruments a higher score indicates better HRQOL. We included in the 
analyses the total scores and the individual subscale scores for social functioning of 
both instruments. For the total score, internal consistency at baseline and the three 
follow-up assessments was .71, .92, .90, and .90, respectively, for the IMPACT-III, and 
.71, .92, .85, and .88, respectively, for the IBDQ. For the social functioning subscale 
score, internal consistency at baseline and the three follow-up assessments was .67, 
.54, .59, and .49, respectively, for the IMPACT-III subscale, and .69, .85, .48, and .51, 
respectively, for the IBDQ subscale.
coping was assessed using the Cognitive Emotion Regulation Questionnaire (CERQ). 
The CERQ contains 36 items, scored 1-5, subdivided into 9 subscales. These scales are 
divided in two domains: adaptive coping (e.g. positive reappraisal) and maladaptive 
coping (e.g. self-blame and catastrophizing). A higher score indicates more use of a 
particular coping style [50]. Internal consistency at baseline and the three follow-up 
assessments was .89, .91, .94, and .94, respectively, for the adaptive coping domain, 
and .87, .88, .87, and .86, respectively, for the maladaptive coping domain.
Illness perceptions were assessed with the Brief Illness Perceptions Questionnaire 
(B-IPQ) [51, 52]. It contains 9 self-report items on cognitive and emotional represen-
tations of illness. Eight dimensions (e.g. consequences of illness, personal control, 
concerns, and understanding) are scored from 0-10. A higher score represents more 
negative illness perceptions. Internal consistency at baseline and the three follow-up 
assessments was .74, .79, .78, and .75.
Sleep problems were assessed using the sleep problem items of the Youth Self-
Report (YSR; for ages 10-17) [53] and the Adult Self-Report (ASR; for ages 18-25) [54]. 
These questionnaires contain three comparable items on sleep problems (scored 0, 1 
or 2), of which the scores were added up: ‘I sleep more than most other people during 
day and/or night.’ and ‘I have trouble sleeping.’
clinical disease activity was assessed with four validated clinical disease activity 
measures around the moments that patients filled out the online questionnaires on 
psychological symptoms. For patients of 10-20 years with CD, the short Pediatric 
Crohn’s Disease Activity Index (sPCDAI) [55] was used; for patients with UC and IBD-U 
the Pediatric Ulcerative Colitis Activity Index (PUCAI) [56]. For patients of 21-25 years 
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with CD, the Crohn’s Disease Activity Index (CDAI) [57] was used; for patients with UC 
and IBD-U the partial Mayo score [58]. All are physician rated forms (not online), that 
provide four categories of clinical disease activity: remission, mild, moderate, and 
severe.
Statistical analysis
We tested differences in demographic and disease characteristics between the two 
groups at baseline using t-tests, Mann-Whitney tests and chi-square tests.
To be able to combine all participants in one analysis (thereby maximizing power), 
despite the use of age-appropriate instruments, we calculated a Reliable Change Index 
(RCI) [59] value separately for anxiety and depression (primary outcomes) for each par-
ticipant, at each assessment. The RCI of an instrument is calculated from the standard 
error of measurement (SEM) of the pretest reliability and the test-retest reliability. The 
RCI can have three possible values; reliably improved; no reliable change; and reli-
ably deteriorated (see Appendix 2 for RCI details). Chi-square tests were used to test 
for differences in RCI values between the two groups. These analyses included only 
patients for whom pre- and posttest data were available (see Table 1 for the details 
on sample sizes for each chi-square test). The proportions of patients who developed 
clinical anxiety and/or depression were compared between groups using a separate 
chi-square test.
For exploratory analyses, we used linear mixed models (taking into account missing 
data) to compare the change on full-range scores from baseline to 6 and 12 months 
follow-up between groups. The outcomes were anxiety (SCARED or HADS-A), depres-
sion (CDI or BDI-II), HRQOL (IMPACT-III or IBDQ), social functioning (subscale of 
IMPACT-III or IBDQ), coping (CERQ), illness perceptions (B-IPQ), and sleep problems 
(YSR or ASR). The starting model for all outcomes included a random intercept and 
fixed factors for time, group, and the interaction between time and group. Next, we 
examined with the use of likelihood-ratio tests whether adding a random slope of 
time and a quadratic term of time and the interaction between the quadratic term 
of time with group improved the model. The restricted maximum likelihood method 
was applied, as this is preferred for relatively small sample sizes [60, 61]. Because we 
had no expectations about the relationship between the random intercept and slope, 
we used an unstructured covariance structure was selected, which is the most flexible 
structure.
Follow-up data were analyzed based on the intention-to-treat principle, unless 
otherwise specified. For the chi-square analyses (with the primary dichotomous out-
comes) this implied inclusion of only those randomized for whom follow-up data were 
available (since follow-up data were required to calculate the RCI). For the exploratory 
analyses (secondary continuous outcomes), the intention-to-treat principle implied in-
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clusion of all randomized patients, also those without follow-up data (since the linear 
mixed models take into account missing data and follow-up data were not required). 
A p -value of <.05 was considered statistically significant. Data were analyzed using 
SPSS version 24.
Sample size and power
Sample size and power were based on anxiety and depressive symptoms as primary 
outcomes. Meta-analytic studies in youth without a somatic disease have shown 
medium-to-large effect sizes for anxiety symptoms [62] and medium effect sizes for 
depressive symptoms [63]. These correspond with j >0.40 and j >0.30, for anxiety and 
depressive symptoms respectively. For the main chi-square analyses this means that 
a sample size of 70 patients would give us enough power for the anxiety outcomes 
(>85%, β = 0.14) and medium power for the depression outcomes (>60%, β = 0.39).
reSultS
Demographic data
In total, 70 patients were randomized; 37 to the PASCET-PI group and 33 to the CAU 
group (see Figure 1). Attrition was very low; only two patients dropped out of the 
PASCET-PI, and only three patients (6 months) and two patients (12 months) did not 
complete follow-up assessments. Demographic variables did not significantly differ 
between the groups (see Appendix 3): percentage males (27.0% vs. 36.4%, p = .401), 
mean age (18.62 vs. 17.69, p = .393), socioeconomic status (p = .348), and ethnicity (p 
= .749). The number of patients included at baseline based on anxiety, depression or 
both did not differ between groups as well (p = .070). The patients’ disease charac-
teristics did not differ between the groups: IBD subtype (% CD 48.6% vs. 54.5%), Paris 
classification at diagnosis (CD location; p = .808, CD behavior; p = .243, UC extent; p 
= .069, UC severity; p = .104), percentage of patients in clinical remission (73.0% vs. 
78.8%, p = .571), and use of IBD medication (% immunomodulators 43.2% vs. 48.5% and 
% biologicals 21.6% vs. 36.4%). However, the median disease duration was longer in the 
PASCET-PI group than in the CAU group (2.59 vs. 1.17 years, p = .039). In the PASCET-PI 
group, 18 patients were aged 10-17 years and 19 patients 18-25 years. In the CAU 
group, 17 patients were aged 10-17 years and 16 patients 18-25 years.
With respect to treatment integrity, adherence to the protocol was good. The mean 
number of sessions followed in the PASCET-PI group was 9.38 (out of 10). The mean 
number of family sessions followed was 2.57 (out of 3), and the mean number of 
booster sessions followed was 2.59 (out of 3). In all sessions, at least 75% of the topics 
were discussed.
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effect of disease-specific cBt on symptoms of depression and anxiety
In the chi-square tests, some cells in the cross-tabulation were smaller than 5. Only 
few patients (0-4) were in the ‘Reliable increase of score / deterioration’ category (i.e. 
deteriorated in anxiety or depression). Therefore, we combined this category with the 
Excluded		(n=178)
• Declined	to	participate	– screening	(n=169)
• No	screening	data	(n=9)
Lost	to	follow‐up (missing	data	post	assessment)
• 6	months	(n=1)
• 12	months	(n=1)
Allocated	to	Care‐As‐Usual	(n=33)
11	care	providers in	6	centers	performed intervention
Number	of	patients	treated	by	each
• care	provider	(median=3,	IQR=2,	min=1,	max=9)
• center	(median=5,	IQR=2.5,	min=1,	max=15)
Allocated	to	Cognitive	Behavioral	Therapy	(n=37)
• Received	allocated	intervention	(n=37)
• Did	not	receive	allocated	intervention	(n=0)
Lost	to	follow‐up	(missing	data	post assessment)
• 6	months	(n=2)
• 12 months	(n=1)
Discontinued	intervention	(n=2;	dropped	out	intervention,	
but	provided	post	assessment	data)
Allocation
Follow‐Up
Step	2:	Inclusion	RCT
Randomized	(n=70)
Enrollment
Analysed
• Baseline	data	(n=33)
• Post	assessment	data	at	6	months	(n=32)
• Excluded	from	analysis	(n=0)
Analysed
• Baseline	data	(n=37)
• Post	assessment	data	at 6	months (n=35)
• Excluded	from	analysis	(n=0)
Analysis	6	months
Allocation
Excluded		(n=304)
• Not	meeting	inclusion	criteria	(n=195)
• Too	severe	anxiety/depression	(n=46)
• Declined	randomisation	(n=61)
• Incomplete	screening	data	(n=2)
Step	1:	Inclusion	baseline	screening
Screened	for	anxiety/depression	(n=374)
Assessed	for	eligibility	(n=552)
Analysed	
• Baseline	data	(n=33)
• Post	assessment	data	at	12	months	(n=32)
• Excluded	from	analysis	(n=0)
Analysed
• Baseline	data	(n=37)
• Post	assessment	data	at	12	months	(n=36)
• Excluded	from	analysis	(n=0)
Analysis	12	months
figure 1 | CONSORT study flow chart
Abbreviations: RCT= randomized controlled trial; IQR= inter quartile range
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‘No reliable change’ category, to test if the PASCET-PI and CAU groups differed with 
respect to the proportions of patients who had improved on anxiety or depression. In 
these main analyses, RCI values for anxiety (χ2 (1) = .226, p = .801) and depression (χ2 
(1) = 2.680, p = .141) after 6 months did not differ between the groups, and neither 
did the RCI values for anxiety (χ2 (1) = .337, p = .626) after 12 months. This indicates 
that in both groups a similar proportion of patients improved. For depression after 
12 months, the RCI values differed significantly between the groups, indicating that a 
higher proportion of patients in the CAU group improved than in the PASCET-PI group 
(χ2 (1) = 5.460, p = .026), see Table 1. In the PASCET-PI group, two patients developed 
clinical anxiety and/or depression during follow-up, versus one patient in the CAU 
group, which was not significantly different (χ2 (1) = .240, p = .543).
To provide more insight into age differences, we also performed the chi-square 
analyses separately for the 10-17-year-olds and the 18-25-year-olds. The results were 
table 1 | Crosstabulation of 6 & 12 month RCI of symptoms of anxiety and depression vs. group
6 months
Reliable increase of score / 
deterioration or no reliable 
change
Reliable decrease of score / 
improvement
Total
rcI categories anxiety (ScAreD or HADS-A)
CAU 11 (34.4%) 21 (65.6%) 32
CBT 14 (40.0%) 21 (60.0%) 35
χ2 = .226, p = .801, φ = -.058 (95%BI .000-.293). Numbers in parentheses indicate row percentages
rcI categories depression (cDI or BDI-II)
CAU 11 (34.4%) 21 (65.6%) 32
CBT 19 (54.3%) 16 (45.7%) 35
χ2= 2.680, p = .141, φ = .200 (95%BI .000-.439). Numbers in parentheses indicate row percentages
12 months
Reliable increase of score / 
deterioration or no reliable 
change
Reliable decrease of score / 
improvement
Total
rcI categories anxiety (ScAreD or HADS-A)
CAU 12 (37.5%) 20 (62.5%) 32
CBT 16 (44.4%) 20 (55.6%) 36
χ2= .337, p = .626, φ = .070 (95%BI .000-.306). Numbers in parentheses indicate row percentages
rcI categories depression (cDI or BDI-II)
CAU 8 (25.0%) 24 (75%) 32
CBT 19 (52.8%) 17 (47.2%) 36
χ2= 5.460, p = .026, φ = .283 (95%BI .036- .521). Numbers in parentheses indicate row percentages
165
7
almost completely similar to the chi-square analyses in the total group (data not 
shown). However, a higher proportion of 18-25-year-olds in the CAU group improved 
on depression after 12 months than in the PASCET-PI group (χ2 (1) = 6.349, p = .019).
The exploratory analyses gave similar results as the chi-square analyses. For all 
outcomes, the residuals of the models were approximately normally distributed. For 
the SCARED and the IMPACT-III, the final model included a fixed factor for time and 
group, a random intercept, and a random slope for time, since the likelihood-ratio 
test indicated that adding a random slope for time improved the model significantly. 
Because this was not the case for all the other outcomes, the respective models did not 
include a random slope for time. For the BDI-II, the final model included fixed factors 
for time group, and for the interaction between time and group, and a random inter-
cept. For all the other outcomes, however, including a fixed factor for the interaction 
between time and group did not improve the model. Therefore, for all other outcomes 
the final model included fixed factors for time and group, and a random intercept. 
For the SCARED, HADS-A, and BDI-II, adding a quadratic term of time significantly 
improved the model. Then adding the interaction between the quadratic term of time 
and group did not improved the model for these outcomes.
sNo significant time-group (PASCET-PI versus CAU group) interaction effect was 
found for anxiety (SCARED: p = .798; HADS-A: p = .997), depression (CDI: p = .693), 
HRQOL (IMPACT-III Total score: p = .117; IBDQ Total score: p = .247), social functioning 
(IMPACT-III Social functioning: p = .407; IBDQ Social functioning; p = .879), coping 
(CERQ Adaptive coping: p = .506; CERQ Maladaptive coping: p = .592), illness percep-
tions (B-IPQ: p = .474) and sleep problems (YSR/ASR: p = .858). The only significant 
time and group interaction was found on the BDI-II (p = .025, favoring the CAU group 
over the course of 12 months). Therefore, for all outcomes except the BDI-II, the ef-
fect of time was similar for both groups. Table 2 presents the coefficients for time 
presented for the model without the interaction of time and group; only for the 
BDI-II the estimate is presented for the model with the interaction of time and group 
included. For all outcomes (except sleep problems; p = .070), the average effect of time 
was significant, indicating that over the course of 12 months, patients improved on 
their psychological outcomes (anxiety, depression, HRQOL, social functioning, coping, 
and illness perceptions). For the SCARED, HADS-A, and BDI-II, the quadratic effect 
was significant. This indicates that for these outcomes the model follows a quadratic 
trajectory over the course of 12 months.
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DIScuSSIon
In the current RCT we examined the long-term effects of a disease-specific CBT on 
psychological outcomes of youth with IBD. The results showed that, overall, both 
groups improved on anxiety and depressive symptoms, HRQOL, social functioning, 
coping, and illness perceptions and that these improvements sustained until the final 
follow-up assessment at 12 months. In both groups a similar proportion of patients 
improved in anxiety and/or depression (main analyses) and the groups did not differ in 
the proportion of patients that developed clinical anxiety and/or depression. However, 
in general, no differences between the CBT and CAU groups were found.
Our results are partly in line with results of earlier similar trials. Levy et al. [20] 
found that three sessions of social learning and cognitive behavioral therapy (SLCBT) 
outperformed educational support, but only in improving HRQOL (after 1 week of 
follow-up), coping and school attendance (after 12 months of follow-up), and in par-
ent- and child-reported distract/ignore coping of the child. In line with our results, no 
beneficial effect of SLCBT was found on anxiety, depression, or coping or functional 
disability. Szigethy et al. [22] compared CBT with supportive nondirective therapy and 
found that CBT outperformed supportive nondirective therapy in improving disease 
activity after three months, with a difference of 10 points in raw disease activity 
scores from pre- to post-intervention. When only data of patients with active CD were 
analyzed, CBT was more effective than supportive nondirective therapy in improving 
disease activity and somatic depressive symptoms after three months of treatment 
[64].
Explanations for the lack of an effect of the disease-specific CBT in our trial may be 
the following. Firstly, most patients in our study experienced no or only mild somatic 
symptoms at baseline, reflected by low IBD disease activity scores. Receiving the full 
protocol of CBT may have been “over-treatment” in patients with a rather low burden 
of disease, somatically as well as psychologically. Many patients remarked that the 
acquired skills would be useful and necessary in times of disease exacerbations. Thus, 
we hypothesize that CBT may be more useful for patients with severe anxiety/depres-
sion and/or those with active disease.
Secondly, patients in the control group may have received more than just standard 
medical care, because they participated in the trial. Via the informed consent form and 
the invitation by the medical staff, they were informed about psychological problems 
in IBD. Then, they were systematically screened with questionnaires and diagnostic 
interviews. This provided them with the opportunity to express their emotions and 
concerns, which may have evoked feelings of reassurance and safety. The created 
awareness may have benefitted all patients, and may have been enough to improve 
168
the subclinical anxiety and depression. This also may be an explanation for the fact 
that so few patients in both groups developed clinical anxiety and/or depression.
It is unexpected and counter-intuitive that at 12 months of follow-up the propor-
tion of patients that had improved on depressive symptoms was the highest in the 
CAU group, albeit this was only the case for the 18-25-year old patients. Youth in this 
age range have a more advanced cognitive development than younger peers. Those 
receiving CBT may find themselves confronted with the life-long impact of IBD (on for 
example long-lasting romantic relationships, work, and career prospects. This may 
maintain the depressive symptoms. Still, this unexpected finding, may have been a 
chance finding, considering the number of statistical tests. and also considering that 
at 3 and 6 months no difference in depression was found between the CBT and CAU 
groups.
Furthermore, at baseline the disease duration in the CBT group was significantly 
longer than that in the CAU group (2.59 vs. 1.17 years). This may have had an effect on 
the outcomes, since several studies showed that a shorter disease duration is associ-
ated with lower HRQOL or more emotional/behavioral problems [65, 66]. Patients in 
the CBT group may have had fewer psychological problems, and, therefore, less room 
to improve. This is not likely, however, considering the fact that both the RCI analysis 
and the exploratory linear mixed models took into account the baseline psychological 
outcomes scores.
In addition, since the PASCET-PI was originally developed and found effective for 
improving mainly depression [22], it was unexpected that we found no differences on 
depressive symptoms. Furthermore, we found no additional effect on anxiety symp-
toms, although we adapted the PASCET-PI to also target anxiety. Szigethy et al. [64] 
only found an additional effect of CBT on somatic depressive symptoms and disease 
activity in patients with active CD. In our study approximately three-quarters of the 
patients were in clinical remission, which may explain differences in results.
We also did not find differences between the groups in improvement in coping 
and negative illness perceptions. For coping or illness perceptions to change after 
psychological treatment, these should explicitly have been made the focus of treat-
ment. The PASCET-PI contains components that may influence coping (e.g. practicing 
with positive thinking) and illness perceptions (e.g. discussing the illness narrative 
of the patient). Perhaps, there was too little focus on challenging coping styles in the 
current protocol. An alternative explanation may be that the patients experienced 
little negative illness perceptions, due to the low levels of disease activity [e.g. 67, 
68]. However, the secondary analyses were exploratory (and conducted in subgroups 
of patients based on age). As a consequence, this study may have not been the most 
suitable to investigate coping and illness perceptions. Future studies should therefore 
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investigate how coping and illness perceptions can be the focus of psychological treat-
ment to improve anxiety and depression.
clinical and future directions
Considering the results of the current study and that of earlier studies into CBT for 
youth with IBD [20, 22, 64], it remains unclear which patients with IBD will benefit 
the most from CBT, how the intervention should be delivered, and which outcomes 
improve the most.
Based on our findings, providing a full protocol of disease-specific CBT seems not 
necessary for preventive purposes. We assume that that patients with more clinical 
anxiety and/or depression likely will benefit more from CBT, as was found in both 
youth [22] and adults with IBD [69]. Moreover, although this is not clear yet, a full 
protocol of CBT may be more helpful for improving their psychological as well as 
somatic symptoms of IBD patients who suffer from active disease. However, since 
these patients are often hospitalized or need intensive pharmacological treatment, it 
is important to find out how the CBT can be delivered best to them (e.g. via telephone 
or Internet). Group interventions in the hospital have been shown to be promising in 
youth with IBD [70] and effective in youth with chronic illnesses (including IBD) [71]. 
Furthermore, apart from anxiety, depression and HRQOL, other clinically relevant 
psychological outcomes such as social functioning, school attendance, or treatment 
adherence may be important to target as well. Psychological interventions aiming at 
these outcomes have been shown to be effective in youth with either IBD or other 
chronic illnesses [72, 73].
Strengths and limitations
One of the strengths of the current study is the randomized and prospective design, 
in which the interviewer and the treating physicians were blinded to the group as-
signment. In addition, we included patients with a broad and clinical relevant age 
range and our findings have external validity since patients came from both rural and 
urban centers (including different therapists). Furthermore, the study had very low 
attrition and we investigated several psychological outcomes. An important limita-
tion is that we did not control for attention placebo effects. We chose to use standard 
medical care as control condition, because it was already known that CBT as state-
of-the-art psychotherapy performs better than placebo for anxiety and depression. 
Therefore, we deemed this as the most clinical relevant comparison, considering that 
this resembles our current care best. Furthermore, the relatively small sample size is 
a limitation, although the study was sufficiently powered. In addition, to cover the 
whole age-range, we had to use several different age-specific instruments, making it 
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difficult to combine all patients in one analysis. Consequently, the exploratory linear 
mixed models could only be performed on subgroups.
conclusion
The current RCT showed that, in general, patients in both the CBT and the control 
group remained stable, improved or deteriorated on their psychological outcomes 
6 and 12 months after baseline. CBT did not have an additional effect in improv-
ing anxiety, depression, HRQOL, social functioning, coping, illness perceptions, and 
sleep problems, when compared to CAU. We think that a full protocol of CBT was 
not necessary in patients with relatively low somatic and psychological burden and 
that the awareness created by participating in an RCT had a positive effect on the 
psychological outcomes of patients in both groups.
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APPenDIx 1. outlIne of tHe PAScet-PI [29, 30] AnD tree DIAGrAm
APPenDIx 1 | Outline of the PASCET-PI [29, 30] and tree diagram
Session number content of session
Session 1
Live (60 min)
Introduction of Act & tHInk model and PASCET-PI, building work 
alliance, psycho-education about IBD and depression or anxiety, illness 
narrative
Session 2
Live (60 min)
Mood monitoring, explaining link between feelings, thoughts and 
behaviors, discussing feeling good and feeling bad, problem-solving
Session 3
By telephone (30 min)
Link between behavior and feelings: Activities to feel better
Session 4
Live (60 min)
Be calm and Confident: relaxation exercises
Session 5
Live (60 min)
Be Calm and confident: positive self versus negative self, training social 
skills
Session 6
By telephone (30 min)
talents: developing talents and skills makes you feel better
Session 7
Live (60 min)
Social problem solving, discussing the Act skills and introduction of the 
tHInk skills with discussing negative thoughts (think positive)
Session 8
By telephone (30 min)
Help from a friend, Identify the ‘Silver Lining’, and no replaying bad 
thoughts
Session 9
By telephone (30 min)
keep trying – Don’t give up, making several plans to use the Act & 
tHInk skills
Session 10
Live (60 min)
Quiz on Act & tHInk model, discussing use of Act & tHInk skills in the 
future, updating illness narrative
Booster 1
By telephone (30 min)
Several plans to use the Act & tHInk skills, updating illness narrative, 
personalizing Act & tHInk skills
Booster 2
By telephone (30 min)
Several plans to use the Act & tHInk skills, updating illness narrative, 
personalizing Act & tHInk skills
Booster 3
By telephone (30 min)
Several plans to use the Act & tHInk skills, updating illness narrative, 
personalizing Act & tHInk skills
Family 1
Live (60 min)
Parental view on IBD, family situation, psycho-education about IBD and 
depression or anxiety, introduction of Act & tHInk model and PASCET-PI
Family 2
Live (60 min)
Parental view on progress, the Act & tHInk skills that are most 
effective for the patient, expressing emotions within family, family 
communication, family stress game
Family 3
Live (60 min)
Parental view on progress, family communication, parental depression or 
anxiety
Abbreviations: IBD= Inflammatory Bowel Disease; PASCET-PI= Primary and Secondary Control En-
hancement Training for Physical Illness.
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APPenDIx 2. cAlculAtIon of relIABle cHAnGe InDex (rcI) 
VArIABleS
Step 1. Calculating the standard error of difference for each participant, separately for 
anxiety and depression:
�� �
�� 	� ��
�����
����� � ������	 �� � �� � � ���
In which x1 and x2 are the individual’s scores on baseline and at follow up, respec-
tively. S1 is the pre-test variance for that instrument. rxx is the test-retest reliability of 
the instrument as reported in the manual.
	 •	 SCARED	(10-20	years):	rxx = .81 [47] | S1 = 13.389| Sdiff = 8.253
	 •	 HADS-A	(21-25	years):	rxx = .89 [74] | S1 = 2.373| Sdiff = 1.113
	 •	 CDI	(10-17	years):	rxx = .86 [34]| S1 = 4.648| Sdiff = 2.459
	 •	 BDI-II	(18-25	years):	rxx = .93 [35] | S1 = 4.38| Sdiff = 1.639
Step 2. Calculating the difference between the follow up and the baseline for each 
participant, separately for anxiety and depression.
Step 3. Calculating the RC value for each participant, separately for anxiety and 
depression.
Step 4. Determining the RCI value for each participant, separately for anxiety and 
depression. Both for anxiety and depression this leads to a variable with three possible 
values: no reliable change, reliable deterioration, and reliable improvement. An RC 
value of between -1.96 and 1.96 indicates no reliable change (p < .05). When RC is 
higher than 1.96, this indicates a reliable increase in the score (p < .05), i.e. reliable 
deterioration (as for all the instruments applies that a higher score represents more 
symptoms). When RC is lower than -1.96, this indicates a reliable decrease in the score 
(p < .05), i.e. reliable improvement.
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APPenDIx 3. BASelIne DemoGrAPHIc AnD DISeASe cHArActerIStIcS
PAScet-PI group 
(n=37)
cAu group 
(n=33)
p-value
Demographic status
Male, n (%) 10 (27.0) 12 (36.4) .401a
Age, mean (SD), years 18.62 (4.27) 17.69 (4.82) .393b
SES, n (%) 
Low 8 (21.6) 4 (12.9)
.348aMiddle 15 (40.5) 10 (32.3)
High 14 (37.8) 17 (54.8)
Ethnicity, n (%) (n = 64)
Dutch / Western 30 (81.1) 25 (80.6)
.749a
Other 7 (18.9) 6 (19.4)
Included on, n (%)
Anxiety 30 (81.1) 20 (60.6)
.070a
Depression 0 (0.0) 3 (9.1)
Both 7 (18.9) 10 (30.3)
IBD subtype, n (%) 
Crohn’s disease 18 (48.6) 18 (54.5)
.808aUlcerative colitis 14 (37.8) 12 (36.4)
IBD-U 5 (13.5) 3 (9.1)
Paris classification at diagnosis, n (%)
CD: location† (n = 36)
L1 4 (22.2) 2 (11.1)
.813a
L2 4 (22.2) 4 (22.2)
L3 6 (33.3) 8 (44.4)
+ L4a/L4b 4 (22.2) 4 (22.2)
CD: behavior (n = 36)
Nonstricturing, nonpenetrating 18 (100.0) 16 (88.9)
.243c
Stricturing, penetrating, or both 0 (0.0) 2 (11.1)
UC: extent‡ (n = 34)
Limited: E1 + E2 11 (57.9) 4 (26.7)
.069a
Extensive: E3 + E4 8 (42.1) 11 (73.3)
UC: severity
Never severe 18 (94.7) 11 (73.3)
.104c
Ever severe 1 (5.3) 4 (26.7)
Clinical disease activity, n (%)
Remission 27 (73.0) 26 (78.8)
.571a
Mild 10 (27.0) 7 (21.2)
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PAScet-PI group 
(n=37)
cAu group 
(n=33)
p-value
Disease duration, median, years 2.59 1.17 .039d
IBD Medications, n (%)
Aminosalicylates 18 (48.6) 12 (36.4) .300a
Immunomodulators 16 (43.2) 16 (48.5) .660a
Biologicals 8 (21.6) 12 (36.4) .173a
Corticosteroids§ 2 (5.4) 5 (15.2) .170c
Enemas 3 (8.1) 1 (3.0) .352c
No medication 2 (5.4) 1 (3.0) .543c
Abbreviations: PASCET-PI= Primary and Secondary Control Enhancement Training for Physical 
Illness; CAU= care-as-usual; SD= Standard Deviation; IBD= Inflammatory Bowel Disease; IBD-U= 
Inflammatory Bowel Disease Unclassified; SES= Socioeconomic Status.
Notes: a chi-square, b ANOVA, c Fisher’s Exact test, d Mann-Whitney test | * UC includes IBD-U pa-
tients, † L1: ileocecal, L2: colonic, L3: ileocolonic, L4a: upper gastrointestinal tract proximal, and 
L4b distal from Treitz ligament ‡ E1: proctitis, E2: left sided colitis distal of splenic flexure, E3: 
extensive colitis distal of hepatic flexure, E4: pancolitis § prednisone (oral and intravenous) and 
budesonide (oral)
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184
GenerAl DIScuSSIon
Aims of the present thesis and main results
Young patients with inflammatory bowel disease (IBD) are facing a lifelong disorder 
that is characterized by episodes of severe clinical symptoms, often accompanied by 
psychological problems such as anxiety and depression. Currently, there is no cure for 
IBD, and treatment is aimed at maintenance of remission while maximizing quality 
of life. Besides medical treatment, focus on the psychological aspects of this disease 
is essential. Therefore, the aims of this thesis were 1) to investigate the psychological 
problems in these patients (aged 10-25 years), and 2) to test the effectiveness of a 
disease-specific cognitive behavioral therapy (CBT) to treat subclinical anxiety and 
depressive symptoms.
Firstly, in our systematic review and meta-analysis in children and adolescents 
with IBD (10-18 years of age), we found pooled prevalence rates of 16.4% for anxiety 
symptoms, 4.2% for anxiety disorders, 15.0% for depressive symptoms, and 3.4% for de-
pressive disorders (see chapter 2). These rates are lower than in adults [1]. However, 
our results should be interpreted with caution, since varying instruments and cutoffs 
were used in the included studies.
Secondly, we studied a large baseline cohort of youth with IBD (n=374, 10-25 years 
of age, the sample of the baseline assessment of the randomized controlled trial (RCT), 
thus including patients with and without anxiety and/or depression). Almost half of 
the cohort experienced elevated symptoms of anxiety and/or depression (see chapter 
4). Subclinical symptoms were found in 23.6% and clinical symptoms were found 12.4% 
of the patients. Having active disease, as well as female gender, and shorter disease 
duration were associated with higher anxiety and/or depressive symptoms. We also 
demonstrated in this baseline cohort that, added to the influence of demographic and 
disease factors, illness perceptions and depression were associated with health-related 
quality of life (HRQOL; see chapter 5). More negative illness perceptions and more 
depression were associated with lower HRQOL. Only for youth with UC/IBD-U, anxiety 
was associated with HRQOL as well. This implies that these psychological factors 
should be targeted in the treatment of youth with IBD.
Thirdly, we performed an RCT to test the effectiveness of a disease-specific CBT 
in two groups (CBT versus care-as-usual [CAU]). The overall results showed that pa-
tients in both groups improved significantly on their subclinical anxiety symptoms, 
depressive symptoms, HRQOL, as well as in social functioning, coping, and illness 
perceptions over the course of 12 months (see chapter 6 and 7). When comparing the 
outcomes between groups, we found no differences in any of the outcomes between 
the CBT group and the CAU group. This raised the question as to which patients with 
IBD would benefit the most from CBT and in what format and dose CBT should be de-
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livered. The results of our study concerning the medical outcomes of disease-specific 
CBT are in line with this, as no effect on the clinical disease activity was found over 
the course of 12 months (see Appendix B).
The abovementioned findings will be discussed more extensively below.
Psychological aspects of IBD in youth
Anxiety and depression in youth with IBD
Several studies have found high prevalence rates for anxiety (39-50%) and depression 
(+/- 25%) separately in youth with IBD [2-5], including a higher risk for anxiety and 
depressive disorders (hazard ratios of respectively 2.28 and 1.74) [6]. In contrast, other 
studies reported low prevalence rates ranging from 0-8% [7, 8]. To provide more insight 
into the combination of IBD and anxiety/depression, we performed a systematic re-
view and meta-analysis in children and adolescents with IBD. The results of the meta-
analysis were quite surprising, as we found that (especially symptoms of) anxiety and 
depression were quite prevalent in these patients (pooled prevalence rates of 16.4% 
for anxiety symptoms, 4.2% for anxiety disorders, 15.0% for depressive symptoms, 
and 3.4% for depressive disorders). However, these rates are not as high as one might 
expect based on earlier studies, summarized in a meta-analysis in adults with IBD [1], 
showing a pooled prevalence rate of 35.1% for anxiety symptoms, 20.7% for anxiety 
disorders, 21.6% for depressive symptoms, and 15.2% for depressive disorders.
In our baseline cohort of youth (age 10-25 years) with IBD, we found that almost half 
of the patients experienced at least some anxiety and/or depression [9], and chapter 
4. More specifically, 28.3% of the patients reported to have elevated anxiety symptoms, 
2.9% reported to have elevated depressive symptoms, and 15.8% reported to have both.
There are several explanations for the mixed findings with respect to the combina-
tion of IBD and anxiety/depression in youth. These explanations concern 1) disease 
factors (most importantly clinical disease activity, but also disease duration, age at 
diagnosis, disease type, and medication use), 2) demographic factors (gender and 
socioeconomic status) and 3) how anxiety and depression are assessed in youth with 
IBD.
1) Disease factors
Clinical disease activity
Firstly, clinical disease activity is an important factor to consider. IBD has a fluctuating 
course, which means that the severity of inflammation (with increased activation of 
pro-inflammatory cytokines) and resulting clinical symptoms will vary over time. This 
fluctuating course can have an influence on the presence of anxiety and depression. 
However, both evidence supporting and opposing this explanation has been found. 
For example, in our meta-analysis we found that the higher the proportion of patients 
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with active disease in a study, the higher the prevalence of depressive symptoms. In 
addition, we found that active disease (defined as having mild, moderate, or severe 
clinical disease activity) was associated with anxiety and depressive symptoms. This is 
also found in other studies in youth [4, 10, 11], as well as in adults [12].
However, patients in clinical remission still can experience anxiety and/or depres-
sive symptoms [13-15], as we also found in our baseline cohort in which approximately 
75% of the patients was in clinical remission [9] and chapter 4. This implies that it 
is important to consider anxiety and/or depression in all IBD patients; not only in 
those with active disease, but also in those with less disease activity. Interestingly, 
the recent study of Gracie et al. [16] provided evidence for the proposed bidirectional 
relationship between IBD activity and anxiety and/or depression. Patients with clinical 
disease activity at baseline had an almost 6-fold higher risk for a later elevated anxiety 
score, and abnormal anxiety and depression at baseline were associated with several 
indicators of increased clinical disease activity. Obviously, these results stress the 
importance of taking into account clinical disease activity when investigating anxiety 
and depression.
Other disease factors
Secondly, other disease factors can play a role in the presence of anxiety and/or depres-
sion. There is some evidence that in patients with IBD, disease duration can influence 
anxiety and/or depression [13] and HRQOL [17]. We also found this in our baseline 
cohort [9] and chapter 4, i.e. shorter disease duration associated with more anxiety/
depression. In contrast, a review did not find an association between disease duration 
and anxiety and/or depression [11]. The studies in this review included patients with 
well-established IBD, with a mean disease duration of 1.2-5.4 years. It is possible that 
disease duration has some effect on the presence of anxiety and/or depression, for 
example in patients that recently have been diagnosed.
Furthermore, age at diagnosis is related to disease duration. However, independent 
of the disease duration, evidence has been reported that an older age at diagnosis 
(during adolescence) was associated with more depressive symptoms [2, 18]. This may 
have to do with the fact that being confronted with a diagnosis of a chronic disease 
such as IBD, can be harder for adolescents than for younger children, since adoles-
cence is period with many changes, which can make the patient more susceptible for 
psychological problems.
In addition, the influence of disease type (CD versus UC) has been studied exten-
sively. In their review, Brooks et al. did not find an association between disease type 
and depressive symptoms [11]. In our meta-analysis, we neither found an association 
between the proportion of patients with CD and the prevalence of depressive symp-
toms [19] / chapter 2. However, the results of both studies should be interpreted with 
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caution. The studies included in the review of Brooks et al. were not powered specifi-
cally to detect the influence of disease type on the presence of anxiety and depression 
[11]. Moreover, in our meta-analysis there was a substantial amount of heterogeneity 
between studies [19] / chapter 2. In adults, on the other hand, a meta-analysis did 
show that patients with CD had a higher prevalence of depressive symptoms than 
patients with UC [1]. It may be that for youth, disease type indeed has no effect and 
depression. That is, having a chronic illness such as IBD in adolescence can have an 
impact, regardless of with type of IBD. An alternative explanation is that, in youth, 
there is insufficient data available yet to draw strong conclusions about the effect of 
disease type on the presence of anxiety and depression.
Moreover, medication use can influence anxiety and depression in youth with IBD. 
Although we did not find an association between medication use and the presence 
of anxiety and/or depression [9] / chapter 4, the review of Brooks et al. [11] reported 
that 4 out of 5 studies showed an association between corticosteroid use and anxiety 
and depression. In contrast, the use of biologicals (e.g. infliximab or adalimumab, 
anti-tumor necrosis factor [TNF] α) was not associated with anxiety and depression 
in three studies [10, 20, 21]. Finally, abdominal pain has been related to the presence 
of anxiety and depression [22, 23]. The review of Sweeney et al. [22] suggests to focus 
on anxiety and depression in psychological treatment for youth with IBD, but also on 
pain-specific emotions, cognitions, and behaviors.
2) Demographic factors
Besides the abovementioned disease factors, some other factors may also play a role 
when discussing anxiety and depression in youth with IBD. Firstly, following the gen-
der differences in anxiety and depression in the general population [24], gender has 
also been studied in youth with IBD. Three studies did not find an association between 
gender and anxiety and/or depression [11]. However, in our own baseline cohort being 
female was associated with more anxiety and depression [9] / chapter 4. In children 
with IBD, a large study by Loftus et al. in anxiety and depressive disorders, found that 
teenage girls had a higher risk for anxiety disorders, and boys younger than 12 years 
had a higher risk of depressive disorders [6].
Secondly, mixed findings are reported with respect to the association between 
socioeconomic status (SES) and anxiety and depression. In youth with IBD, Clark et 
al. [10] found that SES was a strong predictor of depression, but they only included 
infliximab exposure, clinical disease activity and SES in their regression model. Other 
studies in adults with IBD found an association between lower income and more 
depressive symptoms [25, 26]. For Gold et al. conclusions are limited, because also a 
group of patients with functional gastrointestinal symptoms was included. Two other 
studies did not find an association between SES and anxiety and depression symptoms 
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[27, 28]. In our own baseline cohort, with several other demographic and disease fac-
tors taken into account, SES was not associated with anxiety and depression as well 
[9] / chapter 4.
3) Assessment of anxiety and depression in youth with IBD
Lastly, the way anxiety, and more importantly depression, are assessed is important 
when studying these psychological problems in youth with IBD. There is consider-
able overlap in IBD symptoms and symptoms of depression: weight loss/gain, sleep 
disturbance, psychomotor agitation/slowing, and fatigue/low energy, and reduced 
appetite. This is reflected in the often used CDI and BDI-II depression questionnaires. 
Thompson et al. [29] found a 3-factor structure of the CDI in a large cohort of pediatric 
patients with IBD, called ‘mood’, ‘ behavioral/emotional’, and ‘somatic’, with the latter 
factor containing the symptoms that overlap between IBD and depression. Further-
more, within a large sample of adolescents with IBD and depressive symptoms several 
profiles have been identified, including a profile characterized by somatic symptoms 
(severe fatigue, appetite change, decreased motor activity) [21]. However, another 
study found that these somatic symptoms did not differentiate between youth with 
more clinical disease activity and youth experiencing non-somatic symptoms of 
depression [30]. Hence, there is ongoing debate about whether to include or exclude 
items that refer to somatic symptoms in the screening for depression in youth with 
IBD [31]. Recently, in adults, evidence was found for an association between clinical 
disease activity and affective-cognitive depressive symptoms (with somatic depressive 
symptoms left out of the questionnaire) [32]. This indicates that the comorbidity 
between IBD and depression is not solely the result of the somatic symptoms that are 
often assessed. Therefore, including the somatic symptoms in screening instruments 
for depression provides extra information and does not seem to lead to an overestima-
tion of the depressive symptoms.
other psychological factors of IBD in youth
Anxiety and depression are the most studied psychological problems in youth with 
IBD. Nevertheless, other psychological factors are studied in these patients as well.
Firstly, several studies found that youth with IBD have a lower HRQOL when com-
pared to healthy peers [33, 34].
Secondly, coping also may play a role in the psychological outcomes of patients with 
IBD. Children with IBD have been shown to use more avoidant coping than healthy 
controls [35]. In general, however, youth with IBD do not differ in their coping com-
pared to controls [36]. On the other hand, large adult studies showed that patients 
with IBD used avoidant coping more often than controls [36]. With respect to the 
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effect of coping on outcomes and adjustment some studies do find an association [e.g. 
37], whereas others do not [e.g. 38].
Thirdly, regarding illness perceptions, few studies have been conducted in youth 
with IBD [11]. In adults, studies showed that illness perceptions were associated with 
anxiety and depression [39], and with HRQOL [38, 40]. Recently, Van Tilburg et al. 
[41] also found evidence for the effect of pain beliefs on patient-reported symptoms, 
and disability, when controlling for coping, anxiety, depression, and clinical disease 
activity.
Fourthly, symptoms of IBD can affect the social functioning of youth with IBD. 
Indeed, a meta-analysis indicated that youth with IBD have worse social functioning 
compared to healthy controls [42]. In fact, onset of IBD during adolescence is associ-
ated with worse social functioning [43], probably due to increasing responsibilities in 
school and jobs.
Interrelationships between disease and psychological factors
Previous research has shown that there is a complex interplay between psychological 
factors in patients with IBD, especially in how they influence disease outcomes. In 
adults, clinical disease activity, illness perceptions, coping, and anxiety and depres-
sion are associated with HRQOL [e.g. 38, 39, 44]. More specifically, in youth, anxiety/
depression have been shown to mediate the relationship between clinical disease 
activity and HRQOL [45]. Recently, disability (as disease outcome) was found to be 
predicted by a latent construct ‘psychological factors’, consisting of anxiety, depres-
sion, pain beliefs, and coping [41].
However, most studies only examined the unique influence of one or two psychologi-
cal factors on HRQOL. In our study we investigated the combined influence of these 
factors on HRQOL. Adjusted for the influence of demographic and disease factors, 
illness perceptions and depression were associated with HRQOL, whereas anxiety was 
only in youth with UC/IBD-U coping and was not at all [46] / chapter 5. This suggests 
1) that at least illness perceptions and depression should be the focus of psychological 
interventions for youth with IBD and 2) that not only anxiety/depression but also 
HRQOL should be considered as disease outcome.
Disease-specific cBt for youth with IBD
Findings in adults with IBD are mixed with respect psychological treatment for 
patients with IBD. For treatment focused on anxiety, depression, and HRQOL both 
positive and negative findings are reported, but for pain, fatigue, and medication ad-
herence the results are promising [47]. However, the difference between the included 
patients may be an explanation for the inconclusive results, since several studies 
included all patients with IBD, regardless of the presence of psychological problems 
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or low HRQOL. Recently, several studies found that CBT was effective in improving 
anxiety, depression and HRQOL, in adults selected on having elevated symptoms of 
anxiety, depression or a low HRQOL [48, 49]. With respect to the effect of CBT on 
disease outcomes, in general no effects are reported [50, 51].
In youth, promising findings have been reported [52, 53]. Recently, CBT was found 
to be effective in improving depression [54] and HRQOL [55]. Furthermore, Szigethy et 
al. [54] reported that CBT outperformed supportive non-directive therapy in patients 
with CD and moderate clinical disease activity. Levy et al. [55] found no effects of 
their 3-session CBT on anxiety and depression in youth with IBD. In our own RCT, we 
tried to avoid limitations of the previous studies. Firstly, studies often focused only 
on depression. Since anxiety and depression are highly comorbid [56], we focused 
on both simultaneously. Secondly, the Levy et al. study [57] included all children and 
adolescents. As described above in adults, CBT seems to be more effective in patients 
with elevated symptoms of anxiety and depression or low HRQOL. Therefore, we only 
selected patients with elevated anxiety and/or depressive symptoms. Thirdly, we used 
a full-protocol of disease-specific CBT, since Levy et al. [55] mentioned that their 3-ses-
sion therapy may have been too short.
In spite of these methodological considerations, we did not find any differences 
between the disease-specific CBT group and the CAU group in improving anxiety, 
depression, HRQOL, neither in improving social functioning, coping, negative illness 
perceptions, and sleep problems [57,58] / chapter 6 & chapter 7.
Our results, and that of earlier RCT’s into the effect of CBT for psychological 
outcomes in youth with IBD, may be explained by several factors. Firstly, and most 
importantly, mere participating in the study may have elicited awareness for anxiety 
and depression in these patients. They received informed consent forms, discussed 
these with their physician and one of the investigators, filled out questionnaires on 
psychological problems, and received a psychiatric interview. For both groups this 
may have been sufficient to improve from their subclinical anxiety and/or depression. 
It has been described before that merely answering questions or participating in a 
trial can influence behavior and emotions. McCambridge [59] described this ‘question-
behavior effect’ that can occur in RCT’s. Moreover, Arrindell [60] described the re-test 
effect: mean scores of psychopathology often decrease without any formal interven-
tion, perhaps because the first assessment can heighten awareness, which in turn can 
influence an individual’s behaviors and emotions. This awareness can be perceived 
as some form of educational support, like in the control condition of earlier trials in 
youth with IBD [54, 55].
Secondly, in our study patients experienced relatively low disease burden, psycho-
logically as well as somatically. Youth were included with subclinical anxiety and/
or depression, since we were interested in the effect of the disease-specific CBT to 
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prevent clinical anxiety and/or depression, and because randomization of youth with 
clinical anxiety and/or depression to a CAU control group without any mental health 
care is not ethical. Next, approximately three-quarters of the patients had disease in 
remission and the remainder of the patients had mild disease activity. Hence, for pa-
tients with this low disease burden, participation may have been enough to improve 
on their subclinical anxiety and/or depression.
Other explanations for our findings can be provided as well. Thirdly, the disease-
specific CBT that we investigated was originally developed for and has been found 
effective in improving depression. Therefore, the therapy may not have been focused 
enough on anxiety, and the other psychological outcomes such as social functioning, 
coping, and illness perceptions. However, we adapted the PASCET-PI to also target 
anxiety symptoms. In addition, anxiety and depression are highly related, and CBT 
has been found effective for both type of emotional problems, with even higher effect 
sizes for anxiety than for depression [61].
Fourthly, CBT showed to have additional effects, for example on coping [62] and 
illness perceptions [63]. Together, these studies imply that our disease-specific CBT 
could have been able to improve anxiety, coping, and illness perceptions. However, 
this CBT protocol may have had insufficient focus on these outcomes.
Strengths and limitations
Several strengths and limitations have been described in the Discussion sections of 
the previous chapters. Therefore, below the most important will be mentioned.
For our cohort, that provided cross-sectional baseline data, strengths were that the 
sample was mixed, since we included patients from 6 hospitals (academic and non-
academic) and from mixed regions in the Netherlands (large cities vs. smaller cities) 
and that we systematically and consecutively screened all available patients, using 
validated and age-attuned questionnaires and a psychiatric interview.
These strengths also apply to the RCT. Furthermore, and specifically for the RCT, we 
had very low attrition during the follow-up assessments and we had a thorough check 
of treatment integrity (i.e. whether the treatment was provided as intended). The 
treatment integrity results were positive, indicating that the therapy was delivered as 
intended. Almost 90% of the patients in the CBT groups received all 10 sessions and 
in all provided sessions at least 75% of the topics was discussed. Another important 
strength of our RCT was that we aimed at improving both anxiety and depressive 
symptoms, since these are highly comorbid [56]. Finally, we used standard medical 
care as comparison condition, as this, in general, resembles the care-as-usual for 
these patients best. In addition, other comparison conditions (e.g. attention placebo, 
waitlist-control) were not feasible, because a long follow-up was needed to be able to 
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examine flares during follow-up, which is an important medical outcome in youth 
with IBD.
future research
Our results and that of earlier studies have implications for future research into psy-
chological problems and psychological treatment in youth with IBD.
future research – psychological problems in IBD
Most importantly, we do not exactly know yet how psychological problems and IBD 
are related. Although there is evidence that there is a bidirectional relationship [16], 
it is still unclear to what extent, what this means for the medical and psychological 
treatment, and when psychological interventions should be provided. Therefore, 
anxiety and depression should be assessed regularly and repeatedly and thus more 
frequently than in most studies (that have several months between different assess-
ments). Since IBD has a fluctuating course, it is possible that anxiety and depression 
fluctuate as well in these patients. Reed-Knight et al. [64] demonstrated that emotional 
and behavioral problems were relatively stable in newly as well as in previously diag-
nosed youth, with 6 months between the two assessments. However, no other studies 
have been conducted in youth with IBD to examine the course of anxiety and depres-
sion. Yet is unknown how anxiety and depression can fluctuate per week or month. 
With more regular assessments we can learn more about how clinical disease activity 
impacts anxiety and/or depression, and vice versa, especially in youth with IBD. Some 
studies on the bidirectionality of the relationship between clinical disease activity and 
anxiety/depression have been conducted in adults [e.g. 16], but no such study has been 
conducted in IBD youth. Most studies in youth with IBD had a cross-sectional design, 
but future studies should be longitudinal, so more information comes available about 
causality and the course of psychopathology and IBD fluctuations.
Furthermore, to be able to assess of anxiety and depression regularly, as part of 
standard care, short screening questionnaires for these problems should be validated 
in youth with IBD. Currently, studies often use the CDI for assessing depression symp-
toms and the SCARED for assessing anxiety symptoms. Although these instruments 
are well validated and often used in research into anxiety and depression, they are 
lengthy (e.g. 20+ items), which limits their potential as screening instrument during 
a regular medical visit or to be administered, for example, every week. In adults, Ber-
nstein et al. [65] compared several screening instruments for anxiety and depression. 
They included the Patient Health Questionnaire (PHQ-9; depression, 9 items), and the 
thereof derived PHQ-2 (depression, 2 items), Hospital Anxiety and Depression (HADS; 
anxiety, 7 items; depression, 7 items), Kessler Distress Scale (Kessler-6; depression, 
5 items of 6 items in total), Patient-Reported Outcomes Measurement Information 
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System Emotional Distress Depression Short-Form 8a (PROMIS Depression; 8 items), 
Patient-Reported Outcomes Measurement Information System Anxiety Disorder 
Short-Form 8a (PROMIS Anxiety; 8 items), Generalized Anxiety Disorder 7-item Scale 
(GAD-7; anxiety, 7 items), and Overall Anxiety and Severity Impairment Scale (OASIS; 
anxiety, 5 items). All performed adequately as screening tool for anxiety and depres-
sion (compared to a semi-structured psychiatric interview), although the depression 
instruments performed better than the anxiety instruments. Such studies should be 
conducted in youth with IBD as well. However, for youth, less short screening instru-
ments are available than for adults, so new instruments may be needed, since anxiety 
and depression may present differently in youth than in adults [66, 67]. Another possi-
bility to regularly assess anxiety and depression is Ecological Momentary Assessment 
(EMA) or Experience Sampling Method (ESM). These methods often use a smartphone 
application to collect data using short screenings instruments or individual questions, 
several times a day or week. EMA/ESM has been successfully used in chronic pain 
research [68] and in adolescents, to study for example emotional states [69] or coping 
and mood [70].
Next, our results stress the importance of other psychological factors in youth with 
IBD as well. HRQOL has been studied extensively and these patients often have a 
lower HRQOL than healthy youth [34]. We found that illness perceptions are associ-
ated with HRQOL [46]. This may imply that changing negative illness perceptions 
improves HRQOL. It seems important to consider illness perceptions in youth with 
IBD, especially in psychological interventions for these patients. In adults, some stud-
ies have been performed stressing the importance of illness perceptions in the care 
for patients with IBD [e.g. 37, 44]. However, in youth with IBD, studies are scarce. We 
do not know yet what specific illness perceptions youth with IBD have, how these 
can impact outcomes such as HRQOL, and how these should be part of psychologi-
cal interventions. Future research, therefore, should provide more insight in illness 
perceptions in youth with IBD. In our study, we used the Brief Illness Perceptions 
Questionnaire (BIPQ), but the full IPQ provides more detailed information about 
several types of illness perceptions.
Other psychological factors may also be important. Sleep problems are often pres-
ent in youth with IBD, although we only examined these in the RCT and not in our 
baseline cohort. Sleep problems can influence clinical disease activity, but also anxiety 
and depression [71, 72]. Therefore, when considering anxiety and depression in youth 
with IBD, attention has to be given to sleep problems as well. Future studies can 
shed light on how sleep problems are related to anxiety and depression, and whether 
treating sleep problems can influence the disease course or the presence of anxiety 
and depression. Similarly, parental factors can influence anxiety and depression, es-
pecially parental anxiety and depression or stress [45, 73]. Hence, it seems important 
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to also be aware of parental mental health, when assessing and treating anxiety and/
or depression in youth IBD.
Finally, anxiety and depression should also be assessed as outcome parameters in 
drug trials, in addition to quality of life. On one hand because anxiety and depression 
can influence the disease course [74]. On the other hand, it has been shown that anxi-
ety and/or depression can lower treatment adherence in adolescents with IBD [75], 
which can impact the outcomes of trials testing the effectiveness of IBD medication. 
Moreover, corticosteroids can impact anxiety and depression and depression can be 
a side effect of biologicals [11], so trials that investigate the effect of corticosteroids 
or biologicals may be stronger if they also take into account anxiety and depression.
future research – for disease specific cBt for youth with IBD
With respect to psychological treatment for youth with IBD, future research should 
provide information on several topics. Since anxiety and depression are the most 
important psychological problems in these patients, CBT has been investigated 
the most. However, it is not clear yet which patients should be provided with CBT. 
CBT seems beneficial for treating severe depressive symptoms and HRQOL, but was 
equally effective as SNDT [54]. Furthermore, Levy et al. [55] showed that 3-session CBT 
improved HRQOL, but not anxiety and depression. Our own results indicate that CBT 
has no additional effect to standard medical care in improving anxiety, depression, 
and HRQOL. Studies differed in the patients they included (patients with subclini-
cal anxiety and/or depressive symptoms, patients with severe depression, all youth 
with IBD). Selecting patients based on the presence of anxiety and/or depression or 
low HRQOL seems important. Patients with severe clinical anxiety or depression will 
benefit from psychological treatment, such as CBT. However, within patients with 
subclinical anxiety and/or depression, there may be a subgroup of patients that can 
benefit from psychological treatment as well. For example, those with active disease 
or those with negative illness perceptions. Future studies may include both patients 
with both severe clinical as well as subclinical anxiety and/or depression. As smaller 
effects can be expected for subclinical symptoms, sample sizes should be sufficiently 
large to be able to detect these effect as well.
Furthermore, future studies should focus on which type or format of CBT is most ap-
propriate for treating anxiety and depression, and for improving HRQOL. For example, 
CBT in a group format has been shown to have positive effects on parent-reported 
anxiety and depression in children with a chronic illness [76] or on coping and HRQOL 
in a small pilot trial of adolescents with IBD [77]. In addition, more evidence is needed 
on with how much flexibility CBT can provided. In the studies of Szigethy et al. [51, 
53] and in our own RCT [57, 58], a part of the sessions was delivered via the telephone. 
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More research is needed to examine, for example, whether all sessions can be deliv-
ered via the telephone or online using the computer or a smartphone.
Next, to investigate the bidirectional relationship between clinical disease activity 
and anxiety/depression during treatment, future studies should include assessments 
between sessions. In that way, studies are able to examine the effects of changes in 
anxiety and/or depression on changes in clinical disease activity and vice versa. This 
type of design also provides the opportunity to investigate other moderators of the 
treatment effects (e.g. changes in illness perceptions).
clinical implications and recommendations
•	 Systematic	 and	 repeated	 screening	 for	 anxiety	 and	 depression	 during	 medical	
visits in youth with IBD is important, preferably every three months, but at least 
yearly.
•	 For	 the	 screening	 of	 anxiety	 and	 depression	 (in	 youth	with	 IBD),	 cross-cultural	
instruments, covering a broad age-range and with appropriate cutoffs should be 
used, to reduce the current heterogeneity between studies.
•	 Patients	with	subclinical	levels	of	anxiety	and/or	depression	should	be	monitored	
for their mental health by their treating professionals (either by their physician or 
by an affiliated psychologist of the gastroenterology department). This monitoring 
may be sufficient to prevent the development of an anxiety or depressive disorder. 
If not, they should receive a short preventive psychological treatment.
•	 Patients	with	clinical	anxiety	and/or	depression	should	receive	psychological	treat-
ment, either by a medical psychologist with knowledge of IBD or by referral to a 
child and adolescent psychiatrist.
•	 If	 patients	 experience	 severe	 or	 clinical	 anxiety	 and/or	 depression	 they	 should	
receive psychological treatment. In case of a clinical relapse of IBD, timing of 
treatment should be tailored to the patient’s wishes and possibilities. Preferably, 
the treatment is provided by a medical psychologist with knowledge of IBD.
•	 Professionals	working	with	youth	with	IBD	should	be	aware	of	not	only	anxiety	
and/or depression, but also of possible negative illness perceptions.
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editorial: Anxiety And Depression In Inflammatory Bowel Disease
A. Mikocka-Walus, S.R. Knowles
Alimentary Pharmacology and Therapeutics; 2018, 48(6):686-687. doi:10.1111/apt.14912.
Anxiety and depression are common comorbidities in patients with inflammatory 
bowel disease (IBD), with 19% of patients reporting symptoms of anxiety and 21% of 
depression, as compared to 9% and 13%, respectively, in healthy controls [1]. Anxiety 
and depression have been associated with clinical recurrence in adults with IBD [2]. 
Bidirectionality of IBD and mood disorders has also been proposed in adults, with 
IBD activity at baseline associated with an almost six-fold increase in future risk for 
anxiety, and anxiety at baseline (in quiescent IBD) linked to future flares, steroid pre-
scriptions and escalation of therapy [3]. Approximately 25% of IBD cases are diagnosed 
in paediatric populations [4], with 19% of incident cases occurring in the first decade 
of life [5], and poorer outcomes in those with early onset IBD [6]. While paediatric 
IBD is now becoming fairly common, much less systematic knowledge is available on 
anxiety and depression in children with IBD than in adults. The excellent systematic 
review with meta-analysis by Stapersma et al. is therefore timely [7].
Analysing 28 studies (n = 8107) published between 1994-2017, they7 showed the pooled 
prevalence of anxiety symptoms to be 16.4% (95% CI: 6.8%-27.3%), of anxiety disorders to 
be 4.2% (95%CI: 3.6%-4.8%), of depressive symptoms to be 15.0% (95% CI: 6.4%-24.8%), and of 
depressive disorders to be 3.4% (95% CI: 0%-9.3%). Except for anxiety disorders, significant 
heterogeneity was noted among the studies, and there were fewer studies reporting disor-
ders as opposed to symptoms, which is consistent with previous systematic reviews [1, 8].
Reporting anxiety/depression symptoms and disorders separately is a strength of 
the present review. The differences between the two are frequently ignored both in 
practice and in academic papers. Symptoms are derived from screening measures such 
as the Child Depression Inventory, while disorders are typically established during a 
psychological or psychiatric interview, which is more costly and time-consuming, and 
thus less often used in research. Symptoms are common but, as shown [7], are not 
disorders in most cases. This is a reassuring finding for clinicians. Nevertheless, the 
symptoms of anxiety and depression are a sign that there is a need for psychological 
support and, if this can be provided, there is a good chance they will not escalate to a 
diagnosable psychological disorder.
As the rates of anxiety and depression are lower in children than in adults [1, 7, 8], 
pediatric IBD clinics may be ideally situated to provide biopsychosocial integrated care 
which could offer support not only for IBD symptoms and non-intestinal inflammatory 
issues but also, holistically, for overall wellbeing. Studies on psychological therapy, 
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while limited in number, show higher efficacy in children with IBD than adults [9], 
further supporting early psychological interventions in IBD. While the impact of anxi-
ety/depression on dis- ease course in pediatric IBD was outside the scope of the recent 
review [7], it sends an important message to clinicians and policymakers working in 
IBD: it is time to go beyond treating the bowel in our approaches to IBD care.
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We thank Mikocka-Walus & Knowles [1] for their editorial about our systematic re-
view and meta-analysis on anxiety and depression in children and adolescents with 
inflammatory bowel disease (IBD) [2]. Indeed, anxiety and depression are common 
in IBD, and the bidirectional relationship between anxiety/depression and intestinal 
inflammation can be explained in terms of the “brain-gut-axis” [3, 4]. In adult (and less 
so in pediatric) IBD, the association between anxiety/depression and clinical recur-
rence of IBD has been confirmed [5, 6]. In almost 25% of the patients, IBD presents in 
childhood or adolescence with a disease course often more severe compared to adults 
[7, 8]. In addition, adolescence is a challenging life phase with many biological and 
psychosocial changes. IBD disrupts normal psychosocial development, and increases 
the vulnerability to developing anxiety/depression. Furthermore, it is known that 
anxiety/depression in adolescence is associated with anxiety/depression in adulthood 
[9, 10], affecting quality of life, work participation and socioeconomic status [11] with 
subsequently high societal costs [12].
There are several ways to integrate psychosocial support in the care for (pediatric) 
IBD patients. First, for early detection, patients should be regularly screened for anxi-
ety/depressive symptoms. In our Dutch cohort we systematically screened 374 IBD 
patients, aged 10-25 years, and found that 47% suffered from symptoms of anxiety and/
or depression, with the highest prevalence of anxiety [13], and females and patients 
with active disease having the highest risk. Ideally, mental health screening is done 
routinely in the outpatient clinic using a short and easy-to-use screening tool. Second, 
we fully agree with Mikocka-Walus and Knowles that in case of elevated symptoms, a 
psychiatric interview should check if symptoms are mild/subclinical or severe as in a 
clinical disorder. It is important to make this difference in order to determine the best 
treatment strategy. Third, mental health specialists should be part of the multidisci-
plinary IBD team for young IBD patients, to evaluate the outcome of screening and 
provide psychosocial care if necessary.
In pediatric IBD, Szigethy et al. found promising results of two psychological thera-
pies in obtaining remission of clinical depression (cognitive behavioral therapy [CBT]: 
67.8%, and supportive non-directive therapy: 63.2%) [14]. However, in our recently 
published multicenter trial we did not find an additional effect of CBT over care-as-
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usual in improving subclinical anxiety and depressive symptoms in 10-25-year-old IBD 
patients directly post treatment [15], as patients in both groups improved. Whether 
psychosocial interventions also have an effect on inflammatory disease course remains 
questionable. In conclusion, future studies investigating anxiety and depression in 
paediatric IBD should use validated instruments cross-culturally, and, importantly, 
with similar cutoffs. For patients with subclinical anxiety/depression, screening and 
monitoring may be sufficient to prevent their development into disorders, but this 
group could also benefit from e-health (internet-CBT) interventions. Patients with 
clinical anxiety/depression should be referred for CBT. Future research will unravel 
the “dose” and modality of CBT that should be provided to patients with (sub)clinical 
anxiety/depression and the long-term effects of CBT on the course of disease.
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ABStrAct
Background Anxiety and depressive symptoms are prevalent in patients with inflam-
matory bowel disease (IBD) and may negatively influence disease course. Alternatively, 
disease activity could be affected positively by treatment of psychological symptoms. 
We investigated the effect of cognitive behavioral therapy (CBT) on clinical disease 
course in 10-25-year-old IBD patients experiencing subclinical anxiety and/or depres-
sion.
methods In this multicenter parallel group randomized controlled trial, IBD patients 
were randomized to disease-specific CBT in addition to standard medical care (CBT + 
care-as-usual [CAU]) or CAU only. The primary outcome was time to first relapse in the 
first 12 months. Secondary outcomes were clinical disease activity, fecal calprotectin 
and C-reactive protein (CRP). Survival analyses and linear mixed models were per-
formed to compare groups.
results Seventy patients were randomized (CBT+CAU=37, CAU=33), with a mean age 
of 18.3 years (±50% < 18 y) (31.4% male, 51.4% Crohn’s disease, 93% in remission). 
Time to first relapse did not differ between patients in the CBT+CAU vs CAU group 
(n=65, p=0.915). Furthermore, clinical disease activity, fecal calprotectin and CRP did 
not significantly change over time between/within both groups. Exploratory analyses 
in 10-18-year-old patients showed a 9% increase/month of fecal calprotectin as well 
as a 7% increase/month of serum CRP in the CAU group, which was not seen in the 
CAU+CBT group.
conclusions CBT did not influence time to relapse in young IBD patients with 
subclinical anxiety and/or depression. However, exploratory analyses may suggest a 
beneficial effect of CBT on inflammatory markers in children.
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IntroDuctIon
Inflammatory bowel disease (IBD; Crohn’s disease [CD] and ulcerative colitis [UC]) is a 
chronic inflammatory disorder of the intestine, and is often accompanied by embar-
rassing, invalidating and unpredictable intestinal and systemic symptoms [1]. 
Having IBD in adolescence impacts the lives of young IBD patients and is a threat to 
a healthy psychosocial development. Patients may suffer from an altered self-image 
[2], the unpredictability of the disease, social isolation[3], family and school dysfunc-
tion, and school problems [4, 5]. Consequently, having IBD challenges a smooth transi-
tion to adulthood [6]. Studies show that adolescent and adult IBD patients are at risk 
for anxiety and depression [7, 8] Recent meta-analyses in children and adults have 
shown pooled prevalence rates ranging from 16.4-35.1% for anxiety symptoms, and 
15.0-21.6% for depressive symptoms [9, 10].
The bidirectional relationship between IBD and psychological problems can be ex-
plained in terms of the ‘brain-gut’-axis [11], meaning that the presence of anxiety and/
or depressive symptoms or disorders can increase intestinal inflammation and may 
contribute to disease relapse, and conversely, intestinal inflammation can negatively 
influence mood [11, 12]. Several cross-sectional studies support this hypothesis by 
showing an association between clinical disease activity and symptoms of anxiety 
[9, 12-14] or depression [9, 12, 13]. In addition, this association has also been studied 
longitudinally. In a recent systematic review 5 out of 11 studies reported an associa-
tion between depressive symptoms and worsening of disease course [15]. Similarly, for 
anxiety symptoms some studies did report this association [12, 16], while others did 
not [17, 18]. Besides the influence of anxiety and/or depressive symptoms on disease 
activity and disease course, IBD patients with psychological symptoms are at risk for 
school or work absenteeism [19, 20], lower therapy adherence [8], higher health care 
utilization [8, 14], all leading to high societal costs [21]. Therefore, studies on the effect 
of psychological treatment on disease course and these other aspects are warranted. 
At present, cognitive behavioral therapy (CBT) is the most effective evidence based 
psychological treatment for anxiety and depressive symptoms and disorders in pa-
tients of all ages [22, 23] and has been found to be effective in reducing anxiety and 
depressive symptoms in both pediatric [24, 25] and adult [26] IBD patients. 
Studies investigating the effect of CBT on disease activity or disease course in 
patients with both anxiety and/or depressive symptoms or disorders are scarce. A 
randomized trial by Szigethy et al. studied two psychotherapies (CBT and supportive 
nondirective therapy) in adolescents with IBD with both minor and major depression. 
The authors report an improvement in clinical disease activity scores (raw increase 
of ±10 points on both the Pediatric Ulcerative Colitis Activity Index [PUCAI] and the 
Pediatric Crohn’s Disease Activity Index [PCDAI]) in the first 3 months in both groups, 
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favoring CBT [25]. In addition, a pilot study including 9 patients investigated the effect 
of CBT on clinical disease activity (PCDAI, PUCAI) in adolescent IBD patients suffering 
from an anxiety disorder, and showed that clinical disease activity improved from 
mild to inactive in half of the patients after 3 months [24]. 
Therefore, we performed a randomized controlled trial (RCT) in IBD patients aged 
between 10 and 25 with subclinical anxiety and/or depression and evaluated the effect 
of CBT on the course of anxiety, depression, disease course and inflammatory mark-
ers. The current study focused on the effect of 3 months of CBT on disease course in 
the following year. The primary outcome was time to first relapse, secondary outcome 
measures were clinical disease activity, C-Reactive Protein (CRP) and fecal calprotec-
tin. We hypothesized that CBT would promote sustained remission, prolong the time 
until the first relapse and reduce clinical disease activity and inflammatory markers. 
mAterIAlS AnD metHoD
Design
This multicenter parallel group RCT was designed according to the CONSORT guide-
lines for trials of non-pharmacologic treatments [27] and was registered at Clinical-
Trials.gov with study number NCT02265588. Participants were recruited from two 
university and four community hospitals in the South-West of The Netherlands from 
September 2014 until October 2016. Initially, only adolescents aged 10-20 years were 
included in the study, a few months after start of recruitment patients aged 21-25 
years were also recruited. We chose to include adolescent and young adult patients 
because the impacts and challenges of a chronic disease in this unique life phase are 
different compared with what pediatric or adult patients are facing. 
Eligible patients were screened for anxiety and/or depressive symptoms. Patients 
with symptoms of anxiety or depression or both were included, because anxiety and 
depressive symptoms often occur together and can both impact disease activity in IBD 
[16, 28]. Patients with subclinical/elevated symptoms, who did not meet the criteria of 
a psychiatric disorder, were randomized to either a 3-month course of disease-specific 
CBT (CBT+CAU) in addition to care-as-usual or to the control condition, Care as Usual 
(CAU). After randomization, medical and psychological data were collected at base-
line, and at 3, 6, and 12 months. Nine-month medical data was only collected if in 
routine medical care patients had scheduled appointments every 3 month. For more 
information regarding the study design, see van den Brink & Stapersma et al. [29].
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measurements
Demographic characteristics Age and gender were collected at baseline. Socioeco-
nomic status was classified using the occupational level from parents or, if patients 
lived on their own, patients [30]. Ethnicity was derived from the Rotterdam’s Quality 
of Life Interview [31].
clinical characteristics At baseline, disease type, age at diagnosis, disease duration, 
disease phenotype at diagnosis (Paris or Montreal classification) [32], previous and 
current therapy, previous bowel surgery and previous relapses were collected.
Anxiety and depressive symptoms For anxiety the Screen for Child Anxiety Re-
lated Emotional Disorders [33] (SCARED; 10-20 years; cutoff ≥26 for boys and ≥30 for 
girls) and the Hospital Anxiety and Depression Scale – Anxiety Scale [34] (HADS-A; 
21-25 years; cutoff ≥8) were used. For depression the Child Depression Inventory [35] 
(CDI; 10-17 years; cutoff ≥13) and the Beck Depression Inventory – second edition [36] 
(BDI-II; 18-25 years; cutoff ≥14) were used.
clinical disease activity Clinical disease activity was assessed by four validated, 
physician-reported, age appropriate instruments, with higher scores indicating more 
active disease.
In UC patients the Pediatric Ulcerative Colitis Activity Index [37] (PUCAI; 10-20 years; 
score 0-85) and the partial Mayo [38] (pMayo; 21-25 years; score 0-9) were used. In 
CD patients, the Pediatric Crohn’s Disease Activity Index [39] (PCDAI; 10-20 years; 
total score 0-100) and the Crohn’s Disease Activity Index [40] (CDAI; 21-25 years; score 
0-600) were used. 
relapse The presence of a relapse at any time point during follow-up was deter-
mined by the treating physician. For UC, relapse was defined as follows: (a) clinical 
disease activity score above cutoff (PUCAI >34 or an increase of ≥20 points or pMayo 
≥3 [41, 42]) or (b) fecal calprotectin above 250 µg/g [43] or (c) inflammation at endos-
copy and (d) intensification of treatment. For CD, relapse was defined as: (a) clinical 
disease activity score above cutoff (PCDAI >30 or an increase of ≥15 points or CDAI 
score >150 [40, 44]) or (b) fecal calprotectin above 250 µg/g [43] or (c) inflammation at 
endoscopy and (d) intensification of treatment. In addition, perianal disease requiring 
intervention in CD patients was also considered a relapse. If patients experienced a 
relapse at baseline, this relapse was not taken into account and monitoring for relapse 
started after remission was achieved.
Inflammatory markers C-reactive protein (CRP) and fecal calprotectin were ob-
tained during visits to the outpatient clinic as part of routine clinical care.
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recruitment and procedure
Step 1: Screening 
Eligible patients (and parents, for patients age 10-20 years) were informed about the 
study by their treating (pediatric) gastroenterologist. Preferably, patients were recruit-
ed when they were in clinical remission, considering the impact of the intervention. 
The following in- and exclusion criteria were used: (1) a diagnosis of IBD conform 
current diagnostic criteria [45-47] (2) age 10-25 years and (3) informed consent provided 
by patients and (if necessary) parents. Exclusion criteria were: (1) (parental report of) 
intellectual disability, (2) current treatment for mental health problems (pharmaco-
logical and/or psychological), (3) insufficient mastery of the Dutch language, (4) CBT 
in the past year (for at least 8 sessions), (5) a diagnosis of selective mutism, bipolar 
disorder, schizophrenia, autism spectrum disorder, obsessive-compulsive disorder, 
posttraumatic or acute stress-disorder, (6) participation in another interventional study 
and (7) anxiety/depressive disorder. After written informed consent, an email with a 
link to the online questionnaires was sent to the patients (and parents). Anxiety and 
depressive symptoms were assessed using age-appropriate self-report instruments (see 
“measurements”). For more information regarding step 1, see van den Brink et al. [13]. 
Step 2: Inclusion rct
If patients scored above the cutoff of the anxiety and/or depression questionnaire, a 
trained psychologist performed a diagnostic psychiatric interview (Anxiety Disorders 
Interview Schedule - Child and Parent Versions (ADIS-C/P) [48]) by telephone to deter-
mine the severity of the symptoms using age appropriate severity rating scales. The 
Pediatric Anxiety Rating Scale [49] (PARS; 10-20 years; cutoff ≥18) and the Hamilton 
Anxiety rating scale [50, 51] (HAM-A; 21-25 years; cutoff ≥15) were used for anxiety 
symptoms. Depression was rated using the Child Depression Rating Scale Revised 
[52] (CDRS-R; 10-12 years; cutoff ≥40), the Adolescent Depression Rating Scale Revised 
[53] (ADRS-R; 13-20 years; cutoff ≥20) and the Hamilton Depression Rating Scale [54, 
55] (HAM-D; 21-25 years; cutoff ≥17). A psychiatric disorder was defined as meeting 
criteria for an anxiety or depressive disorder on the ADIS-C/P and a score equal to or 
above the clinical cutoff on the rating scale. Patients with subclinical anxiety/depres-
sion (elevated symptoms of anxiety and/or depression not meeting the criteria for a 
psychiatric disorder) were eligible for randomization. Patients with an anxiety/depres-
sive disorder were directly referred for psychological treatment and were excluded 
from the RCT since it would be unethical to randomize patients to the CAU condition.
randomization
Patients with subclinical anxiety and/or depression were randomized to CBT+CAU or 
CAU with a 1:1 ratio. An independent biostatistician provided a computer-generated 
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blocked randomization list with randomly chosen block sizes (with a maximum of 6) 
and stratification by center using the blockrand package in the R software package 
thereby providing numbered envelopes per center. After randomization, treatment in 
the CBT+CAU group started within a maximum of 4 weeks. The physicians assessing the 
disease activity and the psychologist conducting the diagnostic interviews were blinded 
for outcome of randomization. As patients could not be blinded, they were explicitly 
asked not to discuss the outcome of randomization with their treating physician. 
Intervention
The Primary and Secondary Control Enhancement Therapy (PASCET) is a manual-based 
CBT protocol, originally designed to treat depression [56]. In this study the PASCET-
Physical Illness (PASCET-PI) was used, an IBD-specific modification which encompasses 
the illness narrative (i.e. perceptions and experiences of having IBD), disease-specific 
psychoeducation, techniques for coping with pain, social skills training and emphasis 
on IBD-related cognitions and behaviors [57]. The protocol was modified to treat 
anxiety as well, and adjustments were made to make it age appropriate for patients 
aged 21-25 years. Participants received ten weekly sessions in a timespan of twelve 
weeks (6 face-to-face, 4 by telephone), three additional family sessions (for patients 
<18 years and voluntary for patients >18 years living with their parents) and after the 
first 12 weeks three-monthly booster sessions. Patients were considered treatment 
completers if they had followed at least 8 sessions. The therapy was provided by all 
licensed (healthcare/CBT) psychologists, who received onsite training from the devel-
oper (E.M. Szigethy) of the PASCET-PI and executed the therapy in their own hospital 
or center.
CAU consisted of regular medical appointments with the (pediatric) gastroenterolo-
gist every 3 months, involving a 15-30 minute consultation discussing overall wellbe-
ing, disease activity, results of diagnostics tests, medication use, and future diagnostic/
treatment plans, but no psychological intervention.
Sample Size and Power 
In our previously published study protocol, the primary outcome was defined as re-
lapse rate per group in the first year after randomization [29]. As the study continued 
and inclusion appeared challenging, we decided to also include 21-25 year old patients 
and re-estimate the sample size [58]. Adapting the primary outcome to time to first 
relapse reduced the required sample size. 
Literature shows that in general, approximately 40% of IBD patients have at least 
one relapse per year [59, 60]. Based on expert opinion and previous studies [61, 62] a 
30% difference was expected between the 2 groups (survival rate 0.6 CBT; 0.9 CAU). To 
detect a difference of 0.3 in survival rate after 52 weeks of follow up, with a 2-sided 
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significance level of 5% and 80% power, 37 patients were need in each group. With 65 
patients in remission at baseline, the study had a power of 77%. 
Statistical Analysis
Descriptive statistics were computed for demographic and clinical characteristics for 
the entire cohort and each treatment group. T, Chi2/Fisher exact and Mann-Whitney-U 
tests were used, where appropriate, to assess baseline differences between treatment 
groups.
For the primary outcome time to first relapse, survival analyses were performed. 
Kaplan-Meier curves were tested with a two-sided log rank test. For this analysis, 
patients with a relapse at baseline were excluded. For the longitudinally measured 
secondary outcomes clinical disease activity, CRP and calprotectin, differences be-
tween the groups were assessed using linear mixed effects models to account for the 
correlations in the repeated measurements. All 4 clinical disease activity scores were 
converted to a 0-1 score (Supplementary Table 1, step 1). This pooled disease activity 
score enabled us to include all patients in one analysis. As all three secondary out-
comes had a non-normal distribution, transformations were done to assure normality. 
CRP and calprotectin were transformed using the natural logarithm. For pooled clini-
cal disease activity, a two-step logistic transformation was performed (Supplementary 
Table 1, Step 2 and 3). In all three linear mixed models, treatment condition (result 
of randomization), time in months and the interaction between time*treatment were 
added in the specification of the fixed effects. A likelihood ratio test (LRT) was used 
to specify the random effects. With the LRT the model with a random intercept only 
(covariance structure: identity) was compared with the model with both a random in-
tercept and random slope (covariance structure: unstructured). Restricted maximum 
likelihood (REML) was applied as the estimation method. Assumptions of the models 
were checked using residual plots. Considering the previous findings in pediatric 
patients [25], exploratory analyses were performed in patients 10-18 years of age. 
All analyses were performed based on the intention-to-treat (ITT) principle. For pa-
tients with missing and/or incomplete assessments, only available data were used. A 
p-value of <0.05 was considered statistically significant. Data analyses were performed 
using SPSS version 24.0 (IBM SPSS Statistics for Windows, Armonk, NY, USA). 
ethical considerations
This study conformed to the principles of the Declaration of Helsinki and was ap-
proved by the Institutional Review Board of the Erasmus Medical Center and of each 
participating center.
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reSultS
Patient characteristics
A total of 552 patients were eligible to participate, of which 374 patients completed 
the anxiety and depression questionnaires at baseline. Of the 371 patients who com-
pleted both questionnaires, 47.4% experienced elevated symptoms of anxiety and/or 
depression. Of the 134 patients who participated in the diagnostic psychiatric inter-
view, 46 patients (34%) met the criteria for a psychiatric disorder and 88 patients (66%) 
experienced subclinical symptoms of anxiety and/or depression [13]. Of these 88, 70 
patients (80%) gave consent for randomization (CBT+CAU [n=37] CAU [n=33]) (Figure 1).
Of all randomized patients, 68.6% were female, ± 50% was <18 years of age (median 
age [interquartile range] 18.27 [14,5 – 22,37] years. 51.4% had a diagnosis of CD, 80.9% 
had a Western ethnicity and socioeconomic status was respectively low, middle and 
high in 17.1%, 36.8% and 45.6% (data not shown). Patients were included based on 
anxiety symptoms (71.4%), depressive symptoms (4.3%) or both (24.3%). Five patients 
experienced a relapse of IBD at baseline. 
There were no baseline differences between the CBT+CAU versus the CAU group for 
demographic and disease characteristics, except for disease duration (p = 0.03) and 
corticosteroid dependency the past 3 months (p = 0.03) (Table 1). 
Protocol adherence
Thirty-four out of 37 (92%) patients allocated to CBT+CAU completed ≥8 CBT-sessions 
(treatment completers). The other 3 patients followed 5, 3 and 1 sessions respectively. 
The mean number of treatment sessions followed was 9.38. 
During follow-up, 2 patients in the CAU group (at 6 and 9 months) and one patient 
in the CBT+CAU group (at 3 months) developed severe symptoms meeting the criteria 
for a psychiatric disorder (2 patients with anxiety disorders, and 1 with anxiety and 
depressive disorder) and were directly referred for psychiatric/psychological help, 
whereas follow-up data was collected for the ITT analysis. Of these patients, all fol-
low up assessments were completed. Furthermore, on persistent parental request 1 
patient switched from the CAU to the CBT+CAU group after 3 months, follow up data 
was collected, and analyses were performed according to the intention to treat prin-
ciple (CAU group). Three patients missed one or more follow-up assessments (1 CAU 
group, 2 CBT+CAU group): 2 patients missed the 6-month visit and 1 patient missed all 
visits after baseline. Nine-month medical data were collected for 26 patients. 
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Primary outcome: time to first relapse 
During 52 weeks of follow up, 16 patients (43.2%) in the CBT+CAU group and 16 pa-
tients (48.5%) in the CAU group experienced one or more relapse. For the 65 patients 
in remission at baseline, no difference in time-to-relapse between groups was found 
(p 0.915) (Figure 2). 
  
 
 
 
 
  
Assessed for eligibility (n=552) 
Excluded  (n=178) 
   Declined to participate (n=170)
   No screening data (n=8)  
Enrollment 
Excluded (n=304) 
   no symptoms anxiety/depression (n=195)
   Too severe anxiety/depression (n=46) 
   Refused interview (n=42) 
   Declined randomisation (n=18)
Incomplete screening data (n=3)  
Analysed (n=33) 
 Excluded from analysis  (n=0) 
Discontinued intervention, missed one assessment 
& switch to CBT after 3 months (n=1) 
 
Allocated to Care As Usual (n=33) 
Discontinued intervention & missed one or more 
follow-up assessments (n=2) 
Discontinued intervention but provided data of all 
follow-up assessments (n=1) 
Allocated to intervention (n=37) 
 Received allocated intervention (n=37) 
 Did not receive allocated (n=0) 
Analysed (n=37)
 Excluded from analysis (n=0)  
Allocation 
Analysis 
Follow-Up 
Randomised (n=70) 
Screened for anxiety and/or 
depressive symptoms (N=374) 
figure 1 | CONSORT study flow chart
Abbreviations: CBT= cognitive behavioral therapy
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table 1 | Patient characteristics
cBt (n=37)
Median (IQR) or n (%)
cAu (n=33)
Median (IQR) or n (%)
p-value
Gender, Male 10 (27%) 12 (36.4%) 0.40
Age (years) (% <18 years)
Age at diagnosis (years)
Duration of disease (years)
18.5 (16.1-23.0)(48%) 18.0 (13.7-21.8) (51%) 0.37
15.7 (12.8-17.8) 14.9 (11.2-19.6) 0.90
2.6 (1.8-5.3) 1.3 (0.7-3.3) 0.03
Disease Type CD 18 (48.6%) 18 (54.5%) 0.84
UC 14 (37.8%) 12 (36.4%)
IBD-U 5 (13.5%) 3 (9.1%)
Paris 
classification at 
diagnosis*:
CD: location† (N = 36)
L1
L2
L3
+ L4a/L4b
CD: behavior
Nonstricturing, 
nonpenetrating
structuring, 
penetrating or both
perianal disease
UC: extent (N = 34)‡
limited: E1 + E2
extensive: E3 + E4
UC: severity, ever 
severe
0.83
4 (22.2%) 5 (27.8%)
6 (33.3%) 4 (22.2%)
8 (44.4%) 9 (50.0%)
4 (22.2%) 4 (22.2%) 1.00
1.00
18 (100%) 18 (100%)
0 (0%) 2 (11.1%)
4 (22.2%) 4 (22.2%) 1.00
0.07
11 (57.9%) 4 (26.7%)
8 (42.1%) 11 (73.3%)
1 (5.3%) 4 (26.7%) 0.15
Clinical Disease 
activity¥
Remission 29 (78.4%) 26 (78.8%) 0.55
Mild 6 (16.2%) 7 (21.2%)
Moderate 2 (5.4%) 0 (0%)
Severe 0 (0%) 0 (0%)
CRP (mg/L) 2.0 (1.0-5.0) 1 (0.3-4.4) 0.19
Fecal 
calprotectin 
(µg/g)
67.5 (24.8-318.5) 169 (19.5-563.0) 0.73
Current 
medication use
Aminosalicylates 18 (48.6%) 12 (36.4%) 0.30
0.17
0.66
0.83
0.12
1.00
Immunomodulators 17 (45.9%) 16 (48.5%)
Biologicals 8 (21.6%) 12 (36.4%)
Corticosteroids¶ 2 (5.4%) 3 (9.1%)
Enemas§ 4 (10.8%) 0 (0%)
No medication 2 (5.4%) 1 (3%)
Steroid 
dependence past 
3 months
3 (8.1%) 9 (27.3%) 0.03
Baseline relapse 4 (10.0%) 1 (3.0%) 0.36
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table 1 | Patient characteristics (continued)
cBt (n=37)
Median (IQR) or n (%)
cAu (n=33)
Median (IQR) or n (%)
p-value
Relapse 
preceding year
15 (40.5%) 10 (30.3%) 0.39
Bowel resection 
in history
3 (8.1%) 2 (6.1%) 1.00
EIM II 7 (18.9%) 4 (12.1%) 0.44
Hospital type University Hospital 16 (43.2%) 15 (45.5%) 0.85
Anxiety and/
or depressive 
symptoms
Anxiety symptoms 30 (81.1%) 20 (60.6%) 0.08
Depressive symptoms 0 (0.0%) 3 (9.1%)
Both 7 (18.9%) 10 (30.3%)
Abbreviations: IQR= interquartile range, CD= Crohn’s Disease, UC= ulcerative colitis, IBD-U= IBD 
Unclassified, CRP= C-reactive protein; CBT= cognitive behavioral therapy + care-as-usual, CAU= 
care-as-usual.
Notes: *UC includes IBD-U patients †L1: ileocecal, L2: colonic, L3: ileocolonic, L4a: upper gastro-
intestinal tract proximal and L4b distal from Treitz ligament ‡E1: proctitis, E2: left sided colitis 
distal of splenic flexure, E3: extensive colitis distal of hepatic flexure, E4: pancolitis ¥Based on 
clinical disease activity scores (pMayo, PCDAI, PUCAI, CDAI) ¶prednisone (oral and intravenous) 
and budesonide (oral) §aminosalicylate or corticosteroid enemas ||EIM: involving skin (31.5%), 
eyes (1.75%), liver and biliary tracts (10.5%), joints (33.3%) and bones (28.1%).
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figure 2 | Survival curve time to first flare
Abbreviations: CBT= cognitive behavioral therapy + care-as-usual; CAU= care-as-usual
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Secondary outcomes
clinical disease activity
Linear mixed model analysis showed no difference in the course of (pooled) clini-
cal disease activity over time between both groups (interaction time*treatment not 
significant) (Table 2). In addition, no significant changes were found within either 
the CBT+CAU or the CAU group (Table 2). Raw means of the 4 clinical disease activity 
scores over time are displayed in Figure 3. 
Similarly, exploratory analysis in patients <18 years (n=35) showed no significant 
difference between both groups (p = 0.20), or within the CBT+CAU (p = 0.92) or the 
CAU (p = 0.085) group (data not shown). In addition, there was no difference in CD 
versus UC patients (data not shown).
Inflammatory markers: fecal calprotectin and c-reactive protein 
For CRP and fecal calprotectin, no significant differences were found between the 
CAU and CBT+CAU group (interaction term not significant). In addition, no significant 
change was found over time within each group (Table 2, raw means displayed in 
Supplementary Figure 1). 
table 2 | Results Linear mixed models (n=70)
time Interaction time*treatment
β 95% CI p-value β 95% CI p-value
clinical disease activity
Within group CBT -0.006 -0.052 - 0.040 0.80
CAU 0.012 -0.036 - 0.061 0.61
Between groups -0.019 -0.085 - 0.048 0.59
c-reactive protein (mg/dl)
Within group CBT -0.015 -0.050 - 0.020 0.41
CAU 0.021 -0.015 - 0.057 0.24
Between groups -0.036 -0.086 – 0.014 0.158
fecal calprotectin (µg/g)
Within group CBT -0.019 -0.075 - 0.037 0.50
CAU 0.005 -0.052 - 0.063 0.851
Between groups -0.025 -0.11 - 0.056 0.543
Abbreviations: CI= confidence interval, CBT= cognitive behavioral therapy+ care-as-usual, CAU= 
care-as-usual; β= Beta-coefficient
Note: ”Within group” displays whether there is a significant (p-value <0.05) change over time 
within either the CBT or the CAU group. “Between group” reflects whether the course over time 
is significantly different between the CAU and CBT group (p-value interaction time*treatment < 
0.05)
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Exploratory analysis in 10-18-year-old patients (n=35) showed that for calprotectin, 
the interaction between time*treatment was significant (Beta-coefficient (β) -0.11, 95% 
CI [-0.195 - -0.031], p = 0.008). A statistically significant increase was seen in the CAU 
group over time (β 0.085, 95% CI [0.028-0.143], p = 0.004), whereas no change was found 
in the CBT+CAU group (β -0.028, 95% CI [-0.087 - 0.031], p = 0.35). Reverse transforma-
tion to the original scale revealed a 9% increase per month in the CAU group (data 
not shown). For CRP, no change was observed within the CBT+CAU group over time 
(β -0.012, 95% CI [-0.070 – 0.046], p = 0.68), whereas a significant increase in the CAU 
group was observed (β 0.069, 95% CI [0.011 – 0.13], p = 0.022). Reverse transformation 
to the original scale revealed a 7% increase per month in the CAU group. The interac-
tion between time*treatment approached significance (β -0.081, 95% CI [-0.164 – 0.001], 
p = 0.054) (data not shown). For both CRP and calprotectin, there was no difference 
between CD and UC patients (data not shown).
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figure 3 | Raw means of clinical disease activity scores over time
Abbreviations: PUCAI= Pediatric Ulcerative Colitis Activity Index; pMayo= partial Mayo; PCDAI= 
Pediatric Crohn’s Disease Activity Index; CDAI= Crohn’s Disease Activity Index; CBT= cognitive 
behavioral therapy; CAU= care-as-usual
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DIScuSSIon
This study was the first to investigate the effect of CBT versus CAU only on subsequent 
disease course in young IBD patients with subclinical anxiety and/or depression. We 
showed that time to first relapse in the first year after randomization did not signifi-
cantly differ between patients in the CBT+CAU versus the CAU group. Furthermore, 
(pooled) clinical disease activity, CRP and fecal calprotectin also did not significantly 
change over time between the CBT+CAU and the CAU group, or within both groups. 
Exploratory analyses in 10-18-year-old patients suggested a significantly different 
course of fecal calprotectin between groups, with an increase in the CAU group. In 
addition, the difference in the course of CRP between the CAU and CBT+CAU group ap-
proached significance, with an increase in the CAU group. These results could suggest 
a possible positive effect of CBT on fecal calprotectin and CRP levels in 10-18-year old 
patients, with perhaps a positive influence on intestinal inflammation in the longer 
term. However, this should be replicated in larger patient cohorts.
Within the ‘brain-gut-axis’ it is hypothesized that a decrease in anxiety/depressive 
symptoms is accompanied by a decrease in (intestinal) inflammation and vice versa 
and that it may promote sustained remission. In the current trial both groups equally 
improved in anxiety/depressive symptoms and HRQOL after 3 [63] and 6-12 months 
(Stapersma et al. in revision). Therefore, it is not surprising that we did not find a dif-
ference in clinical outcomes. As an improvement in anxiety and depressive symptoms 
within the CBT+CAU and CAU group over time was observed [63], improvement in 
clinical outcomes within both groups could have been expected. Low baseline clinical 
disease activity and low baseline inflammatory activity could also explain why we did 
not find an improvement in clinical disease activity scores, CRP or calprotectin in the 
whole sample. 
Several studies reported on the effect of CBT on clinical disease course, specifically 
relapse rate, clinical disease activity and CRP. Time-to-relapse has not been studied 
before. Three studies included adolescent [24, 25, 64], and three included adult [65-68] 
IBD patients. Only 2 pediatric studies selected patients based on anxiety [24] or depres-
sion [25]. In all these studies, mostly patients in clinical remission or with mildly 
active disease were included. At first, Levy et al. tested the effectiveness of a brief 
(3 session) CBT (versus education support condition) in 185 adolescent IBD patients 
unselected for anxiety and depression and mainly in disease remission (63%). In line 
with our results, they reported no difference in relapse rate between the 2 conditions. 
An exploratory analysis in patients who experienced ≥2 or more flares in the year 
prior to the study, showed a decrease in relapse rate following CBT (CBT 16.7%, CAU 
52.9% p = 0.04) [64]. However, this sub-analysis was limited by the liberal definition 
of relapse, without considering objective items such as treatment intensification. 
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Second, Szigethy et al. studied the effect of two psychotherapies (CBT versus support-
ive nondirective therapy) in 217 adolescents with IBD and minor/major depression. 
Although it is not reported in the article, looking at the mean PCDAI and PUCAI 
scores, it can be assumed that most patients were in remission or had mildly active 
disease. An improvement in depressive symptoms, HRQOL and pooled clinical disease 
activity after 3 months was found in both groups. However, it should be noted that 
this improvement corresponded with a rather small, not clinically relevant, decrease 
in raw disease activity scores of ±10 points on the PCDAI /PUCAI that was reported to 
be larger in the CBT group [25]. A third study of interest was performed by Mikocka-
Walus et al.: it investigated whether adding 10 sessions (face-2-face or online) CBT to 
standard medical care influenced clinical disease activity in 176 unselected adult IBD 
patients. Approximately 75% of patients had quiescent disease at baseline. No differ-
ence in remission rates after 12 months (73.2% CBT vs 71.7% CAU) or in clinical disease 
activity scores or CRP levels after 12 and 24 months were reported [66, 67]. 
In conclusion, studies reporting on the effect of CBT or other psychotherapies on 
disease course in IBD patients with (sub)clinical anxiety and/or depression are scarce.
[69] Only 1 trial in pediatric IBD patients in remission or with mildly active disease 
reported a small improvement in clinical disease activity after CBT (and supportive 
non directive therapy) [25]. As far as we know, no studies are available investigating 
the effect of psychotherapy on disease course in IBD patients with at least moderately 
active disease and suffering from (sub)clinical anxiety/depression .
Our finding that CBT did not influence time to relapse, relapse rates or clinical 
disease activity is in accordance with the 2 previous studies in patients unselected for 
anxiety/depression [64, 66]. In contrast, Szigethy et al. did find a small improvement 
in disease activity over time in both psychotherapy groups, favoring CBT [25]. In addi-
tion, due to the short follow up, it is unclear how this improvement would evolve in 
the longer term. It should be noted Szigethy et al. is the only RCT to date performed 
in patients selected for emotional symptoms (minor/major depression).
It is possible that CBT is more effective in improving disease course (reducing in-
flammation) in patients with more severe anxiety/depression, as more improvement 
in psychological symptoms can be gained. This could be supported by Szigethy et al. 
who also included patients with major depression (±60%). In studies that did not select 
patients on anxiety/depression [64, 66, 67], no improvement in clinical disease activity 
was found and only one study [68] found a decrease in anxiety/depressive symptoms. 
Considering we did not find an effect of CBT on clinical disease course, it is pos-
sible that CBT has an effect on other measures of disease course, such as disability, 
healthcare use (e.g. visits to the Emergency Room) and school absenteeism. This is 
supported by a study by Keerthy et al., reporting a significant reduction in IBD-related 
healthcare use following CBT [70]. We attempted to analyze school absenteeism in 
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our sample, but could only collect data from patients 10-18 years because in The 
Netherlands only elementary and high schools register (reasons for) absenteeism. For 
18 out of 35 children data was available (CBT: n=6, CAU: n=12), unfortunately, due to 
high heterogeneity of the registration methods used and missing data, analysis was 
not possible.
It is not likely that baseline differences influenced our results. First, the longer 
disease duration in the CBT+CAU group could be accompanied by better coping strate-
gies, providing an advantage in learning certain CBT-specific skills. As the improve-
ment of psychological symptoms was similar in both groups [63] (Stapersma et al., 
in revision) and disease course did not change over time, any influence of disease 
duration is unlikely. Second, baseline corticosteroid dependency in the past three 
months was higher in the CAU than in the CBT+CAU group (27.3% vs. 8.1%). This could 
indicate higher disease activity in the CAU group. However, considering there were 
no differences in other markers of disease activity (baseline clinical disease activity 
scores, relapse rates, CRP, fecal calprotectin and current steroid use) between both 
groups (see Table 1), it is plausible that this baseline difference was attributable to a 
type-I-error. 
Strengths and limitations 
Major strengths of this study are its multicenter RCT-design and the unique study 
population: pediatric and young adult IBD patients from regional as well as tertiary 
medical centers, which increases generalizability. In addition, and contrary to other 
studies [24, 25], we included patients based on subclinical anxiety and/or depression 
as these symptoms often occur together. Moreover, because CBT has previously been 
found to have a significant effect over and above placebo in previous studies [71], 
CAU was chosen as a control condition because it resembles current clinical care best. 
These 2 aspects combined provided us with the opportunity to determine whether 
CBT prevents the development of subclinical into clinical disorders. Additionally, 
we included all IBD-types, and pooling of clinical disease activity scores enabled us 
to study disease activity for all patients simultaneously. To investigate the course of 
disease, we followed patients for 1 year after randomization, which is longer than 
in previous studies [25, 65, 68]. Furthermore, the use of an IBD-specific CBT protocol 
and the low attrition, especially when compared to other studies [25, 64, 66, 67], 
strengthen our study. Lastly, we were the first to incorporate fecal calprotectin levels 
and assess the effect of CBT on CRP levels in children.
Inevitably, our trial has some limitations. First of all, the study was relatively under-
powered, as not all eligible patients were willing to participate in our trial with a time-
consuming psychological intervention. This is a well-known problem in RCTs with a 
psychological intervention [25, 66]. Another limitation is the relatively unequal result 
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of randomization (37 vs 33), most likely due to randomization with random block sizes. 
Furthermore, the large number of patients with a Western ethnicity (80.9%), reduce 
the generalizability of our findings. Additionally, considering the majority of included 
patients were in clinical remission at baseline, we could not investigate whether the 
effect of CBT on disease activity would be greater in a population with active disease. 
Moreover, it would have been interesting to have included factors such as treatment 
adherence or IBS symptoms because they can both impact disease outcomes but are 
also affected by psychological symptoms. As previously mentioned, the effectiveness 
of CBT on psychological outcomes is published in separate publications [63] (Sta-
persma et al., in revision). It is known that parental behavior and psychopathology are 
important determinants for children’s behavior. Therefore, a questionnaire measur-
ing parental anxiety and depression was incorporated in the study design, which will 
be part of future analyses. Lastly, impact of disease was evaluated using the disease 
specific health related quality of life questionnaires, questionnaires that partly assess 
impact of disease. Unfortunately, validated patient reported outcomes of for example 
disease burden (symptom burden or disability) are not available for pediatric IBD. If 
available, they would have provided additional insight regarding experienced disease 
burden. Similarly, we did not include a validated measure of fatigue in our design, 
although this is a common invalidating complaint in IBD patients, possibly responsive 
to psychological interventions.
Directions for future research
The variation in study design, and mixed results from the available studies investigat-
ing the effect of CBT on disease course, force us to be careful drawing conclusions. 
Large, sufficiently powered studies, that factor in high attrition rates in sample size 
calculation, are necessary. In addition, several subgroups of patients (e.g. severe 
anxiety/depression, patients with at least moderately active IBD) need to be studied 
to determine whether there are certain patient groups in which CBT does influence 
disease course. Furthermore, other formats of psychotherapeutic interventions ánd 
other treatment modalities (e.g. group or e-therapy) with varying intensity should also 
be investigated in patients with (sub) clinical anxiety/depression, as most studies have 
been performed in patients unselected for psychological problems. 
conclusions
In conclusion, CBT added to CAU does not influence subsequent clinical disease course 
in young IBD patients with subclinical anxiety and/or depression. However, the find-
ings suggest that CBT may have a positive effect on inflammatory markers in pediatric 
patients. 
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Supplementary table 1 | Stepwise transformation clinical disease activity scores
Step 1: S’
S’: transformation to a [0,1] scale by dividing each individual score by the maximum score for that 
instrument (PCDAI 100, CDAI 600, PUCAI 85, pMayo 9).
Step 2: S’’
S” = [S’ * (n-1) + 0.5]/n
(n=number of patients included in RCT: 70)
Step 3: S’’’
S’’’ = Ln (S’’/1-S’’)
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In this thesis several studies are described, investigating anxiety and depression in 
youth with inflammatory bowel disease (IBD), including outcomes of a randomized 
controlled trial (RCT) testing the effectiveness of a disease-specific cognitive behav-
ioral therapy (CBT) for these patients.
In chapter 1, the general introduction describes the background of the present 
studies. IBD has two main types; Crohn’s disease (CD) and ulcerative colitis (UC). Ap-
proximately 25% of all patients receives the diagnosis of IBD before they are 18 years 
of age, and for patients up to 25 years of age this is +/- 35%. The last decade more 
attention has been given to the psychological aspects of IBD. Youth with IBD have a 
lower health-related quality of life (HRQOL) than healthy peers, but the most studied 
psychological problems are anxiety and depression. In general, youth with IBD have 
a high risk for anxiety and/or depression. The association between inflammation and 
anxiety/depression may be explained by the brain-gut axis. Inflammation can affect 
the brain and induce anxiety and/or depression. On the other hand, increased anxiety 
and/or depression can increase inflammation. In this way a vicious circle arises in 
which inflammation and anxiety/depression negatively influence each other, to an 
increasing extent. Psychological problems such as anxiety and/or depression can have 
serious consequences. They can influence the disease course, can lower medication 
adherence, and can negatively impact HRQOL. The brain-gut axis implies that treating 
anxiety and/or depression may also improve the disease course. There is evidence 
that a disease-specific CBT can improve depressive symptoms, HRQOL, and school 
attendance. However, earlier studies focused on either anxiety or depression, or did 
not select youth on the presence of any psychological problems. Therefore, this study 
was designed to investigate anxiety and depression in youth with IBD, and to test 
the effectiveness of a disease-specific CBT on both subclinical anxiety and depressive 
symptoms, HRQOL and other psychological outcomes (social functioning, coping, ill-
ness perceptions, and sleep problems).
In chapter 2, the results are described of a systematic review and meta-analysis 
into the prevalence rates of anxiety and depression in pediatric IBD. Previous studies 
showed varying prevalence rates from 0% - 50%; most studies found relatively high 
prevalence rates. For our review, we identified 28 studies (N = 8107, mean age: 14.3 
years). Pooled prevalence estimates were 16.4% (95% confidence interval [CI] 6.8%-
27.3%) for anxiety symptoms and 4.2% (95% CI 3.6%-4.8%) for anxiety disorders. Pooled 
prevalence estimates were 15.0% (95% CI 6.4%-24.8%) for depressive symptoms and 
3.4% (95% CI 0%-9.3%) for depressive disorders. Meta-regression showed no influence 
of disease type or gender on all prevalence rates, but studies with a higher percentage 
of active disease showed a higher rate of depressive symptoms. Our results should be 
interpreted with caution, due to varying instruments/cutoffs to assess symptoms, and 
because only a few studies investigated disorders. We recommend to use the same 
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instruments, cross-culturally, to gain a better insight into the prevalence rates for 
anxiety and depression in pediatric IBD, and into the underlying mechanisms.
chapter 3 describes the study protocol of a RCT to test the effectiveness of a disease-
specific CBT for youth with IBD and subclinical anxiety and/or depression. Youth with 
IBD were screened for symptoms of anxiety and depression (baseline cohort, N = 374, 
10-25 years). Those with elevated scores received a psychiatric interview. Patients with 
subclinical (and not clinical) anxiety and/or depression were randomly assigned to 
medical care-as-usual (CAU) or CAU plus disease-specific CBT. The main outcomes were 
1) reduction of subclinical anxiety and/or depressive symptoms and 2) sustained remis-
sion for 12 months. Secondary outcomes were health-related quality of life (HRQOL) 
and psychosocial functioning, and we assessed inflammatory cytokines in peripheral 
blood mononuclear cells, and whole blood RNA expression profiles.
In chapter 4, several disease factors were examined as risk factors for anxiety 
and depression in youth with IBD. Since youth with IBD are at risk for anxiety and 
depression, this study aimed to (1) describe the prevalence and severity of anxiety 
and depressive symptoms in the large baseline cohort of young IBD patients, and 
(2) identify demographic and disease risk factors for anxiety and depression. Youth 
with IBD (N = 374, 10-25 years) were screened for anxiety and depression. Patients 
with elevated scores for anxiety and/or depression received a psychiatric diagnostic 
interview. Demographic and disease characteristics were retrieved from medical 
charts. Three-quarters of patients had IBD in remission. Subclinical anxiety/depressive 
symptoms were present in 35.2%, and clinical symptoms in 12.4% of patients. Elevated 
symptoms of either anxiety (28.3%), depression (2.9%) or both (15.8%) were found and 
did not differ between adolescents (10-17 years) and young adults (18-25 years).
Using multiple logistic regression analyses, we found that having active disease and 
being female was significantly associated with elevated depressive symptoms, whereas 
being female and having shorter disease duration was significantly associated with 
elevated anxiety/depressive symptoms. Therefore, it is recommended to screen youth 
with IBD for psychological problems, such as anxiety and depression. Female patients 
and those with active disease are the most vulnerable.
In chapter 5, we examined the associations of demographic, disease and psychologi-
cal factors with HRQOL. Previous studies mainly investigated the unique contribution 
of one or two factors to HRQOL. However, combining all factors simultaneously in one 
study provides more insight. Data were collected on clinical disease activity, illness 
perceptions, coping, anxiety, depression, and HRQOL in our baseline cohort consisting 
of 262 youth (age 10-20 years, 46.6% male). Multiple linear regression analyses were 
performed in two disease type groups separately (CD, UC/IBD-U). Illness perceptions 
and depression were significantly associated with HRQOL, whereas anxiety only was 
in youth with UC/IBD-U and coping was not at all. In both disease type groups, more 
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negative illness perceptions and more depression were associated with lower HRQOL. 
Therefore it is important to pay attention to these psychological factors in the medical 
care for youth with IBD, and in psychological interventions for these patients.
chapter 6 presents the direct post-treatment results of the RCT, testing the ef-
fectiveness of a disease-specific CBT (CBT group: N = 37 vs. CAU group: N = 33). At 
post-treatment, the group that received 3 months of disease-specific CBT did not differ 
from the control group. In both groups a similar proportion of patients remained 
stable, improved or deteriorated on their symptoms of anxiety and depression. Explor-
atory linear mixed models showed that, in general, patients in both groups improved 
on their anxiety and depressive symptoms, as well as in their HRQOL, regardless of 
age, gender, and disease type. This may be explained by the awareness created for 
psychological problems in both groups by merely participating in the study or by the 
low burden of disease that patients experienced.
In chapter 7, we discuss the results of the RCT 6 and 12 months after the baseline 
assessment. Not only did we test the effect of the disease specific CBT on anxiety, de-
pression, and HRQOL, but also on social functioning, coping, illness perceptions, and 
sleep problems. The results were comparable with the direct post-treatment results 
described in Chapter 6. In the CBT group and the CAU group a similar proportion of 
patients remained stable, improved or deteriorated on their symptoms of anxiety and 
depression. Again, in exploratory linear mixed models, patients in both groups im-
proved on their psychological outcomes, 6 and 12 months after baseline. Participating 
in the study may have created awareness that was sufficient for these patients with 
subclinical anxiety and/or depression to improve. CBT may be more useful for patients 
with severe anxiety/depression or those with active disease.
Finally, chapter 8 provided a general discussion, with a discussion of the main find-
ings and conclusions, and recommendations for future research and clinical practice. 
Although several studies reported high prevalence rates of anxiety and depression 
in youth with IBD, our meta-analysis showed pooled prevalence rates of 16.4% for 
anxiety symptoms, 4.2% for anxiety disorders, 15.0% for depressive symptoms, and 
3.4% for depressive disorders. These prevalence rates are lower than those are found 
in adults. In our large cohort of youth with IBD, we found that 35.2% of the patients 
had subclinical symptoms of anxiety/depression, and that 12.4% had severe clinical 
symptoms of anxiety/depression. Furthermore, having active disease, being female, 
and having shorter disease duration were associated with higher anxiety/depressive 
symptoms. In addition, we demonstrated in our cohort that, added to the influence 
of demographic and disease factors, more negative illness perceptions and more 
depression were associated with lower HRQOL. The results of the RCT showed that all 
patients improved on their anxiety symptoms, depressive symptoms, HRQOL, as well 
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as on their social functioning, coping, and illness perceptions over the course of 12 
months. We found no differences between the CBT group and the CAU group.
This is the first European study screening a large cohort of youth with IBD on sub-
clinical and clinical anxiety and depression. Another strength of the current research 
is that our cohort was mixed (academic versus community, and urban versus rural 
hospitals). Moreover, we systematically screened all available youth with IBD with 
validated, and age-attuned questionnaires and a psychiatric interview. Strengths of 
our RCT were that we had very low attrition, that treatment integrity was checked 
carefully, but most importantly that we aimed at improving both anxiety and depres-
sion simultaneously.
Future research is needed to examine how anxiety/depression and inflammation are 
related, by using more regular assessments of both the psychological symptoms and 
the clinical disease activity. For this purpose, short (disease-specific) screening instru-
ments for anxiety and depression should be validated in youth with IBD. With respect 
to psychological treatment for youth with IBD and anxiety/depression, studies should 
examine which patients should be treated with psychological treatment, what format 
should be used, and with what treatment dose. In addition, future longitudinal studies 
should use more intermediate assessments to be able to test the bidirectionality of 
the relationship between anxiety/depression and inflammation and to test possible 
moderators of treatment effects.
Recommendations for clinical practice are that youth with IBD should be screened 
systematically for anxiety and depression, and that patients with severe anxiety/
depression should receive psychological treatment by psychologists with expertise 
with the disease. Preferably, parents should be engaged in the treatment, to optimally 
coach their children in coping with IBD. For patients with subclinical anxiety and/or 
depression, monitoring might be sufficient to prevent that these symptoms develop 
into clinical disorders and have an even larger impact on the disease course.

Samenvatting
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In dit proefschrift worden verschillende studies beschreven naar angst en depressie 
bij jongeren met inflammatoire darmziekten (inflammatory bowel disease; IBD), inclusief 
studies naar de effectiviteit van een ziekte-specifieke cognitieve gedragstherapie 
(CGT).
In Hoofdstuk 1 wordt een algemene inleiding gegeven met de achtergrond van de 
studies. IBD heeft twee hoofdtypen, namelijk de Ziekte van Crohn (ZvK) en colitis ul-
cerosa (CU). Ongeveer 25% van de patiënten krijgt de diagnose voordat ze 18 jaar zijn 
en voor patiënten onder de 25 jaar is dit ongeveer 35%. De laatste jaren wordt steeds 
meer aandacht geschonken aan de psychologische aspecten van IBD. Jongeren met IBD 
hebben een lagere gezondheid gerelateerde kwaliteit van leven (health-related quality of 
life; HRQOL) dan gezonde jongeren. De meest onderzochte psychologische problemen 
bij jongeren met IBD zijn angst en depressie. Over het algemeen hebben jongeren 
met IBD een groter risico op het hebben van angst en/of depressie. Het veelvuldig 
samen voorkomen van angst/depressie met IBD kan mogelijk worden verklaard door 
de zogenoemde brein-darm as (of de brain-gut axis), waarmee het brein en de darmen 
met elkaar communiceren. Ontstekingen (oftewel inflammatie) in de darmen kunnen 
het brein beïnvloeden en zo leiden tot angst en depressie. Anderzijds kunnen angst 
en depressie een toename van inflammatie veroorzaken. Op deze manier ontstaat een 
vicieuze cirkel, waarin inflammatie en angst/depressie elkaar negatief beïnvloeden, 
in toenemende mate. Angst en depressie kunnen ernstige gevolgen hebben voor 
jongeren met IBD. Deze psychologische problemen kunnen het ziektebeloop negatief 
beïnvloeden, medicatietrouw verminderen en een lagere HRQOL veroorzaken. De 
brain-gut axis impliceert dat het behandelen van angst en depressie er mogelijk ook 
voor kan zorgen dat het ziektebeloop kan verbeteren. Er zijn aanwijzingen dat een 
ziekte-specifieke CGT depressieve symptomen kan verminderen, en HRQOL en de 
aanwezigheid op school kan verbeteren. De eerdere studies hadden echter als nadeel 
dat er apart naar angst of depressie werd gekeken of dat patiënten niet werden gese-
lecteerd op eventueel aanwezige angst- en depressieve symptomen. Daarom was deze 
studie ontworpen om onderzoek te doen naar angst en depressie bij jongeren met IBD 
en om de effectiviteit te onderzoeken van een ziekte-specifieke CGT op én angst- én 
depressieve symptomen.
In Hoofdstuk 2 beschrijven we de resultaten van een systematische review en 
meta-analyse naar hoe vaak angst en depressie bij kinderen en adolescenten met 
IBD voorkomen, oftewel wat de prevalentie hiervan is. Hierbij zijn systematisch alle 
beschikbare studies verzameld (op een dergelijke manier dat een ander dezelfde stu-
dies zou vinden) om een algemene conclusie daarover te trekken. Eerder onderzoek 
vond sterk uiteenlopende prevalenties van 0% tot 50%, hoewel er toch veel onder-
zoeken hoge prevalenties vonden. Uit onze zoektocht kwamen 28 studies (N = 8107, 
gemiddelde leeftijd van de patiënten: 14.3 jaar). De gepoolde (ofwel samengevatte) 
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prevalenties waren 16.4% (met een 95% Betrouwbaarheidsinterval [BI] van 6.8%-27.3%) 
voor angstsymptomen en 4.2% (met een 95%BI van 3.6%-4.8%) voor angststoornissen. 
De gepoolde (oftewel samengevatte) prevalenties waren 15.0% (met een 95%BI van 
6.4%-24.8%) voor depressieve symptomen en 3.4% (met een 95%BI van 0%-9.3%) voor 
depressieve stoornissen. Met meta-regressie analyses kan je bekijken of bepaalde 
factoren nog invloed hebben op de samengevatte prevalenties. Hieruit bleek dat het 
ziektetype of geslacht geen invloed had, maar dat onderzoeken met relatief meer 
patiënten met actieve ziekte hogere prevalenties vonden van depressieve symptomen. 
Echter, deze resultaten moeten met voorzichtigheid worden geïnterpreteerd. De stu-
dies verschilden namelijk zeer sterk in welke instrumenten ze gebruikten en welke 
cutoff waarden ze hanteerden voor het bepalen van angst- of depressieve symptomen. 
Ook waren er maar weinig studies die onderzochten hoeveel angst- en depressieve 
stoornissen er voorkomen bij kinderen en adolescenten met IBD. We maken ons 
daarom ook sterk dat in vervolgonderzoek dezelfde vragenlijsten met vergelijkbare 
cutoff waarden gebruikt worden in verschillende landen en culturen. Op die manier 
kunnen we beter inzicht krijgen in hoe vaak angst en depressie voorkomen bij kinde-
ren en adolescenten met IBD en welke factoren daarmee samenhangen.
Hoofdstuk 3 is een beschrijving van de onderzoeksopzet van de RCT om de ef-
fectiviteit te onderzoeken van een ziekte-specifieke CGT voor jongeren met IBD en 
subklinische angst- en/of depressieklachten. Jongeren met IBD kunnen angst- en de-
pressieve klachten ervaren. De relatie tussen IBD en angst en depressie kan mogelijk 
verklaard worden door de brein-darm as. Deze as houdt in dat het brein en de darmen 
met elkaar communiceren. Dit betekent dat het behandelen van angst en depressie 
de ontstekingen in de darmen kan verminderen en daarmee het ziektebeloop kan 
verbeteren. Jongeren met IBD worden gescreend met vragenlijsten voor symptomen 
van angst en depressie. Bij degenen met verhoogde angst en depressie werd een 
psychiatrisch interview afgenomen. Patiënten met verhoogde angst en/of depressie, 
maar niet met klinische angst en/of depressie, werden willekeurig verdeeld over 
twee groepen. De ene groep krijgt de standaard medische zorg van de (kinder-)MDL-
arts, de andere groep krijgt de standaard medische zorg plus een ziekte-specifieke 
CGT. De belangrijkste uitkomsten zijn 1) het verminderen van angst en depressieve 
symptomen en 2) het in remissie blijven van de IBD gedurende 12 maanden. Andere 
uitkomsten zijn HRQOL en psychosociaal functioneren. Daarnaast onderzoeken we 
ook ontstekingsstoffen (cytokinen) en RNA expressie profielen in het bloed.
In Hoofdstuk 4 onderzochten we risicofactoren voor het hebben van angst en/of 
depressie bij jongeren met IBD. Aangezien deze patiënten een verhoogd risico hebben 
op angst en/of depressie, wilden we met deze studie 1) onderzoeken hoe vaak angst 
en depressie voorkomen bij jongeren met IBD en 2) er achter komen welke demogra-
fische en ziektefactoren een risico geven op angst en depressie. Jongeren met IBD (N 
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= 374, 10-25 jaar oud) werden met vragenlijsten gescreend op angst en depressie. Bij 
patiënten met verhoogde scores werd een psychiatrisch interview afgenomen. Demo-
grafische en ziektefactoren werden gehaald uit de medische dossiers van de patiënten. 
Driekwart van de patiënten had IBD in remissie (dus weinig tot geen ontstekingen in 
de darmen). Milde angst en/of depressie werd gevonden in 35.2% van de patiënten, 
ernstige angst en/of depressie werd gevonden bij 12.4%. Meer specifiek vonden we 
bij 28.3% verhoogde angstklachten, bij 2.9% verhoogde depressieve klachten en bij 
15.8% beiden. Deze aantallen verschilden niet tussen adolescenten (10-17 jaar oud) en 
jongvolwassenen (18-25 jaar oud). Met multipele logistische regressieanalyses vonden 
we dat het hebben van een actieve IBD en vrouw zijn significant gerelateerd waren 
aan depressieve symptomen. Vrouw zijn en korter geleden de diagnose IBD hebben 
gekregen waren significant gerelateerd aan angst en/of depressieve symptomen. Het 
is daarom belangrijk om jongeren met IBD te screenen op psychologische problemen, 
zoals angst en depressie. Vrouwelijke patiënten en degenen met een actieve IBD zijn 
het meest kwetsbaar.
In Hoofdstuk 5 deden we onderzoek naar de onderlinge verbanden van demografi-
sche, ziekte- en psychologische factoren met HRQOL. Eerder onderzoek keek meestal 
naar individuele verbanden en combineerde dan één of twee factoren met HRQOL. 
Het is echter sterker om alle factoren in één keer te onderzoeken, zodat je rekening 
houdt met de onderlinge samenhang tussen deze factoren. We verzamelden data over 
de ziekteactiviteit, ziektepercepties, coping stijlen, angst, depressie en HRQOL in 262 
jongeren met IBD (10-20 jaar oud, waarvan 46.6% mannelijk). Multipele lineaire regres-
sieanalyses werden toegepast in twee aparte groepen voor elk ziektetype (één groep 
voor ZvK en één groep voor CU en IBD-ongeclassificeerd; IBD-U). Ziektepercepties en 
depressie waren significant gerelateerd met HRQOL, terwijl dit niet het geval was voor 
coping stijlen. Angst was alleen bij jongeren met CU/IBD-U gerelateerd aan HRQOL. In 
beide ziektetype groepen waren meer negatieve ziektepercepties en meer depressie 
gerelateerd aan een lagere HRQOL. Het is daarom belangrijk om deze psychologische 
factoren aandacht te geven in de medische zorg voor jongeren met IBD en om deze 
factoren aan te pakken in psychologische behandelingen voor deze patiënten. Daar-
mee lijkt hun HRQOL verbeterd te kunnen worden.
Hoofdstuk 6 was een beschrijving van de resultaten van de directe nameting van 
de RCT. De groep die 3 maanden lang een ziekte-specifieke CGT kreeg verschilde niet 
van de controle groep die alleen de standaard medische zorg kreeg. In beide groepen 
zat een vergelijkbaar aantal patiënten dat stabiel bleef wat angst en depressie betreft. 
Daarnaast zat er in beide groepen een vergelijkbaar aantal patiënten van wie de 
angst- en depressieklachten afnamen. Exploratieve lineaire mixed models lieten zien 
dat de patiënten over het algemeen allemaal vooruitgingen op het gebied van angst, 
depressie, maar ook in hun HRQOL. Leeftijd, geslacht en ziektetype hadden hier geen 
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invloed op. Deze resultaten kunnen mogelijk verklaard worden door de bewustwor-
ding die bij patiënten in beide groepen gecreëerd werd doordat ze deelnamen aan het 
onderzoek. Een andere factor die een rol speelde is dat de patiënten weinig ziektelast 
ervoeren, wat betreft hun IBD en wat betreft hun angst- en depressieklachten.
In Hoofdstuk 7 gaven we de resultaten van de RCT na 6 en 12 maanden na de 
eerste meting. We onderzochten hierbij verschillende psychologische uitkomsten. We 
keken niet alleen naar het effect van de ziekte-specifieke CGT op angst, depressie 
en HRQOL (zoals in Hoofdstuk 6), maar ook op sociaal functioneren, coping stijlen, 
ziektepercepties, en slaapproblemen. De resultaten waren vergelijkbaar met die uit 
Hoofdstuk 6. In beide groepen zat een vergelijkbaar aantal patiënten dat stabiel bleef 
of vooruitging in hun angst- en depressieklachten. Wederom wezen exploratieve 
lineaire mixed models erop dat patiënten in beiden groepen vooruitgingen in hun 
psychologische uitkomsten, 6 en 12 maanden na de eerste meting.
Tot slot gaven we in Hoofdstuk 8 een algemene discussie, waarin we alle belangrijk-
ste uitkomsten bespraken en conclusies en aanbevelingen gaven voor vervolgonder-
zoek en voor de klinische praktijk. Ondanks dat verschillende eerdere onderzoeken 
hoge prevalenties vonden van angst en depressie bij jongeren met IBD, kwamen de 
volgende prevalenties uit onze meta-analyse: 16.4% voor angstsymptomen, 4.2% voor 
angststoornissen, 15.0% voor depressieve symptomen en 3.4% voor depressieve stoor-
nissen. Deze prevalenties zijn lager dan de prevalenties die gevonden zijn volwas-
senen met IBD. In onze eigen grote groep met jongeren met IBD vonden we dat 35.2% 
milde angst- of depressieklachten had en dat dit 12.4% was voor ernstige angst- en 
depressieklachten. We vonden ook dat een actieve IBD, vrouw zijn en korter geleden 
de diagnose IBD hebben gehad risicofactoren zijn voor het hebben van angst en/of 
depressie. Daarnaast vonden we in onze groep dat meer negatieve ziektepercepties 
en meer depressie samenhangen met een lagere HRQOL, bovenop de invloed van 
demografische en ziekte factoren, zoals leeftijd, geslacht, sociaal economische status, 
ziektetype en ziekteactiviteit. De RCT leerde ons dat alle patiënten verbeterden in hun 
angst- en depressiesymptomen, hun HRQOL, maar ook op het gebied van hun sociaal 
functioneren, coping stijlen en ziektepercepties gedurende 12 maanden follow-up.
Dit onderzoek had verschillende sterke punten. In onze grote groep patiënten (374 
deelnemers die één meting meededen) waren verschillende typen patiënten vertegen-
woordigd. Enerzijds, omdat universitaire en perifere ziekenhuizen meededen. Ander-
zijds bevonden de ziekenhuizen zich in meer stedelijke gebieden en meer landelijke 
gebieden. Alle patiënten werden systematisch onderzocht met vragenlijsten, maar 
ook met een psychiatrisch interview. Voor onze RCT geldt dat sterke punten waren 
dat er zeer weinig patiënten stopten met de behandeling, dat we grondig hebben 
onderzocht of de behandeling daadwerkelijk is uitgevoerd zoals van te voren bedacht 
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was (behandelintegriteit genaamd) en dat ons doel was om èn angst èn depressie aan 
te pakken, aangezien deze veelvuldig samen voor komen.
Toekomstig onderzoek is nodig om nog beter uit te vinden hoe angst en depressie 
samenhangen met ontstekingen in de darmen. Hiervoor is het belangrijk dat de angst 
en depressie, maar ook de ziekteactiviteit veel regelmatiger gemeten worden dan in 
de meeste onderzoeken word gedaan, bijvoorbeeld wekelijks of maandelijks in plaats 
van om de drie of meer maanden. Om dit onderzoek te kunnen doen moeten korte 
screeningsinstrumenten voor angst en depressie gevalideerd worden in jongeren met 
IBD. Verder zouden studies naar psychologische behandeling van jongeren met IBD 
moeten uitvinden welke patiënten het meest geholpen zijn met psychologische be-
handeling en hoe deze het beste gegeven kan worden. Dit kan bijvoorbeeld slechts een 
aantal sessies zijn of door sessies online of telefonisch te doen. Daarnaast is het goed 
als onderzoeken naar de effecten van psychologische behandelingen tussenmetingen 
doen om zo inzicht te krijgen in hoe de wederkerige relatie tussen angst/depressie 
en ontstekingen in de darmen eruit ziet als je behandeling geeft. Ook kunnen zo 
factoren worden ontdekt die het succes van een behandeling kunnen voorspellen 
(zogenoemde moderatoren).
Voor de klinisch praktijk is het belangrijk dat jongeren met IBD systematisch ge-
screend worden op angst en depressie. Degenen met ernstige angst en/of depressie 
kunnen dan psychologische behandeling, zoals CGT, krijgen. Patiënten met milde 
angst en/of depressieklachten hebben er mogelijk voldoende aan dat deze klachten in 
de gaten worden gehouden, zodat de klachten niet erger worden en een grote invloed 
hebben op de darmontsteking.
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Workshop Grant Writing, Erasmus MC 2015 0.1
PhD Day, Erasmus MC 2015-2017 0.45
Science Café Child and Psychiatry/Psychology, Erasmus MC 2016-2018 1
Inventarisatiebijeenkomst Zorginstituut 2016 0.15
teaching activities
master’s thesis Supervision
M. van den Heuvel (Child and Adolescent Psychology, Leiden 
University)
2014-2015 3.0
Sleep problems impact quality of life and feelings of anxiety and depression 
in Dutch adolescents with inflammatory bowel disease
L. van den Berg (Clinical Child and Adolescent Psychology, Erasmus 
University Rotterdam)
2015 3.0
Cognitive coping and its relation with anxiety, depression, and quality of life 
in adolescents with inflammatory bowel disease
N. Akbas (Clinical Child and Adolescent Psychology, Erasmus 
University Rotterdam)
2015-2016 3.0
Verhoogd angstklachten en een verslechterde kwaliteit van leven bij kinderen 
en jongeren met inflammatory bowel disease
R. Gutlich (Clinical Child and Adolescent Psychology, Erasmus 
University Rotterdam)
2016 3.0
Kwaliteit van leven bij kinderen en adolescenten met IBD
D. Ormskerk (Clinical Child and Adolescent Psychology, Erasmus 
University Rotterdam)
2017 3.0
De invloed van ouderlijke stress en familie functioneren, op kinderen en 
adolescenten met inflammatoire darmziekten
other teaching activities
Supervising 2nd year medical students, Erasmus University 
Rotterdam “Writing a systematic review”
2015-2017 2.1
Supervising 3rd year medical students, Erasmus University 
Rotterdam
2015-2019 2.0
Lecture IBD in children, Tilburg University 2015 0.15
Lecture Minor Medical Psychology, Erasmus MC 2015-2016 0.3
Training PASCET-PI (CBT) 2015-2016 0.3
Lecture Anxiety disorders, OCD and tic disorders, VUmc 2019 0.15
clinical activities
PASCET-PI (CBT) Training prof.dr. E. Szigethy 2014 0.6
SCREEN patient demonstration, outpatient clinic Child and 
Adolescent Psychiatry/Psychology, Erasmus MC
2014 0.2
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Year Workload 
(ectS)
Practical WISC-III-NL Child and Adolescent Psychology, Erasmus 
University Rotterdam
2014-2015 0.3
CHIP Parent Workshop 2016-2017 0.2
Psychologist outpatient clinic Child and Adolescent Psychiatry/
Psychology, Erasmus MC
2017-present
Training ADOS-2 2018 2
Training WISC-V 2019 0.3
other activities
Organization committee Science Café Rotterdam, Bibliotheek 
Rotterdam
2015-2018
Coordination of Research meetings Child and Psychiatry/
Psychology, Erasmus MC
2015-2016
Organization of monthly Science Café Child and Adolescent 
Psychiatry/Psychology, Erasmus MC
2016-present
Reviewing articles (Journal of Crohn and Colitis, Journal of 
Psychosomatic Research, Journal of Clinical Psychology in Medical 
Settings)
2018-present
HAPPY-IBD: A Study into Anxiety and Depression in Youth 
with Inflammatory Bowel Disease
Screening and the effect of a cognitive behavioral therapy
Luuk Stapersma
HAPPY- IBD: A Study into Anxiety and Depression 
in Youth with Inflammatory Bowel Disease
Screening and the effect of a cognitive behavioral therapy
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